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1 Introduction 
1.1 Adult Hematopoiesis 
Hematopoiesis is derived from the ancient Greek words αῖͨµα (blood) and ποιεῖν (to make). 
This term describes the continuous and complex process of blood cell formation. The 
production of blood cells, which is in adults primarily restricted to the bone marrow, involves 
cell renewal, proliferation, differentiation and maturation. The basis of this process are 
hematopoietic growth factors and cytokines but most importantly the hematopoietic stem 
cells (HSC), a small cell population which is capable of self-renewal and has the ability to give 
rise to differentiated progeny. Blood cells are mainly subdivided into lymphoid and myeloid-
erythroid cells. The lymphoid lineage consists of B-cells, T-cells and natural killer cells. These 
leukocytes are part of the immune system. B-cells produce highly specific antibodies against 
antigens and develop into memory B-cells upon activation. There is a variety of T-cells with 
different functions. They can coordinate immune response or directly attack infected or 
cancerous cells. Natural killer cells also recognize and eliminate foreign cells. Erythrocytes, 
which are derived from the myeloid-erythroid lineage, are responsible for the transport of 
respiratory gases. Thrombocytes, granulocytes and monocytes are the leukocytic fraction of 
this lineage and they are responsible for coagulation, immune response and phagocytosis 
(after differentiation), respectively. 
In 1961 Till and McCulloch conducted a series of experiments which revealed the ability of 
bone marrow cells to confer engraftment to lethally irradiated mice (Till and Mc 1961). In 1994 
Morrison and Weissman isolated two types of multipotent cell types, the long-term 
hematopoietic stem cell (LT-HSC) and the short-term hematopoietic stem cell (ST-HSC) 
(Morrison and Weissman 1994). LT-HSCs are characterized by their ability of self-renewal for 
life in a lethally irradiated recipient. ST-HSCs originate from LT-HSCs and have only limited self-
renewal capacity (Weissman 2000). These, in turn, differentiate into multipotent progenitors 
(MPPs). They have the ability to give rise to oligolineage progenitors, from which the 
differentiated progeny is generated. The committed oligolineage progenitors derived from 
MPPs are the common myeloid progenitors (CMP), which give rise to the myeloid-erythroid 
lineage, and the common lymphoid progenitors (CLP) generating the lymphoid lineage (B-cells, 
T-cells and natural killer cells). CMPs then differentiate into megakaryocytic-erythrocyte 
progenitors (MEP) and granulocyte-monocyte progenitor (GMP) before they differentiate and 
proliferate into lineage specific mature blood cells: megakaryocytes or erythrocytes and 
granulocytes, monocytes or mast cells (Iwasaki and Akashi 2007). Dendritic cells can be 
generated from myeloid and lymphoid progenitors. Mature dendritic cells are found outside 
the blood and function as antigen-presenting cells.  
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1.2 Leukemia 
Leukemias are hematological disorders, which develop from the clonal proliferation of 
malignant white blood cells, also known as blast cells that accumulate in bone marrow and 
blood. Leukemias can be generally divided in to acute and chronic forms. Acute leukemias are 
usually very aggressive and require immediate treatment due to a rapid increase of immature 
blood cells. Genetic lesions are thought to cause an increased rate of proliferation, reduced 
apoptosis and block of cellular differentiation in these cells. Acute leukemias are defined by 
the presence of a minimum of 20 % blast cells in the bone marrow. Chronic leukemias, in 
contrast, are characterized by the appearance of more mature but still abnormal cells and 
longer disease progression therefore an immediate treatment is usually not necessary. 
Depending on the affected cell type, leukemias are further subdivided in myeloid and 
lymphoid leukemia. Despite the many different subtypes, leukemias and other hematological 
malignancies (Non-Hodgin–lymphoma, Myeloma and Hodgkin lymphoma) represent only 7 % 
of all malignant diseases in females and 9 % in males (Smith et al. 2010). 
1.2.1 Acute Myeloid Leukemia (AML) 
AML has an age-standardized incidence of approximately 3 in 100,000 with a median onset of 
>60 years (Bishop 1999). It is the most common form of acute leukemia in adults. It is 
characterized by abnormal blasts in the bone marrow that are also found in the peripheral 
blood. Initially, the different subtypes of AML were defined based on morphologic parameters, 
mainly on the degree of maturation. The so called FAB-classification (French-American-British) 
has been replaced by the classification of the World Health Organization (WHO), which is 
mainly based on cytogenetic and molecular genetic abnormalities.  
1.2.2 Chronic Myeloid Leukemia (CML) 
CML is a malignant clonal disorder of hematopoietic stem cells. In addition to myeloid cells, 
there is also an increase of erythroid cells and platelets in the blood. The annual incidence is 
between 1-2 cases per 100,000, the median age is 60-65 years (Baccarani and Dreyling 2010). 
From an initial benign chronic phase the disease turns into a stage of blast crisis within a view 
years. The final stage of blast crisis, which is similar to an acute leukemia, is often preceded by 
an accelerated phase. The cytogenetic hallmark of this disease is the reciprocal t(9;22) 
(q34;q11) chromosomal translocation. This translocation results in the BCR/ABL1 fusion gene, 
the resulting BCR/ABL fusion protein has tyrosine kinase activity. Therefore patients are 
treated with tyrosine kinase inhibitors. The progression of disease is frequently accompanied 
by additional chromosomal abnormalities.  
1.2.3 Acute Lymphocytic Leukemia (ALL) 
ALL is characterized by the malignant transformation of lymphoid progenitor cells. Most of the 
ALLs derive from B cells, but they can also derive from T cells. Malignant cells mostly 
accumulate in bone marrow but also spill into the peripheral circulation. In children, ALL is 
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much more common than in adults. A number of translocations have been found in this 
disease. In childhood ALL, the most common translocation is the t(12;21) resulting in the 
TEL/AML fusion gene. In adults we often find the BCR/ABL fusion gene, which is associated 
with poor prognosis. The MLL/AF4 fusion gene is also common in ALL. 
1.2.4 Chronic Lymphocytic Leukemia (CLL) 
CLL is a disease of the elderly with a high incidence in the Western world. In CLL, mature 
appearing B-lymphocytes accumulate in blood, bone marrow, liver, spleen and lymph nodes. 
The disease is biologically very heterogeneous. This heterogeneity is reflected in the diverse 
clinical courses the disease can take. In benign cases, patients may never receive treatment. In 
other cases, however, the disease can take a very aggressive course with a short survival time 
or the disease may be indolent for years and then transform into an aggressive form. Rai and 
Binet independently developed two clinical staging systems for better risk stratification in 
newly diagnosed CLL (Rai et al. 1975; Binet et al. 1981). These two staging systems are based 
on physical examination and standard laboratory test (i.e. lymph node status, platelet and red 
blood cell counts; enlargement of lymph nodes, spleen and liver). The discovery of biological 
markers in CLL like the IGHV mutational status and chromosomal abnormalities as determined 
by fluorescence in situ hybridization (FISH) has further improved the prediction of individual 
CLL cases.  
1.3 Oncogenesis 
Today there is a consensus that cancer is a multistep process of genetic alterations that give 
rise to the transformation of normal human cells into malignant cells. In 1914, Theodor Boveri, 
a German biologist, published his book Zur Frage der Entstehung Maligner Tumore (Gustav 
Fisher Verlag Boveri 1914) where he proposed the somatic mutation theory of tumorigenesis. 
Later, genetic alterations like chromosomal translocations, deletions or point mutations were 
experimentally proven to be associated with cancer. Therefore Boveri is generally 
acknowledged as the father of the somatic mutation theory of oncogenesis (Barrett 1993). 
Many other scientists have contributed and expanded this theory. In studies on patients with 
hereditary or sporadic retinoblastoma Knudson discovered that these patients need two hits in 
both alleles of a protective (tumor suppressor) target for the retinoblastoma to evolve 
(Knudson 1986). Knudson developed his two-hit hypothesis long before the retinoblastoma 
gene RB1 was discovered and its function in cell division, proliferation and regulation of cell 
death was characterized (Chau and Wang 2003). This two-hit model is the basis for today’s 
understanding of tumor suppressor genes. A tumor suppressor gene can still be protective in 
the heterozygous state (i.e. if only one copy of a tumor suppressor gene is non-funtcional). But 
if the second allele of the tumor suppressor is inactivated due to a mutation, often point 
mutations or deletions, its protective effect on the cell is lost. Quite often, the phenomenon of 
loss of heterozygosity at the tumor suppressor gene locus is a sign that the second hit has 
occurred.  
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In addition to tumor suppressors, a second type of genes, the so-called oncogenes, are 
involved in tumorigenesis. Oncogenes are mutated proto-oncogenes. Proto-oncogenes 
typically stimulate cell division and block cell differentiation in normal cells. Mutations like 
point mutations, deletions, gene amplifications or translocations in oncogenes are always 
dominant and lead to abnormal cell growth due to a gain of function. In 1976 Peter Novell 
proposed the clonal evolution model for tumor cell populations (Nowell 1976). He 
hypothesized that a normal cell which acquired a genetic alteration will have a growth 
advantage compared to its normal neighboring cells resulting in a clonal expansion of genomic 
instable cells, which acquire further alterations. Cells with most growth promoting additional 
alterations will be selected, eventually resulting in rapidly multiplying cancer cells (Nowell 
1976). He considered leukemias to be early in this evolutionary process and solid tumors to be 
late. Michal Renan tried to answer the question how many alterations – that occur after birth - 
a specific tumor would exactly require to evolve (Renan 1993). Mathematically he showed that 
there is a group of tumors resulting from many somatic mutations like the prostate cancer 
(12 mutations), which usually evolve at older age, and a group of tumors that require fewer 
somatic mutations, like tumors affecting the brain and nervous system (4 mutations). These 
tumors are often found in younger people and often associated with an inherited 
predisposition (Renan 1993). Renan also hypothesized that hematopoietic malignancies 
require fewer genetic alterations than solid tumors, as malignancies of the hematopoietic 
system don’t need to acquire properties that allow the malignant cells to metastasize. This 
hypothesis held true for leukemias and Hodgkin’s disease but not for multiple myeloma (Renan 
1993).  
CML is an example for the progression of a relatively indolent disease to a more aggressive 
state due to additional alterations. At the start of CML, almost all patients have a 
t(9;22)(q34;q21) translocation resulting in the BCR/ABL fusion protein. With disease 
progression, they accumulate additional genetic alterations leading to a more aggressive form 
of the disease. This “multistep theory of cancer” (Vogelstein and Kinzler 1993) was further 
refined by Hanahan and Weinberg. Based on common molecular, biochemical and cellular 
traits, they proposed that six capabilities (hallmarks) are shared by most or all human tumors: 
self-sufficiency in growth signals, insensitivity to growth-inhibitory signals (antigrowth), 
evasion of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis (Hanahan and Weinberg 2000). Survival, 
proliferation and dissemination of tumor cells is possible through two enabling characteristics: 
the development of genomic instability and tumor-promoting inflammation (Hanahan and 
Weinberg 2011). A single genetic lesion can affect more than one of these processes and also 
the same process can be disrupted by several lesions.  
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1.3.1 Genetics of Leukemias 
Hematopoietic stem cells and their progeny are very well studied as well as diverse leukemias. 
Kelly and Gilliland proposed that myeloid leukemias are the result of at least two broad classes 
of mutations: (1) Class I mutations resulting in an increased proliferation of HSCs and (2) class II 
mutations which cause impaired differentiation and/or apoptosis (Kelly and Gilliland 2002). So 
far, a great number of chromosomal rearrangements have been identified and many of them 
have been studied in mouse models. Transcription factors play a major role in normal 
hematopoietic development and are frequently affected by translocations in AML. Very 
common are translocations that affect the core binding factors like the translocation 
(8;21)(q22;q22) resulting in the production of the AML/ETO or RUNX1/RUNX1T1 fusion protein 
or the translocation t(15;17)(q24;q21) and its fusion protein PML/RARα, which is found 
exclusively in promyelocytic leukemia. From mouse models we know that fusion proteins like 
PLM/RARα and AML/ETO, which belong to the Class II mutations (impairing hematopoietic 
differentiation), do not, on their own, lead to the development of leukemia (Pollock et al. 
1999; de Guzman et al. 2002). Typical examples for Class I mutations, which confer 
proliferative advantage, are constitutively activated tyrosin kinases like BCR/ABL or mutations 
in N-RAS, K-RAS or FLT3. These alterations alone are also not able to cause leukemia. They lead 
only to leukocytosis with normal maturation and cell function (Kelly and Gilliland 2002). An 
AML phenotype (increased proliferation and impaired differentiation) could be observed when 
both types of mutations collaborate as it was shown for mutated FLT3 and PML/RARα (Kelly et 
al. 2002).  
However, the simplistic concept of class I and class II mutations is not sufficient to explain the 
plethora of mutations we find in AML. The functional grouping of mutations into two classes 
cannot always be upheld. From bone marrow transplantation models in mice we know that 
certain bona fide class I mutations as well as certain class II mutations on their own can induce 
aggressive leukemias. The same applies for the two-hit concept of a tumor suppressor as 
mentioned earlier, in CLL we find cases where the tumor suppressor gene TP53 is only 
monoallelicly affected but these cases have an equally poor disease course as do cases with 
biallelic disruption of the TP53 gene. We still do not understand how all the alterations in 
cancer interact, how cancer is initiated and which factors influence individual disease course.  
With next-generation sequencing (NGS) technologies we are, for the first time, able to 
systematically identify genomic lesions in cancer in an unbiased fashion across the entire 
genome. In addition, this technology can provide us with information about the chronological 
evolution of alterations during disease course. The information generated by next-generation 
sequencing projects of cancer genomes has already transformed our view of cancer and will 
undoubtedly provide us with critical information in the future.  
NGS experiments produce terabytes of data within a short time. The analysis of these data is 
very challenging. One of the biggest challenges in this analysis is to distinguish between driver 
mutations, which contribute to leukemogenesis, and passenger mutations, which just 
happened to be there in the transformed cell.  
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1.4  Biomarkers in Oncology 
“Biomarker” is a very broad term. A biomarker can be any measurable indicator of a 
physiological or pathological cellular or organismal process. The working group of the National 
Institute of Health (NIH) defined biomarker as “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (Biomarkers Definition Working Group 
2001; Oldenhuis et al. 2008). The World Health Organization (WHO) further expanded the 
term by including incidence and outcome of disease: “any substance, structure, or process that 
can be measured in the body or its products and influence or predict the incidence of outcome 
or disease” (WHO International Programme on Chemical Safety 2001). Therefore a biomarker 
can be everything from a blood pressure measurement, the concentration of metabolites or 
other substances in body fluids or the result of cytogenetic or molecular analyses. Most 
important for oncology are the detection and evaluation of prognostic and predictive markers. 
A prognostic biomarker is able to provide information about the overall cancer outcome 
regardless of therapy. However, based on presence or absence of such a prognostic marker a 
treatment can be selected (Oldenhuis et al. 2008). A predictive biomarker, in contrast, 
provides information about the expected effect of a given therapy. A marker that is predictive 
can at the same time be a therapeutic target, like the BCR/ABL fusion protein in CML. Next 
generation sequencing technologies enable us to detect many potential markers but they need 
to be validated thoroughly before they can be used in clinical applications: “a clinical useful 
prognostic marker must be a proven independent, significant factor, that is easy to determine 
and interpret and has therapeutic consequences” (NIH consensus conference 1991; Oldenhuis 
et al. 2008). The number of mutations that occur in a certain tumor does not make that task 
easier. Here again the discrimination between driver and passenger mutations is very 
important for the identification of prognostic and predictive factors in cancer.  
1.4.1 Prognostic Biomarkers in CLL 
The clinical staging systems in CLL developed by Binet and Rai are still of great relevance to 
predict outcome in newly diagnosed patients. However, predicting the individual disease 
course in CLLs still remains elusive because of the great heterogeneity. Certain chromosomal 
aberrations and the mutational status of immunoglobulin heavy variable chain region are still 
the most relevant and best studied prognostic biomarkers in CLL.  
1.4.1.1 IGHV Mutational Status  
For a long time the general opinion in the CLL community was that the disease derives from 
naïve B-cells that do not have mutations in the immunoglobulin heavy chain variable genes 
(IGHV). Nowadays we know that CLL originates from two groups of antigen-experienced 
mature B-Cells, which can be distinguished according to the mutational status in their IGHV 
genes. The initial suggestion of Schroeder and Dighiero that CLL may carry mutated IGHV 
genes has been confirmed by several groups (Schroeder and Dighiero 1994; Oscier et al. 1997; 
Fais et al. 1998). A key finding was the discovery that the mutational status of the IGHV genes 
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correlates with the patients’ prognosis (Hamblin et al. 1999; Damle et al. 2002). Patients with 
mutated IGHV status (≈60 %) have significantly better prognosis and an indolent disease 
course as compared to patients with unmutated IGHV status who have a much more 
aggressive disease course. To answer the question whether both CLL types have different 
precursors, gene expression analysis revealed that -contrary to expectations - unmutated CLL 
(U-CLL) and mutated CLL (M-CLL) have a very similar profile suggesting a common precursor. 
The similarity of the gene expression profile of CLL and CD27+ cells, a memory cell marker 
found in all B-CLL cases, implies that this common precursor is an antigen-experienced 
memory like B-cell (Klein et al. 2001; Damle et al. 2002; Klein and Dalla-Favera 2010). In 
normal B-Cell development, B cells enter lymphoid tissues where they are either activated by T 
cells (T cell dependent immune response) and pass through germinal centers where they 
experience somatic hypermutation in their V-genes, or they are activated in a T cell 
independent fashion and do not traverse the germinal center (no hypermutation). Both B cell 
types differentiate into plasma or memory cells. Therefore, U-CLLs might bypass germinal 
center somatic hypermutation through a T cell independent mode of activation (Chiorazzi et al. 
2005; Klein and Dalla-Favera 2010). Lately, whole genome bisulfite sequencing in CLL revealed 
a DNA methylation signature that distinguishes three subtypes (Kulis et al. 2012). In contrast to 
gene expression profiling, methylome analysis using whole-genome bisulfite sequencing, 
revealed that U-CLLs have methylation pattern similar to pre-germinal center B cells and the 
methylome of M-CLL was similar to memory B cells. However, a third methylation pattern was 
recognized suggesting that this CLL subtype derives from an experienced, germinal center–
independent B cell with low levels of somatic hypermutation (Kulis et al. 2012). This data 
demonstrate that we still understand only very little about CLL progenitor cells. It also shows 
out that there is more than one progenitor for CLL, as one can also deduct from the variable 
clinical course of CLL, suggesting that this disease should be divided in different subtypes. The 
IGHV mutational status had great impact on the understanding of the biological background of 
CLL and certainly it is a valuable prognostic tool.  
To define the IGHV status of a patient sample, the IGHV status of the dominant clone needs to 
be evaluated by multiplex polymerase chain reaction (PCR). Then the dominant clone is 
sequenced and its sequence is compared to the germline sequence of the IGHV gene. A cut-off 
value of 98 % homology was defined to distinguish between unmutated (≥98 %) and mutated 
cases (<98 %) (Hamblin et al. 1999). As this technique is so laborious and expensive it cannot 
be performed in every laboratory. In addition, a mutational status cannot be precisely 
identified for each case. Therefore, this marker does not fulfill the NIH criterion of a prognostic 
marker which should be easy to assay (NIH consensus conference 1991; Oldenhuis et al. 2008). 
The expression of CD38 and ZAP-70 has been shown to be surrogate markers for IGHV 
mutational status, which can be detected by flow cytometry or real time PCR. For both 
surrogate markers there is no full concordance with the IGHV status and each of them has 
emerged as independent prognostic marker for CLL.  
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1.4.1.2 Chromosomal Aberrations  
80 % of all CLL cases have chromosomal deletions and/or amplifications when assayed by FISH 
using a defined panel of probes. Patients’ survival correlates with genomic aberrations from 
the most adverse aberrations to more favorable in the following order: deletion 17p13 > 
deletion 11q22-q23 > trisomy 12 > no aberration > deletion 13q14 as sole abnormality (Dohner 
et al. 2000). The deletion 17p13 affects the tumor suppressor TP53, which explains the dismal 
prognosis associated with this alteration. The deletion on chromosome 11 affects the ATM 
gene, which plays a crucial role in the DNA damage repair pathways. Multivariate analysis 
revealed that the FISH markers detecting 17p13 deletions and 11q22-q23 deletion are 
independent prognostic factors. They are independent of IGHV gene mutational status, age, 
leukocyte count and lactate dehydogenase level (Krober et al. 2002). 
However, the predictive power of the FISH status or the IGHV mutational status is limited and 
these markers cannot fully explain the heterogeneity and the biology of CLL. Identifying new 
markers is important for prognosis prediction and for the identification of novel diagnostic 
targets. 
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1.5 Sequencing Technologies 
A decade ago the human genome project was completed. The 3 billion base pairs of the 
human genome were sequenced using the conventional capillary-based Sanger method (see 
3.5.2). In total, the costs for the whole human genome amounted to 3 billion US-Dollars. 
Simultaneous sequencing was limited by the number of capillaries (usually 96) of the 
automated sequencing machines. This automated Sanger-sequencing technology is also 
sometimes called “first-generation” sequencing technology.  
1.5.1 Next Generation Sequencing Technologies 
Since that time, alternative sequencing strategies have been developed to lower the 
sequencing costs and to dramatically increase the output of the sequencing machines. For this 
massive parallel sequencing of DNA, several new platforms were developed. This “second-
generation” of sequencing technologies, which are commonly called “next-generation” 
sequencing technologies, have significantly changed genome research. NGS technologies are 
based on PCR clonally amplified templates and sequence data is achieved in a cyclic process.  
With the new developed sequencing platforms, the costs for sequencing dropped dramatically. 
The National Genome Research Institute, a division of the National Institute of Health, has 
tracked the costs of DNA sequencing performed at the sequencing centers funded by the 
institute (http://www.genome.gov/sequencingcosts/). These data is freely available and 
demonstrate the remarkable improvements in DNA sequencing technologies. According to 
these data, we are close to the 1000 Dollar human genome. From the graph one can easily see 
the time point in 2008 when the sequencing centers switched from Sanger sequencing to NGS 
technology.  
The first commercially available next-generation sequencing platform was launched in 2005 by 
454 Life Sciences (Margulies et al. 2005), which was purchased by Roche in 2007. Shortly 
thereafter, Solexa’s Genome Analyzer and the SOLiD platform from Agencourt were released. 
These three platforms became the most commonly used sequencing platforms. In 2006, 
Applied Biosystems acquired Agencourt and Solexa was purchased by Illumina. All three 
platforms use adapter-ligated fragment libraries.  
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Figure 1 Costs per genome. Within twelve years the sequencing costs per genome dropped from 95 million to 
5.826 U.S. $ (Logarithmic scale on Y axis). Data adapted from the National Genome Research Institute 
(https://www.genome.gov/sequencingcosts/).  
1.5.1.1 454 Pyrosequencing 
The 454 platform is based on an emulsion method for DNA amplification and an instrument 
using pyrosequencing technology (Margulies et al. 2005). Pyrosequencing relies on the 
detection of pyrophosphate, which is released during nucleotide incooperation by a 
polymerase. The complementary strand of a single stranded DNA is synthesized by adding only 
one of the four bases to the sequencing reaction at a time. The pyrophosphate, stoichio-
metrically released, when a base is successfully incorporated serves as fuel for a set of 
downstream reactions that generates visible light produced from a luciferase-catalyzed 
reaction: (1) one of the four dNTPs is added complementary to the DNA template using a 
sequencing primer (2) the released pyrophosphate (PPi) is converted into ATP by ATP 
sulfurylase in the presence of adenosine 5´ phosphosulfate (APS) (3) this ATP in turn provides 
the energy for the luciferase mediated conversion of luciferin to oxyluciferin. The light 
emission is detected by a CCD camera and is proportional to the number of incorporated 
deoxynucleotides of one type. Before starting the next sequencing reaction, unbound dNTPs 
needs to be removed. One can read the sequence when the type of dNTP added to each 
reaction is compared with light emission. It is important, not to use dATP as sequencing 
substrate as it is also a substrate for luciferin which would result in light emission, therefore 
dATPαS is used instead. 
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Figure 2 454 Sequencing Technology. A) Genomic DNA is fragmented before the sequencing adapters are ligated to 
each of the fragments. Thereafter, single stranded fragments are bound to beads which provide oligonucleotides on 
their surface that are complementary to the ligated adapters. Only one fragment is bound to a bead and each bead 
is captured in a droplet of PCR reagents in oil emulsion. The fragments are amplified so that each bead carries 
millions of copies of the initially bound fragment. The beads that carry single-stranded DNA copies after 
denaturation are spread across the wells of a nano titer plate in order to perform pyrosequencing. The reagents for 
sequencing are deposited into the wells in form of small beads that carry the reagents. B) The pyrosequencing 
process is summarized. Starting from the sequencing primer the first nucleotide is incorporated. Nucleotides are 
delivered in a sequential fashion. The released pyrophosphate is substrate of the sulfurylase enzyme which converts 
APS into ATP which itself provides energy for the conversion of luciferin into oxyluciferin catalyzed by luciferase. C) 
A camera detects light emission, which is proportional to the number of integrated nucleotides. Homopolymers 
have different signal values as indicated on the right. Images for this figure were taken from Margulies et al and 
Mardis (Margulies et al. 2005; Mardis 2008a). 
For the 454 sequencing, genomic DNA is sheared to generate a random library and adapters 
are added to the fragments. By limiting dilution, single DNA fragments are isolated and bound 
to beads (one fragment per bead) which have oligomers attached on their surface that are 
complementary to the adapter sequence of the DNA fragments. Within the droplets of an 
emulsion the fragments are clonally amplified. Each bead carries ten million copies of a unique 
DNA template (Margulies et al. 2005). For subsequent sequencing the emulsion is broken and 
the DNA strands are denaturated. The beads, which now carry single-stranded DNA clones, are 
deposited into wells of a fibre-optic slide. Enzymes (sulfurylase and luciferase) which are 
necessary for pyrosequencing are immobilized on smaller beads which are also deposited into 
each well. In the sequencing instrument the reagent solutions and the four nucleotides are 
flushed over the plate in a sequential fashion. If a nucleotide is attached by the polymerase, it 
will emit a burst of light. This light emission is directly proportional to the number of a 
particular nucleotide incorporated. After each cycle a washing step with apyrase, which 
degrades nucleotides, is performed to ensure that no nucleo des remain in the wells. Ini ally 
the GS-FLX instrument produced an average read length of   2̴50 bp per bead and a throughput 
of   1̴00 Mb of sequence data per 7-h run (Mardis 2008a). The long fragments generated make 
it easy to assemble fragments into large contigs. A drawback of this technique is the difficulty 
in accurately reading homopolymeric sequence stretches, because the linearity of signal 
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response is not well preserved for more than 8 identical nucleotides in a row (Margulies et al. 
2005).  
1.5.1.2 SOLiD Sequencing  
Like in the 454 technology, in SOLiD (Sequencing by Oligo Ligation Detection) sequencing the 
templates are also amplified with an emulsion-based PCR approach. For sequencing, the 
fragments are attached to a class slide. Instead of polymerization, this technology uses 
sequential ligation of dye-labeled 8-mer oligonucleotides of which each probe assays two base 
positions at a time (Breu 2010). The ligation process starts with the annealing of a universal 
sequencing primer. The 8-mer oligos used for ligation are designed in a way that always two 
positions correspond to a specific fluorescent dye. As there are four different bases we have 16 
possible dinucleotide combinations. Therefore each of the four fluorescent dyes encodes four 
different combinations of bases. At first an octamer will bind next to the sequencing primer 
where it becomes ligated. With a camera the fluorescence of the ligated oligo is recorded. In 
the next step the fluorescent label is chemically cleaved together with the last three bases of 
the octamer. By repeating these steps the sequence of a template is determined up to a read 
length of 35 bases (Mardis 2008a). At that point, only every fifth base is labeled. In the next 
step the extended primer is stripped from the template. To fill the gaps in the sequence, the 
whole ligation process is repeated by using a universal sequencing primer which is shifted one 
or more bases to the left. Several rounds are performed until the complete sequence is known. 
Alternatively the gaps can be filled up by using octamers where the positions of the labeled 
bases are shifted (Shendure and Ji 2008). In the example in Figure 3 the labeled bases are at 
position one and two. After five ligation rounds the data can be combined to generate a 
complete sequence. The ligation steps can be performed from both sides of a fragment so that 
one can also obtain paired-end information. The advantage of this technique is the high 
accuracy of base calling, as each base is queried twice. It is easier to discriminate SNPs from 
base calling errors as a SNP is characterized by a two color change. Initially it took 5 days to 
generate 3000 Mb of paired-end data with a read length of 35 bp (Mardis 2008a).  
 
 
Figure 3 SOLiD Sequencing Technology. A) Fragments which were amplified by emulsion PCR are deposited onto a 
glass slide. B) Fluorescent-labeled 8-mers with dinucleotides encoded at position one and two. The cleavage site is 
between the 5
th
 and 6
th
 nucleotide. C) A universal sequencing primer is bound to the fragment prior to the first 
ligation step. After ligation the fluorescent signal of the ligated 8-mer is detected. After signal detection of the 8-
mer by a camera, unextended strands are capped and the label is chemically cleaved. By repeating these steps, the 
sequence is extended. When a strand is completed the extended nucleotides are melted off. The entire process is 
repeated four more times with sequencing primers that are shifted one or more bases to the left. Every base of the 
template is interrogated twice as each fluorescent label encodes a two base combination. D) Color code for the 16 
possible dinucleotides. E) As each base is read twice, the accuracy in base-calling is improved. Images for this figure 
were taken from Mardis 2008 and Breu 2010 (Mardis 2008b; Breu 2010). 
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1.5.1.3 Illumina Genome Analyzer 
This is the sequencing technology used in the current work to analyze 25 CLL exomes and their 
matched normal controls. As the technique is already described in material and methods 
section (3.7) it will be only briefly reported here. This technology has its origins by the work of 
Pascal Mayer and colleagues (Adessi et al. 2000). Like the 454 and SOLiD platform, it is also 
based on adapter flanked libraries, which are initially clonally amplified. In contrast to the 
other methods described, the fragments are bridge amplified while they are attached onto a 
glass slide, the flow cell. The fragments remain immobilized on the flow cell while the reagents 
flow through. Elongation starts after binding of a universal sequencing primer. All four 
nucleotides, labeled with different dyes, and the polymerase are run through the flow cell. The 
nucleotides have a modified 3’-OH group which allows the incorporation of only one 
nucleotide at a time. An image is taken before the moiety at the 3’-OH as well as the 
fluorescent dye is removed from the incorporated nucleotide. As the DNA synthesis is 
terminated after adding one nucleotide but continued when the blocking group is removed, 
the nucleotides are called “reversible terminators” and the method referred to as “sequencing 
by synthesis”. Initially this process could be repeated to generate 32 to 40 bp long reads 
(Mardis 2008a). In one run 1300 Mb could be generated in 4 days (Mardis 2008a). Incomplete 
cleavage of fluorescent dyes or 3’-OH terminators can cause signal decay or dephasing (loss of 
synchronicity) which is limiting for read length (Shendure and Ji 2008). With the improvement 
of the technology, the read length could be extended. In this work we performed paired-end 
sequencing with a read length up to 80 bp. With this technology a high output per run can be 
obtained. The most common error type of this technique is substitution (Shendure and Ji 
2008).  
1.5.2 Third Generation Sequencing 
As there is always a next generation, the current generation (second generation) which we call 
now “next generation” is going to be replaced by “third-generation” sequencing technologies. 
Characteristic for second generation sequencing are the clonal amplification of single 
molecules and the sequence identification by alternating washing and scanning operations. 
These characteristics are also the major drawbacks of second generation sequencing 
technologies: (1) the clonal amplification based on polymerases, introduces PCR errors in the 
template and also amplification bias (2) all the clonally amplified fragments need to be 
synchronously prolonged, if this is not the case we see dephasing, especially at the end of a 
read; for this reason the read length is limited (3) the “wash-and-scan” technology takes time 
and requires large amount of sequencing reagents. By sequencing a single molecule without 
“wash-and-scan”, third generation sequencing will overcome these drawbacks.  
The Ion Torrent sequencer is one of two technologies on the edge of second and third 
generation sequencing technologies. Instead of using cameras this technology measures the 
pH change as a result of hydrogen ions during DNA synthesis. Similar to the 454 technology it 
also has problems with homopolymers and it still uses clonally amplified DNA molecules in the 
individual sequencing reactions. The first commercial available technology that can image 
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single DNA molecules is the Helicos Genetic Analyser Platform. Both Ion Torrent and Helicos 
machines still use a “wash and scan” technique. Third generation sequencing strategies 
overcome “wash and scan” and they are based on single molecule level, they can be 
subdivided into three categories: (1) observation of a DNA polymerase how it synthesizes DNA 
in real-time (sequencing by synthesis) (2) individual detection of bases as they pass through a 
nanopore (nucleotides cleaved of by endonuclease) (3) direct imaging of individual DNA 
molecules for example by transmission electron microscopy (Schadt et al. 2010). Most of these 
third generation sequencing technologies are still under development but might have the 
potential to replace the technology we currently use.  
1.5.3 Data Analysis 
The technical progress in NGS sequencing technologies is revolutionizing cancer research. At 
the same time these new technologies produce an overwhelming flood of data providing 
computational challenges: (1) Availability of computational power and processing speed to 
deal with the quantity of data. (2) Alignment and assembly of short reads to the reference 
genome. (3) Simultaneous analyses of matched tumor and non-tumor samples to identify 
cancer related variants.  
With the development of NGS techniques also a variety of data analysis tools were developed. 
For each approach, the appropriate tools need to be selected and combined to generate an 
analysis pipeline to produce valid results. The hundreds of millions of sequence reads 
generated by a NGS platform need to pass several quality controls and they need to be 
mapped to a reference genome prior to variant calling. Variants can be detected with one of 
the numerous variant callers that have been developed so far.  
1.6 Aim of Project 
It was the aim of this work to identify novel genetic lesions in 25 well-characterized CLL relapse 
samples using next-generation sequencing technologies. For this purpose, an exome 
enrichment strategy was established in the laboratory. In addition, a bioinformatics analysis 
pipeline was set up to detect single nucleotide variants (SNVs), small InDels and to derive 
quality measurements like exome enrichment efficiency, coverage and sequence quality. 
Candidate genetic lesions identified in the NGS experiments were validated using Sanger 
sequencing. 
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2 Materials 
2.1 Reagents 
Reagent Company 
  
Agencourt® AMPure® XP beads 
Bromphenol blue 
Beckmann Coulter, Brea, CA, USA 
Roth, Karlsruhe, Germany 
ddH2O Millipore, Eschborn, Germany 
dATP NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
DNA-molecular weight marker VI Roche Diagnostics, Mannheim, Germany 
dNTP mix 10mM each NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
Dynabeads MyOne Streptavidin T1 Invitrogen Dynal, Oslo, Norway 
Ethanol Merck, Darmstadt, Germany 
Gel Red™ Biotium, Hayward, California, USA 
Isopropanol Merck, Darmstadt, Germany 
Magnesium chloride (MgCl2 25 mM) Roche Diagnostics, Mannheim, Germany 
Nuclease free water Ambion, USA 
Oligonucleotides  Metabion, Munich, Germany 
Orange G Sigma-Aldrich, Steinheim, Germany 
PE Adapter Oligo Mix Illumina, San Diego, CA, USA 
PE-PCR Primer 1.0 Illumina, San Diego, CA, USA 
PE-PCR Primer 2.0 Illumina, San Diego, CA, USA 
3100 POP6™-Polymer Applied Biosystems, Foster City, CA, USA 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
Potassium dihydrogen phosphate (KH2PO4) Merck, Darmstadt, Germany 
Q-Solution Qiagen, Hilden, Germany 
RLT buffer Qiagen, Hilden, Germany 
Sodium acetate anhydrous (NaOAc) Biomedicals, Illkirch, France 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
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Reagent Company 
Sodium hydrogen phosphate 
(Na2HPO4*2H2O) 
Merck, Darmstadt, Germany 
Sucrose Sigma-Aldrich, Steinheim, Germany 
Ultra Pure™ Agarose Invitrogen, Carlsbad, CA, USA 
Water for on-line analysis (sequencer) Merck, Darmstadt, Germany 
2.2 Enzymes  
Enzymes Company 
  
F&P Super-Polymerase Bio&Cell, Feucht, Germany 
Herculase II Fusion Enzyme with dNTPs Agilent Technologies, Santa Clara, CA,USA 
Klenow Fragment NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
Klenow Fragment (3’→5’ exo-) NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
T4 DNA Ligase NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
T4 DNA polymerase NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
T4 Polynucleotide Kinase (PNK) NEB, Ipswich, MA, USA 
 (NEB Next DNA Sample Prep Reagent Set1) 
2.3 Kits  
Kits Company 
  
Agilent DNA 1000 Assay Agilent Technologies, Santa Clara, CA, USA 
Agilent High Sensitivity Assay Agilent Technologies, Santa Clara, CA, USA 
Big Dye® Terminator v1.1                          
Cycle Sequencing Kit 
Applied Biosystems, Foster City, CA, USA 
cBOT paired end cluster generation kit Illumina, San Diego, CA, USA 
CENTRI Sep8 well strips Princeton Seperations, NJ, USA 
QIAamp DNA-mini kit Qiagen, Hilden, Germany 
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Sure Select Human All Exon 50 Mb (V3) Agilent Technologies, Santa Clara, CA, USA 
Taq PCR Master Mix kit Qiagen, Hilden, Germany 
Tru Seq SBS Kit V5-GA (36 cycles) Illumina, San Diego, Ca, USA 
The flow cell for next generation sequencing is included in the cBOT paired end cluster 
generation kit as well as all buffers and enzymes for cluster generation. The TruSeq SBS Kit V5-
GA (36 cycles) includes all enzymes and buffers for sequencing on the Illumina Genome 
Analyzer IIx. All cBOT and Genome Analyzer runs were performed by Stefan Krebs at the Gene 
Center in Munich.  
2.4 Buffers and Solutions 
Name Components  
AE buffer 
(Qiagen) 
 
10 mM 
0.5 mM 
Tris-HCl pH 9.0 
EDTA 
Bromphenol blue loading dye for marker 15 g  Ficoll 
 0.1 mg Bromphenol blue 
 ad 100 ml ddH2O 
   
DNA molecular weight marker VI 200 µl (50µg) Marker  
 800 µl  ddH2O 
 300 µl  Bromphenol blue 
loading dye 
   
1x Ligase buffer 
(supplied with NEBNext DNA Sample Prep 
Reagent Set1 for adapter ligation) 
66 mM 
10 mM 
1.0 mM  
1.0 mM 
7,5 % 
Tris-HCl pH 7.6 
MgCl2 
DTT 
ATP 
Polyethylene 
glycol 
   
1x NEBuffer 2 
(supplied with NEBNext DNA Sample Prep 
Reagent Set1 for Klenow Fragment 3’→5’ exo
-
) 
50 mM 
10 mM  
10 mM 
NaCl 
Tris-HCl pH 7.9 
MgCl2 
 1.0 mM DTT 
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Name Components  
   
Orange G loading dye, 5x 
(for agarose gel electrophoresis) 
10 g  
50 mg 
Sucrose 
Orange G 
 ad 50 ml ddH2O 
 
 
  
 
1x PBS (Phosphate buffered saline) 136 mM NaCl 
 2.5 mM KCL 
 10 mM Na2HPO4*2H2O 
 2.0 mM KH2PO4 
  Aqua bidest 
  Autoclave 
   
1x Phosphorylation reaction buffer 
(supplied with NEBNext DNA Sample Prep 
Reagent Set1 for generating blunt ends) 
50 mM 
10 mM  
10 mM 
Tris-HCl pH 7.5 
MgCl2 
DTT 
 1.0 mM ATP 
   
5x Sequencing buffer  
(Supplied with BigDye Terminator v1.1) 
400 mM 
10 mM 
Tris-HCl pH9 
MgCl2 
   
10x TBE (Tris-Borate-EDTA) buffer 1.0 M  Tris  
 0.9 M  Boric Acid 
 10 mM EDTA EDTA 
 
Purchased from Invitrogen and diluted 1:10 
with dH2O for gel electrophoresis 
   
1x TE (Tris-EDTA)buffer 1.0 mM  Tris pH 8.0 
 1.0 mM  EDTA 
 Purchased from Invitrogen 
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2.5 Oligonucleotides  
Oligonucleotides used for validation sequencing and screening of genomic DNA were designed 
either with the programs ExonPrimer or Primer 3 plus. ExonPrimer is a Perl script written by 
Tim M. Strom (Institute of Human Genetics, Helmholtz Center Munich). It is linked to the UCSC 
Genome Browser in the section “Sequence and Links to Tools and Databases” on each gene 
description page. The design algorithm for the oligonucleotides is based on Primer 3, an open 
source primer design tool (Rozen and Skaletsky 2000). All primers were designed with an 
annealing temperature between 60 and 63 °C. A second UCSC based tool called In-Silico PCR 
was used to verify that there was just one, unique amplicon for each pair of primers.  
2.5.1 Oligonucleotides for Validation of Single Nucleotide Variants 
Oligonucleotide Patient Sequence (5’→3’) Product Size (bp) 
ABCC10-324F P1 CAGTGTTCTTACTTAGGGCATTGTC  
ABCC10-324R P1 AAACAAGCAGCCAGCACCTC 303 
ARHGEF17-320F P1 GATGGGACAGTGAAGCCTCC  
ARHGEF17-320R P1 AAGTCTGCGTGTGGGCTAGG 336 
C1orf27-319F P1 GTCTTTTGATCAAGGGTTTAGCC  
C1orf27-319R P1 AGCAGAATAAAAGCAGATTGTTCAC 347 
CHD2-14F P1 TTTGACAATTTGCATGGCTC  
CHD2-14R P1 ACATGAATGAACAGGCACCC 312 
DMP1-18F P1 CAATAATGAAATCCATCTGTGAGG  
DMP1-18R P1 AACATCATTTCCTTCCATTCC 378 
FAR2-15F P1 CCCATTACAAATGCTTTCCA  
FAR2-15R P1 TGGATTTTCAGATTAGGTGTGTTC 399 
FOLR4-321F P1 CCCTAGACACTTGCCGATCC  
FOLR4-321R P1 TTAATATAATAACAGGGCATGGCAC 314 
GRHPR-13F P1 ATCTGGTTGTCCCTAGCCTG  
GRHPR-13R P1 CCACTGCTGAGAAGCAGACAG 416 
IL28A-21F P1 CTCACACCTGCTCTCCCTTC  
IL28A-21R P1 GACGCTGCTCAGAGCTCAC 355 
PCDHGA4-322F P1 ACCACACCCGGCTGCTC  
PCDHGA4-322R P1 TACCCGGGGAAGAAGATTCC 1065 
RUFY1-323F P1 GCTTGTTGCTCTGGTTGCTG  
RUFY1-323R P1 CTCCTAAATGGCCCACCCTC 601 
ACOX2_29aR P2 TCCTTGAGGGAGCATTATGG  
ACOX2_29F P2 AGCAATGCACAGGTCTTCCT 196 
ADAMTS12_30F P2 CCCTGCTTTCTCAGTGGTTG  
ADAMTS12_30R P2 GAAGGCAGGGGCTGATG 348 
CDH12_25F P2 CCTGGATTCCACAATTCTACG  
CDH12_25R P2 AAATACACAATGCATATTCCCC 360 
CREBBP_325aF P2 CTGTTTTCGCGAGCAGGT  
CREBBP_325aR P2 TGCTCCGAGCTCCCG 220 
METRNL_327F P2 TCCTCACTGACTCTCTGTGGGTG  
METRNL_327R P2 ATCACCAGCCCCGTGATG 522 
OR4A47_369F P2 GGTGATGGCCTATGACTGCT  
OR4A47_369R P2 CTTTTTGCCTCCCTTTCTGA 359 
PAPD5_22F P2 TGAGTGTCAGTTAAAACAAGTTTCC  
PAPD5_22R P2 TGCAACTGTGCTCACCAAAC 274 
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Oligonucleotide Patient Sequence (5’→3’) Product Size (bp) 
RB1_24F P2 AGACAAGTGGGAGGCAGTGT  
RB1_24R P2 GCAAGAAAAGATTATGGATAACTACA 341 
SRD5A1_326F P2 CCAGGTAAGTATTCACTAGCATCTCTG  
SRD5A1_326R P2 CACAGAATAAACTGGAATTCAGCG 351 
TCHHL1 _23F P2 AAGCATCTGAACACAATGATCC  
TCHHL1 _23F P2 TTTGTTTTAGCTGGTGTCTGG 532 
ZNF227_370F P2 CAGTCAGGCCATAGATTTTCG  
ZNF227_370R P2 GATGGCGAAGATTCAAGCTC 278 
ATXN2L_35F P3 GTGCTCCCTAACTCTGGCTC  
ATXN2L_35R P3 CTCCAAGACCCCTCACTCC 421 
C2orf67_82F P3 GCTCTACATGGAAAGTCCCAGA  
C2orf67_82R P3 TGGGCTCCCCTAATTTCTTT 233 
EBF2_331F P3 CACATGTGGCCTGACTGTGC  
EBF2_331R P3 AACTTTCTCCCAAAAGGCCC 325 
MAGI2_34F P3 TCATTCTCTCACCACCAGCC  
MAGI2_34R P3 CACCCTTTCATTGCCCTG 441 
MED12_38F P3 TTCCTTCTTTTCTCCTGCCC  
MED12_38R P3 TCAGCCACTTAGGTTGTCCC 291 
RPS6KA3_37F P3 GATAATTTTGCTATTCCTTTCACG  
RPS6KA3_37R P3 GCAGAGATGTGAAGCACAGG 391 
SCUBE2_33F P3 GAGGCCAGATCACACATGG  
SCUBE2_33R P3 TGGCCACTGCAAGAGCTAAG 253 
XPO1_42aF P3, 4, 14, 15 TGAACAGAAAAGAGGCAAAGAT  
XPO1_42aR P3, 4, 14, 15 TTCATTTATTTTGTCCTGGACTC 249 
ADAMTS20_40aF P4 GCCAAGAAACGGAGGAAATTA  
ADAMTS20_40aR P4 AAAATTTACATCAAAGAACCAGCA 218 
CCDC111_49F P4 GAGTCCCCTGATCCATTCTG  
CCDC111_49R P4 TTCTGTACCCTTACATTTTGATAGG 734 
CSF2RB_44F P4 GTGAAGTCAGGGTTTGAGGG  
CSF2RB_44R P4 ATGACTGAGGAAGGTCAGGC 492 
CYB5D1_50F P4 AGTACGTGCTGAGGAGCAAAG  
CYB5D1_50R P4 ATCCCCGCTCTCCATTTC 458 
CYFIP2_41F P4 AACATCTGCCAGGACTCCAC  
CYFIP2_41R P4 GCAAACTTTGTTTATGTCAAACC 280 
EMR2_43F P4 TCCTGTCCTGTTGTGTTCCA  
EMR2_43R P4 CAGTGGTGATGGAGGATGTG 210 
GRM6_45F P4 ATGTGGTGAGGACTGTGTGG  
GRM6_45R P4 CGAGGCAAGAGGAAGAAAGG 329 
PPP1R1B_333F P4 CAGGACAGCCGGATGGATAC  
PPP1R1B_333R P4 GGATAGAGTGGGTTTCTGGGG 387 
RBPMS2_47F P4 AAGGAAGCGCTGTTGTCATC  
RBPMS2_47R P4 CGAGATTCACTCCCGCTG 216 
SF3B1_48F P4 GTTGATATATTGAGAGAATCTGGATG  
SF3B1_48R P4 TTTAAAATTCTGTTAGAACCATGAAAC 536 
ARHGEF5_385F P5 CCCTGCCTCTCCTAACCTCT  
ARHGEF5_385R P5 AGCTGCAGGAAGTGAACACA 227 
BRDT_79F P5 TGGCAGTTTTTAAATGTTCCTG  
BRDT_79R P5 GTGCTCCCATCAACAGAGGT 249 
CAPZA3_56F P5 GGAAATTGCAACATGCTGAG  
CAPZA3_56R P5 AGGAAAATAACCATTCCCAAG 560 
IFT52_57F P5 TTGATTTAATTCTCTAGTCCTGACC  
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IFT52_57R P5 TGGTACTGAGAAGCTGGACTC 209 
KAT5_55F P5 AAGCTCCTGGTTGACCCTG  
KAT5_55R P5 CTGTGAGGCACCGATAGTGG 450 
MYH2_386F P5 TGCAGTATTAACAGTAAGCGTGTGG  
MYH2_386R P5 GGAAAATTCCTGGGTAACAAGTTAAG 279 
MYH7_76F P5 CCTGTCCTGTGCTCTTCCTC  
MYH7_76R P5 CCCTCACTGCCAATCCTC 250 
PCLO_53bF P5 GCAGCAGAAAGGAAGAGAGC  
PCLO_53bR P5 TCTTCATAGGCAGCATCAGC 249 
TIAM2_77F P5 AGAGACTGCAACGGACACCT  
TIAM2_77R P5 AGTCCTCTGCAGGCACTTTG 181 
TRIML1_387F P5 CAATGGAAATCTCACATACCTAAGAGG  
TRIML1_387R P5 GTGACGAGACCCAGAGGCTG 398 
GRK7_86F P6 GGGAGACCTCAAGTTCCACA  
GRK7_86R P6 CTTGCCACCCTTCATCTCC 217 
KIAA1843_84F P6 TCTGTGAGTCCATCCTGCAC  
KIAA1843_84R P6 AAAGGATGCCATGCTAATTTTT 249 
KLRC4_85F P6 CCCCTCTCTCAGTGCCTCTT  
KLRC4_85R P6 GAAATGTTTCAAGGCGCTTC 202 
ANKS1B_60F P7 GTTGCTTCAAAAGCGACTCC  
ANKS1B_60R P7 ACACATTCCATTCCCAGACA 485 
BAZ1A_66F P7 AACAGCCACATGGAGTAATTG  
BAZ1A_66R P7 TGACCAAAATTCTGGACCAAG 292 
BMP2K_71F P7 CCAATGTGAAAGGAAGGAAC  
BMP2K_71R P7 TAATGACCGACCATTCAACG 353 
C12orf51_335F P7 AGGGAAACAGTGATGCCTGC  
C12orf51_335R P7 CATTCTGATTTTCATCCAGCTCC 264 
COL18A1_336F P7 AAGCATGTCCCACCCTCCTC  
COL18A1_336R P7 TCTCAGGGACACTCTCCTGC 238 
FRAS1_61F P7 TGATAATTTAGCCTCCAGTCTCC  
FRAS1_61R P7 CCTCAAAACAAAGAGTGCACAG 397 
KIAA2022_63F P7 TGTTCAATGATGAGGATTCTGTC  
KIAA2022_63R P7 TGGAGGCCATCATGAATCTC 594 
KLHL6_64F P7 CTCAGCTCCTGCAATGGG  
KLHL6_64R P7 TCAAGATTGGGCTCTCACAC 424 
KLHL6_74F P7 AGTGGTTAAGAGGGAAGAAACC  
KLHL6_74R P7 GGACTGGAGGAGGGTGAGAG 441 
LIMD1_73F P7 GACCCTTCGCCAGCATC  
LIMD1_73R P7 AGGAAGGATCCTCACAGGG 650 
LRP1B_69F P7 GAGTGGGAGTATCATTTGAGCC  
LRP1B_69R P7 AAGCAAAGAGGGAAAGGAAAG 535 
MARCH6_67F P7 TTTCTGGGGCCCACTTTAG  
MARCH6_67R P7 CAGCCTGCTTGAGAACTGG 338 
NBPF4_72F P7 CTGTGTGGCGTGGGTCAC  
NBPF4_72R P7 GGTTGGAGCATCATGGATTT 489 
NOX1_337F P7 CGCAACCACTGTCTGGAGC  
NOX1_337R P7 CCTCCACCTCCAACCTCAAAC 577 
OTUD7B_70F P7 AAGGGTGGCAAGGAGGAG  
OTUD7B_70R P7 AGGTGGCATATGGTGGTAGG 511 
ROBO1_62F P7 GCCTTCAGGTAGAGTGAAGGAG  
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ROBO1_62R P7 TGTCAGTGCAATTATAACATCTAAGG 324 
UNC13C_68F P7 TTACAGTGATTCTCAGCTCTCTTTAC  
UNC13C_68R P7 TGTGGTACTTGACTCATTTGCAG 616 
ANKFN1_339F P8 GACGCAGGGCAAGGAAGAG  
ANKFN1_339R P8 CTAAAATTACCGGCGCCACC 237 
CELSR3_252F P8 CAGAACCCCGTCATGAACTC  
CELSR3_252R P8 GGACCAAGGGTTTCCAGAAT 193 
DIO2_338F P8 AGAGGGTGAAGGGGAACCAG  
DIO2_338R P8 CTGGTCCCCAGCATATGAGC 344 
DOCK10_244F P8 CATATTCTGATATGGAATACTGACTCG  
DOCK10_244R P8 CCTCCCTCATGTGGTCATCT 178 
FREM2_250F P8 CGTCATCCAAGATGGTCACA  
FREM2_250R P8 GGGAAAATGGCAATGACTGA 162 
GRIA2_246F P8 GAAAGATGAGATTTGTTCATATTGTG  
GRIA2_246R P8 TTGGACTTCCGCACTCTAGC 238 
LRFN5_247F P8 CCTTCCTGGACTTCAAGCAC  
LRFN5_247R P8 GGATCTCTCAGCAGGCAAAG 240 
LRRC7_241F P8 TGGTGACAAGCCATCAGATAA  
LRRC7_241R P8 TTCATGCTTCACTACATGTGCTT 224 
MYO6_249F P8 AACCTCTTTGATAGACAAATGGTATT  
MYO6_249R P8 CTTCAGAAGCACCAGCACAC 233 
PASD1_243F P8 CCACGTGAGTGTCTCATCAGTT  
PASD1_243R P8 GGAAACTGAGGAATGCTGGA 170 
PDE1C_340F P8 GCTTTGAACAGAGAGCTCCAAC  
PDE1C_340R P8 TTGGAAACGTGTTGCTTTGG 308 
RBM46_253F P8 ACTATGGGGCCACACCATT  
RBM46_253R P8 TCAACTGCACCAGGCTTAAA 165 
TNFAIP3_242F P8 GAGAGCACAATGGCTGAACA  
TNFAIP3_242R P8 GGATGATCTCCCGAAACTGA 202 
TNS3_245F P8 TCCGGTTAATTGTCTCCACA  
TNS3_245R P8 CAGCAAGGACCACCCAGTAT 152 
TTN_240F P8 GGCAGCCCTATCATTGGTTA  
TTN_240R P8 CACATCACTGGGGTCACTGT 186 
ADAM8_97F P9 CCCAAGAAGGACATGTGTGA  
ADAM8_97R P9 CTTGCAGCCTGGTAGGATGT 294 
ADAMTS14_99F P9 TGGGTTGGACCTCACTCTCT  
ADAMTS14_99R P9 AGGACACATGGACACTCACG 247 
AMHR2_341F P9 GCCTCTGCATTCACTCCCAC  
AMHR2_341R P9 CACACCCCAGGATGTGTCTG 301 
ARSK_93F P9 CACCCTGGATTCTGAGTGAA  
ARSK_93R P9 TCCTAGCATGAGAAGCAGCA 247 
ASH1L_92F P9 TTGGAGGATTCACTCCCAAC  
ASH1L_92R P9 CCCTCTTACCTGCCAAAGTC 231 
DNAH5_344bF P9 GGGTGAGACGATTGAATTGG  
DNAH5_344aR P9 TTTCCTGTATTTTAATGCTGAATCT 177 
MRO_91F P9 CTCGGCCTTTGTTTTGTTTG  
MRO_91R P9 TAGGGTCTGGCGTCTCAACT  219 
MYH2_371F P9 CTGTGTCACTGTCAACCCCTA  
MYH2_371R P9 GGGACGATCTCAAGGAATGTG 240 
PTPRT_96F P9 CAGAGGGGGAAAGTGTTCAA  
PTPRT_96R P9 TCCACTTCAAGGAAAATCAGG 222 
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SCD5_98F P9 AAGCTCAGGGACCATTGTTG  
SCD5_98R P9 TCTTTCCCCTCCTCCCATAC 246 
SCRN2_343F P9 CCATCCAGGTGGGAAGAATG  
SCRN2_343R P9 TCCTTCATATTTCCAGAGTCCCAC 350 
SIPA1L1_95F P9 CCTTGGTCTCTGGACCTCTG  
SIPA1L1_95R P9 GGAGGCACTTTCACATCCAC 230 
SKIV2L2_94F P9 CTTCTGGGCTACGAGAGACA  
SKIV2L2_94R P9 GGTGGGACTTAAAATCTCAAAGA 398 
TOP2A_90F P9 TGGCTCGATTGTTATTTCCA  
TOP2A_90R P9 TGGCAAAGGTTCTTCTCCAT 224 
AKR1C4_104F P10 TTTCGTTGCTCCTTCAGGTT  
AKR1C4_104R P10 TCATCTCCACACAATCCCATT 244 
COL5A2_106F P10 CACCTACCATTCTTTGGGAAA  
COL5A2_106R P10 AAATGTTCGTGTCAAGATACCC 376 
ERCC8_103F P10 TGGGTGAGGGGTACAGTCAT  
ERCC8_103R P10 TGCGTTTATTATGTGGCTTCA 249 
KIF9_382F P10 TCTTGCCCCAGTGGATTCAG  
KIF9_382F P10 TGCAAAGGTCTGAGGATGGG 217 
KLRC2_373F P10 AAGCCTGTAAGGATGCGTAA  
KLRC2_373R P10 CAAATGTATTATTCACTGAAGGAAGC 333 
PRKCA_105F P10 CCAGTTCCAAAGCAAACCAT  
PRKCA_105R P10 TGGGGCGATATAATCTGGAG 201 
RANBP2_102F P10 GGAAAGCTGGGCTTTAGGAT  
RANBP2_102R P10 CAAATGTTCTGCTTTCTTCAGTG 300 
ARMC4_109F P11 GGCAGCCTTTTTAGCATCAT  
ARMC4_109R P11 GGCATTAAATGACAAGAAGGTGT 299 
ATM_115F P11 AAGGTCCTGTTGTCAGTTTTTCA  
ATM_115R P11 GGCTGAGATTTTTGGGGTCT 241 
EGR2_346F P11 CCTCGCAAGTACCCCAACAG  
EGR2_346R P11 CAGCTCCAGTGGACAAAGGG 529 
FAM179A_113F P11 TGGGGACAGGTATTTTTGGA  
FAM179A_113R P11 CTACCTGGTGTCCTGGTTGG 295 
GPR61_345F P11 CCAGGGTCGCTGGACTAGG  
GPR61_345R P11 ACACACCCACCAGCACAGAG 570 
KCNJ5_112F P11 ACTGGATGGGTGGACGATTA  
KCNJ5_112R P11 TTCATTTCTGCCAGCTCCTT 746 
MRE11A_110F P11 GCATAAACACTGTGAATACTGAAGG  
MRE11A_110R P11 TTCCCACTGTCAATTTGTTTAAGA 356 
NRBP1_111F P11 CCTGGCCTGACATCAGTGT  
NRBP1_111R P11 AAATCCTCCATTTTAACACTCCA 285 
SLC2A2_347F P11 TCAGGGAGGGGCTTTCATTC  
SLC2A2_347R P11 TGGAGGAAGTACAGTAGGGGATG 316 
ZFP161_108F P11 AACGCCTGGAAGGAGAATTT  
ZFP161_108R P11 TGTCAGCAGCATCTCCAATG 387 
ABCA9_121F P12 GACGGCTTTGTTTCTCTGCT  
ABCA9_121R P12 CCACCCCTAGACACTGTTTCA 296 
ACSM2_407F P12 AGTGAGGCCCCTAGGATTGT  
ACSM2_407R P12 CGTTCCCATGTATCCTGGTT 187 
ADAM17_125F P12 TTGAAAGTAAGGCCCAGGAG  
ADAM17_125R P12 CCAAAATCCCTGTGGAGAGA 188 
CASP6_131F P12 CCTTTGGATGTAGTAGATAATCAGACA  
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CASP6_131R P12 TCTGTGAGCTTCAGGATGGA 250 
CDH12_124F P12 CAAGGCCACAGATGCAGAT  
CDH12_124R P12 CGCACTGAAGCTTTATGGCTA 214 
CTAGE5_348F P12 AACATGGCATTTTGGAAACTAGAG  
CTAGE5_348R P12 GGCAACACAGCCATGCTAATTC 301 
FLNB_130F P12 CATACCTGGGTCTCCCTTCA  
FLNB_130R P12 GGGAAGTGTGGCACGAGT 300 
KIAA0240_118F P12 CCAGGGCTCAGTAGTTGGTC  
KIAA0240_118R P12 CTTCCAGAGGCAGCAAATGT 399 
KIAA1586_122F P12 TGATTCAATTTGTAATTTAGTGCAT  
KIAA1586_122R P12 TCTTTGAAACTGTAGATGCCTCAT 296 
KIAA1712_123F P12 TTCCATCACAACAAAGAAAGAAAA  
KIAA1712_123R P12 TCATCAGGTGCCAATCAGAA 213 
LGR5_120F P12 TGGATGCTAACCACATCAGC  
LGR5_120R P12 GAAACTGTTAAAAGAGAGCAAAATCA 248 
PACS2_132F P12 AGAGAAAGCCCTTCAGAAACC  
PACS2_132R P12 CAGGACTCAGGCCTCTTGAC 500 
PAM_126F P12 AGGGTGCAGAACATGAGAGG  
PAM_126R P12 AAGTCCTTTTCATTGATGAATTTTT 273 
PRPS1L1_374F P12 CCAAGACGCCGAATATCAAA  
PRPS1L1_374R P12 GCAACAAGCTTGGCAGAGAT 343 
PTPRU_129F P12 CCTGAGCGAGAATGATACCC  
PTPRU_129R P12 CCAGCCCACCTGATATTCAT 214 
RIMS2_128F P12 GCTATCATATGAACCAAATGTAGGTA  
RIMS2_128R P12 CAAAAGAAGAAAATTAACACAAAGG 288 
RNASE2_119F P12 CAATGCAATGCAGGTCATTAAC  
RNASE2_119R P12 GGATACTGTGGAGGGTCTCG 300 
BHLHB9_140aF P13 GATTGCAATGGGTGTCCATA  
BHLHB9_140aR P13 CTGTCCCGGTGAGTTCAAAG 232 
C20orf54_146F P13 GCTAGGTGGTGAAGCTGGAA  
C20orf54_146R P13 ATGACCACCGTGAGGTAGGA 242 
FAM32A_375F P13 CTCTCCAGCAAATGGAAAGG  
FAM32A_375R P13 AGCAGAAGATGCAAGGGTGT 562 
GANC_143F P13 TCACTTGGCCTTCTTTTGCT  
GANC_143R P13 CCACGTGTGCATGGTAGAAC 250 
GTSF1_144F P13 TGTGCCTGGAATGCTGTAGT  
GTSF1_144R P13 GGAGGGTGTTAGAGGGCAAA 204 
HPSE_145F P13 TTGTGGTGCCAATCTAACCA  
HPSE_145R P13 CCATTGCCTAGTTCCCAAGA 220 
IGFN1_147F P13 CTCTGCCGTCTCTCCTGAAG  
IGFN1_147R P13 CCACCCTGAAGTGGTATTCG 248 
MYL12A_350F P13 CTTTCCAGACTCTTTAATAGGCCC  
MYL12A_350R P13 AAACTACTACTTAGGGCAGAAGCAGC 524 
OR5W2_139F P13 TTGATCGGTACAAGGCCATC  
OR5W2_139R P13 AATTGCTAGATTGTGGCTGAG 720 
ADAMTS3_159F P14 CCCACTCCAGATCTCTGTGTC  
ADAMTS3_159R P14 TTCACAGGTGTTTTCCTTTGG 371 
ARSD_160F P14 CGACTCCGAGCCCCTGTA  
ARSD_160R P14 GCATGAACAGAACGGGAAAT 164 
CCDC56_162F P14 GCGGACTACAACTCCCAGAG  
CCDC56_162R P14 GTGTCAGCTTCTCCCGAGTC 188 
2  Materials                                                                                                                                                 35 
 
 
Oligonucleotide Patient Sequence (5’→3’) Product Size (bp) 
CCDC85A_157F P14 GAGCACTCCAAGCACAGGA  
CCDC85A_157R P14 GTGCTTGGGCAGCGTTTC 186 
COL4A3_164F P14 GGAAAGTTGCTGATGTGGAGA  
COL4A3_164R P14 AAATTTACCCTTAGGTCCAGGAG 158 
FLNC_155F P14 CATCGTGAACACCCTGAATG  
FLNC_155R P14 CACCGTACTTGATGGCAATG 158 
FUBP1_156F P14 GCCGCCATTTTCTTTCTTTC  
FUBP1_156R P14 GCCAATTACCGTGAGCTTTC 247 
GRIK1_376F P14 ACAGAAACCGAACCCTGATG  
GRIK21_376R P14 CGACCCATTTGCACAAAGAT 204 
OR2L8_151aF P14 GCAGCACCCACCTCACTGTA  
OR2L8_151aR P14 CCTGAGACCTTAGGCAGAAAGTG 247 
OR5J2_153F P14 TGTGTTTCGGAGTGTTCATCA  
OR5J2_153R P14 TCACAGAAGAAGTGGCTGACA 235 
PLS1_150F P14 TTTTGTGTTATTGGTAAAATGATGAAA  
PLS1_150R P14 CAATGAATCAGTGACTAAAAGATCAAA 345 
SLC6A11_154F P14 AGCAGAGAGAGGGACCTTCC  
SLC6A11_154R P14 AAAGATGGCCACGAAGAGAA 171 
SLC6A5_152F P14 GGAGATGCATGGACTCCTGT  
SLC6A5_152R P14 TGCAGCTCTCTTAGGTTTCCT 363 
SMCHD1_351aF P14 TTGCAGGCGTGATCATTTTA  
SMCHD1_351aR P14 AAAGCACAAGCTCGTGAACA 388 
ZNF512B_158F P14 TCCTGAAGGCTGACAGGTCT  
ZNF512B_158R P14 TTCCACCTGCCAGATTTTTC 193 
DNAH7_171F P15 AAATTGCCATGGATGGTCTT  
DNAH7_171R P15 CGATAACTGAGAATTTGTCCATCTT 166 
FLJ32682_180F P15 CCTTCTTGACTGTCCCGTTG  
FLJ32682_180R P15 GGCAATACTCGAGCCACAAT 238 
ITIH4_353F P15 GCTTGCTGTGGGATCTGGG  
ITIH4_353R P15 GTGTCATCCACAGGCAGCAG 694 
KRT20_174F P15 GGCAACAGAGCAAGATTCTG  
KRT20_174R P15 GAACCGTGCTTCCTTTATCAAC 285 
KRT4_178F P15 CTAACCCAAGGAAAGCTGGA  
KRT4_178R P15 GTAGGTGGCGATCTCGATGT 287 
L2HGDH_175F P15 CCCTGTTTCTCTTGTTCTGTAGC  
L2HGDH_175R P15 ATGCCATACCTTGCCACACT 183 
MYEF2_176F P15 TGCATGTGAAAATGGTGAGTT  
MYEF2_176R P15 GGCACAAAAACAAAGTGTTGC 280 
PCLO_354F P15 CAGCACATGCAGTGACATTGG   
PCLO_354R P15 AAAGAAGCCACATTTTCATCCTG 605 
RBM25_177F P15 TGTGCTATGCACTTTAGGAGC  
RBM25_177R P15 TCTAAACATGTTCATTGGTGAATC 511 
SF3B1_352F P15 TCTGCTGACAGGCTATGGTTC  
SF3B1_352R P15 TGAAGAGAATACTCATTGCTGATTACG 725 
SLIT2_172F P15 AAAGGTTATCCTCTTCTCCTTCC  
SLIT2_172R P15 AAAACTGAGGCCAGTAATGATTC 292 
XPR1_173F P15 CCAATTAGTGTCATCCCCACA  
XPR1_173R P15 TGTACAACCTAGCAGCCTTGG 212 
AKR1B1_355F P16 CCAGCAGGTCTGTGAAGGAC  
AKR1B1_355R P16 AATGGCAGGCAGATTGCTTC 217 
ARHGAP18_187F P16 CAGTACCATTTTCTCTGGTTTTG  
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ARGHAP18_187R P16 TGATCCACTTGAGACCTTACATTAAC 263 
ASMTL_191F P16 GGAGACGCTCCTGGATGA  
ASMTL_191R P16 CAGTCACGACTACACGCTCCT 311 
DEFB114_188F P16 CATTGTCGTGTAGCTCTACAAATATC  
DEFB114_188R P16 CCACACCTCTCTGCACTGG 519 
DOCK1_189F P16 CCCTCAAGTCTGGATGATAGAA  
DOCK1_189R P16 CAACAACTCACACGACCTCAA 340 
DST_186F P16 CTGTGAAGCACTGTGGCTCT  
DST_186R P16 CTGCCAGTTGCTCTTTCACA 315 
LAMA5_193F P16 AGCAGGCAGAGGTGCACTA  
LAMA5_193R P16 CAGGGACAACACCACTCACA 250 
OBSCN_190F P16 GCTACCCTGCTCCCAGATTA  
OBSCN_190R P16 TGTGCCACTGTGTACCAAGG 336 
DNAJC13_194aF P17 GCACATGGGACTGCTTATGA  
DNAJC13_194aR P17 TCATCCACGTGGCACTTCTA 238 
GRIN2A_357aF P17 TCCGACGTCTACCTTCTTCC  
GRIN2A_357aR P17 GAGAACAGCCTCGTCTTTGG 298 
ICAM5_356F P17 GATAGTGCATGTCAAGTGCTTAGG  
ICAM5_356R P17 CCTTCGCATTCCTCTGGTCC 418 
LAMA1_358F P17 GAAGGGAAAGGGAAACCTGG  
LAMA1_358R P17 TTCAATACCCAGGAAACTACTGTGG 312 
SLC26A5_380F P17 TGCTGTGGGTCATAACTTCCTG  
SLC26A5_380R P17 AAAATTCCTTGTGAAGTAGGCAGTATC 464 
DUSP13_205F P18 ATGGACTCACTGCAGAAGCA  
DUSP13_205R P18 CCACTCCTAACGTGGGTCTT 199 
GPC6_198F P18 CCTGCGTACGTCCTTGTGTA  
GPC6_198R P18 GTGCCAGGAGAGTCTTCCAA 282 
PDE2A_359F P18 CAGGTTGAGATCCCCTGACC  
PDE2A_359R P18 AGCCCTAGCCAGCCTCTCAG 578 
SIAH3_443F P18 TTGAACATCAGGGGAGTGGC  
SIAH3_443R P18 TCCTGTTTCCTCAGCACCAAC 463 
ADAMTS13_211F P19 CTAATGGGGTCTGGCTCTTG  
ADAMTS13_211R P19 CTGGTGAGCCTGGAAGACAT 270 
APOB_206F P19 AGGGAAAATCAAACACAGTGG  
APOB_206R P19 AGTTGAGGGAGCCAGATTCA 396 
CHPF_216F P19 TCCAGAATACCAGCCATCTG  
CHPF_216R P19 TGCAAGTCCAGCGTGTATTC 328 
FBXO47_209F P19 TAAAAGTGGTTCCCCGTGAG  
FBXO47_209R P19 GCAGCTCCCTGTAGGTCAAT 214 
FGF14_210F P19 GGAAAACAGAAATGGGCAAA  
FGF14_210R P19 GTTGACTGGTTTGCCTCCAT 228 
IL3RA_213F P19 AGGCGTCAACAGTACGAGTG  
IL3RA_213R P19 AAATGTGAGAGGCCAACGTC 301 
KRAS_214F P19, P22 TTTGTATTAAAAGGTACTGGTGGAG  
KRAS_214R P19, P22 CCTTTATCTGTATCAAAGAATGGTC 280 
MYO18B_207F P19 AAAACTGAGCTCTCCGACCA  
MYO18B_207R P19 TGGGAGGAAGTCATCGAAGT 250 
STX17_208F P19 TGCTACACCTTCTATTGTGGAGA  
STX17_208R P19 CTGTTGCTGCTGATGCTTCT 244 
TKTL2_360F P19 CCTTCAAAGGTCGGGGTATTC  
TKTL2_360R P19 TTATCATTGACACCGTGGCG 781 
2  Materials                                                                                                                                                 37 
 
 
Oligonucleotide Patient Sequence (5’→3’) Product Size (bp) 
C3orf15_225F P20 GAGACTGCAGGAGGAGAGGA  
C3orf15_225R P20 TTCTAGGCAGCTTCCACACA 178 
CDK20_222F P20 TAGTCCTAGACCCCCGAGGA  
CDK20_222R P20 GAGCGACTGAGGGTGAGAAT 296 
HOOK1_219F P20 GATGTCTGGAAAATTGACCTTTG  
HOOK1_219R P20 AGGCTTTTACAACCCCTCCC 156 
OR9Q1_220F P20 CTTTGGTTCCATCGACTGCT  
OR9Q1_220R P20 AAGATCACCACCATGGAAGC 327 
PCSK1_221F P20 AAATATTGCAGAGCTGCCTGA  
PCSK1_221R P20 GCTCCCTATGAAATTCTCCATC 339 
SCEL_361aF P20 CCCAGCCCTCTGAGATGAT  
SCEL_361aR P20 GGGGGAGAAATAGAGAGTTCCA 227 
SF3B1_218F P20 GCTGCTGGTCTGGCTACTATG  
SF3B1_218R P20 GAGTCCAGTCTGGGCAACAT 349 
SF4_224F P20 TCATCCTCATCCTCGTCCTC  
SF4_224R P20 GAGATGCAAGGACAGCACAA 226 
USP8_223F P20 CAGCCAAGGCAAGGTTTTT  
USP8_223R P20 GCATCTCAGGTTGGGTATTGA 378 
CHRD_363F P21 CAGCTGCCGCTGGTAAAGAC  
CHRD_363R P21 TCATTCCCTCCCCAAAGGAC 582 
CXCR4_239F P21 TGAACCCCATCCTCTATGCT  
CXCR4_239R P21 CATCTGTGTTAGCTGGAGTGAAA 178 
DSP_231F P21 GCTTCTTTCTTGGAATGTGAGG  
DSP_231R P21 TTTCTGCAGGTTCTGATCCA 169 
EYS_230F P21 CTTGGGAGAAAGAATCTCTGTG  
EYS_230R P21 GCCATCATAGTTTAGAGCCACA 181 
FASTK_236F P21 GAACTGACTCCCCACGTGAT  
FASTK_236R P21 CCAAATACTCCACACGCAAA 183 
HEATR3_362F P21 TCAGTCCGGTTTTCACATGC  
HEATR3_362R P21 TCCTACACCAACAGTTCTTCTCCC 288 
MLH3_228F P21 TGGTGTCATCCCAACATCAG  
MLH3_228R P21 GAGGCTCTGATAAGAACATCTGA 177 
SCN10A_233F P21 TGCTGCAAACTGGATACCAC  
SCN10A_233R P21 AGGGACTATGCCTCCCCTTA 156 
TESK2_229F P21 TCAAACCAGAAGAGAAGTAAAATTCA  
TESK2_229R P21 CATTTCCTTCTCCTCCACCA 178 
TP53_235F P21 CATGAGCGCTGCTCAGATAG  
TP53_235R P21 CCAAATACTCCACACGCAAA 166 
TRAF3_234F P21 GAAATAAAATAACGAGTGCTGGTG  
TRAF3_234R P21 AGTCGCGAATCTTCCAGATG 231 
VEGFC_227F P21 GCTGTGGACCCCACAAAG  
VEGFC_227R P21 ATTCACAGGCACATTTTCCA 177 
ZDHHC20_232F P21 TCTCATGAGTTGCCCTCACA  
ZDHHC20_232R P21 TGCCTTCTTCAGCTCCATTC 223 
AHSG_263F P22 GTTGTCTTGCCTGGGAGGAG  
AHSG_263R P22 AGGCTTGGACAAAATGGTGG 466 
COL11A1_260F P22 GCTTGAGTAGTAACAAAATCGCATC  
COL11A1_260R P22 GAAAAGACATTAAGATGGACATGGAC 457 
CSMD1_257F P22 GTTTCACATGGCAATTCTTTGG  
CSMD1_257R P22 CATATAAGCAAAATGGGAACATGTAAG 461 
DDX3X_259F P22 ATGCTGTGTTGAAAGCCCG  
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DDX3X_259R P22 TCCTAGCAAGTTCTTTCCTGCAC 595 
DOCK4_256F P22 TCTTTGATTTCCCCTTTTCTGTTAG  
DOCK4_256R P22 AGCCACCTGCAACGTGACTG 284 
FAT3_262F P22 AACAACATCACGCTAGTGCAGG  
FAT3_262F P22 TCCCGTAGCGTCCTCGC 457 
KMO_264F P22 TGTGCGTATCATCGTGTAGATGC  
KMO_264R P22 TCAGTAATCCCAAAGTTTCAAAGC 346 
SETD2_408F P22 TTGCCAACAGTTTTGTATGGTTTAC  
SETD2_408R P22 AATCAGAAAAGCCACCTCGC 258 
TSHZ2_261F P22 GCCAACATCCTGTCGGATTC  
TSHZ2_261R P22 GAACACGGCCGATTGACATC 608 
UCHL1_265F P22 CAAGTCAGTTCAAGCACATTTCAC  
UCHL1_265R P22 GCCAAGTGCCATAAAGTCACAC 256 
WDR33_267F P22 TCCCATCTACTTCTGGTCACACTG  
WDR33_267R P22 GCAGCAGATACAGGCAAGGC 346 
CACNB1_300F P23 AACTTGCCTTGCTTTGTTGTG  
CACNB1_300R P23 CTCGCTCCCTCCCCTCC 600 
DDX43_410F P23 GGAGAATGTCTTGCTTGGGG  
DDX43_410R P23 TCTAACAATCAGATATCACTGGTTTCG 289 
HERPUD2_365F P23 TCCCTGTCCTGAAGTGGGAG  
HERPUD2_365R P23 AACATTCTTTCATCATGTTGGTCC 344 
MCC_301F P23 CCCATCTGGCTGTTTTGCTC  
MCC_301R P23 GAGCCTGGTGCTTCCAGATAAC 279 
NRAS_299F P23 ATGTGGCTCGCCAATTAACC  
NRAS_299R P23 CAGAATATGGGTAAAGATGATCCGAC 240 
PRMT1_307F P23 CAGGACACGCTGTTCTCCAG  
PRMT1_307R P23 GAAGCAGGGCATCACCCC 474 
TBCC_364F P23 CAGCGCGACGTTCTTTTGAC  
TBCC_364R P23 TGTGACAATAAGTAAACTTCGAGACCC 525 
UMOD_412F P23 AGGGAAGGATCTCTGGGTGG  
UMOD_412R P23 GGATCCGCGCACACGAG 499 
MSH6_283F P24 AACCTCTGCTTCCAGGTTCAAG  
MSH6_283R P24 ATGGTGAGTGCGTGCTCTAAAA 579 
MURC_281F P24 CCTGTTGCCTGTTATCAAGCTG  
MURC_281R P24 AAGATGTGACACTGGAAACCTCTG 587 
ZNF292_282F P24 CTCAACTGTGGAAGGCAGTGG  
ZNF292_282R P24 TTCCCATTGGCTTTGGTCTG 663 
C13orf26_366aF P25 GACCTCTCCTCCCCTGTGTA  
C13orf26_366aR P25 TGGCAAAAGCAATGTATTGTG 469 
C1orf84_276F P25 CTCCCATCCCTCAACCCC  
C1orf84_276R P25 CTCTGCAAGGTTGGAGACCC 584 
CDAN1_279F P25 GTTTGCCTCCATTCCCTTCC  
CDAN1_279R P25 GCAGCCCACTTCCTTTATTCC 540 
CDC23_368F P25 AAAGATAGTTCCTGGATGTTTGTTTG  
CDC23_368R P25 AGTGGGTGACAATCCAACCC 505 
ERC2_367F P25 CAAGCGGCACTTGACATTTTC  
ERC2_367R P25 GGATGTAGATATCTTCCAACCTGTG 583 
FAT4_270F P25 GAGATCTCTCTGCCTTTGTGGG  
FAT4_270R P25 TGAGTGGCTTAGGGAGCTGG 582 
HMCN1_272F P25 TCTGTTTATCTCACAGGATGGCTG  
HMCN1_272R P25 GGGACCCCAGTTATGTGTCC 502 
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Oligonucleotide Patient Sequence (5’→3’) Product Size (bp) 
ODZ1_275F P25 GAAGACCTGGTGCTCATCGG  
ODZ1_275R P25 TCCGTCACATTGAAAGGCAG 575 
PKP2_274F P25 CAGTATTTCTGGTCTCCTGGTTTG  
PKP2_274R P25 GCATAAGCTGAGACCGAAGCC 420 
POT1_271F P25 TGGTTCGTAGGTTGTGCATCAG  
POT1_271R P25 TGCATGAATATTGAGGCTCGTC 515 
STC1_273F P25 TGCCCATCCTCTTTGTCAGG  
STC1_273R P25 CCCTCCCAGTCTGGCTCTG 348 
VWF_277F P25 TGAAAATGCCCAGACCAGTG  
VWF_277R P25 CTCAGCCACAGCACCTCAGAT 520 
ZC3H18_278F P25 TGGAGCCAAGGCTTTCAGTG  
ZC3H18_278R P25 AGAGCTGCATGCCGGACC 399 
2.5.2 Oligonucleotides for Validation of Small Insertions and Deletions 
Oligonucleotide Patient Sequence (5’→3’) Product Size (bp) 
NOTCH1 P3 ACAGCTACTCCTCGCCTGTG  
NOTCH1 P3 TACTTGAAGGCCTCCGGAAT 205 
DZIP1L_46aF P4 GGATGCAAAGGGAATCTCG  
DZIP1L_46aR P4 GCAAGAATGGGACCCTTACA 250 
POLN_59F P5 AATTCTGGAGAATAATGGAAAGTC  
POLN_59R P5 ACCAGAAATGCCAAGGTCAC 473 
RNF219_421F P10 TTCAAACCATGTTGGCTTCAG  
RNF219_421R P10 CCAGAGATTCTGTCCTTTCCTCAC 459 
MBL2_134F P12 GAAAGGTCAGTCCTGGGTCA  
MBL2_134R P12 GGACTTTTTCCAGGGTCTCC 233 
MYST4_135F P12 CAGTAGGCAATCACCTGCAA  
MYST4_135R P12 TTGGGGGAGAGCTTTGAATA 242 
SPINK7_137F P12 TGGAGAGTGTGCTGAATCTCAT  
SPINK7_137R P12 CCTCTCGAATCCCCCTAAAC 250 
SUSD4_429F P16 CCGGACAGACTGGCTTATTG  
SUSD4_429R P16 GCTAGGCTCTTTCTCCCCTC 288 
MATN2_430F P16 TCCTACCATTCCCTTTTCCTCTG  
MATN2_430R P16 TGAGAGAGTTCCATGGTCACAG 263 
OR4A16_424F P21 CAGTCCCTGTTCTCCTGAGC   
OR4A16_424R P21 GGGGCTGCCAATAGTAGTCA 207 
CIB2_432F P22 GGAAGAAAGTCTGGGAGCCG  
CIB2_432R P22 GTGCCCCAGCCTCACCC 155 
DNAJC2_434F P22 GGGCAACAAGAGCAAAACTCTG  
DNAJC2_434R P22 GCTGGGGACACCTCACTTTG 496 
STAG2_405F P22 CAGTGCCTCATTTATTGAACACC  
STAG2_405R P22 TGTTAATTGAGATAGCACTGTAACTGG 440 
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2.6 Laboratory Equipment 
Equipment Company 
Agilent 2100 Bioanalyzer Agilent Technologies, Santa Clara, CA, USA 
Balance BP 1200 Satorius, Göttingen, Germany 
Blitz-Mikrozentrifuge Fisher Scientific, Wohlen, Switzerland 
cBOT Illumina, San Diego, California, USA 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge Biofuge pico Heraeus, Germany 
Centrifuge Rotanta 460R Hettich, Kirchlengern, Germany 
Centrifuge Savant Speed Vac Savant 
Electrophoresis power supply Gibco BRL by Life Technologies, USA 
Fridge (+4 °C, -20°C) Liebherr, Germany 
Fridge Hera freeze (-80°C) Heraeus, Germany 
Gel Jet Imager Intas 
Genetic Analyzer automated DNA 
Sequencer ABI PRISM 3100 
PE Applied Biosystems, Foster City, CA, USA 
Glassware Schott, Jena, Germany 
Horizontal 11-14 Gelelectrophoresis 
System 
Gibco BRL by Life Technologies, USA 
Microwave Panasonic 
NanoDrop® ND 1000 spectrophotometer Nano Drop Technologies, Wilmington, USA 
Pippetes Eppendorf, Hamburg, Germany 
Qubit® Fluorometer Invitrogen by Life Technologies GmbH, 
Darmstadt, Germany 
Rotator Labinco, Breda, Netherlands 
Sonicator Bioruptor Standard, Diagenode, Liège,  
Belgium 
Thermocycler T Professional Biometra, Göttingen, Germany 
Thermocycler T3 Biometra, Göttingen, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
Vortex-Genie II Scientific Industries, Bohemia, N.Y., USA 
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2.7 Consumables 
Consumables Company 
96 well plate septa (sequencing) Applied Biosystems, Foster City, CA, USA 
96 well sequencing plates for ABI 3100 Applied Biosystems, Foster City, CA, USA 
Gloves latex Semperit 
Gloves nitril Kimberly Clark 
Cyclerseal Sealing Film  Axygen, Union City, CA, USA 
Glassware Schott, Jena, Germany 
Microcentrifuge tubes 1.5 ml Eppendorf, Hamburg, Germany 
Non-skirted 96-well PCR plate 0.2 ml Thermo Scientific, UK 
NucleoFast 96 PCR plates (purification) Macherey-Nagel, Dueren, Germany 
Parafilm Pechiney Plastic Packaging, Chicago, USA 
PCR single cap 8er-soft strips 0.2 ml Biozym, Oldendorf, Germany 
PCR soft tubes 0.5 ml Biozym, Oldendorf, Germany 
PCR tubes 0.2 ml Eppendorf, Hamburg, Germany 
Pipette tips Sarstedt, Nümbrecht, Germany 
Qubit assay tubes 0.5 ml Invitrogen by Life Technologies GmbH, 
Darmstadt, Germany 
Strip caps (8) Applied Biosystems, Foster City, CA, USA 
2.8 Computer Operating System, Software and Programs 
2.8.1 Software and Programs 
Software Link/ Company Used for:  
BEDtools sourceforge.net Coverage computation 
BWA 0.5.8 bio-bwa.sourceforge.net Mapping 
Corel DRAW® 12 Corel Cartoons / Figures 
Data Collection 
Software 2.0 
Applied Biosystems Sequencing 
EndNote X5 www.endnote.com Bibliography management 
Intas sotware www.intas.de Documentation of agarose gels 
MS office Microsoft Text editing, data analysis, graph 
generation 
42                                                                                                                                                 2  Materials 
 
 
NCBI database www.ncbi.nlm.nih.gov Multiple usage 
Picard picard.sourceforge.net Summary statistics (exomes) 
Primer 3 Plus www.primer3plus.com Primer design 
R program www.R-project.org. Venn diagrams, heatmaps, 
boxplots  
SAMtools samtools.sourceforge.net Analysis of exome data 
Sequencing Analysis 
Software 5.1.1 
Applied Biosystems Base calling 
snpEFF snpeff.sourceforge.net Variant Annotation 
VarScan 2 
Graph Pad Prism 
varscan.sourceforge.net 
GraphPad Software, Inc 
Variant calling 
Graphs 
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3 Methods and Patient Samples 
3.1 REACH Study Cohort 
The REACH study, conducted at 88 centers in 17 countries was performed in concordance with 
the principles of the Declaration of Helsinki based on ethic principles for medical research in 
human subjects. This trial was sponsored by F. Hoffmann-La Roche. All patients gave written 
informed consent after adequate explanation of aims, methods, objectives and potential 
hazards of the study (Roche Protocol BO17072F). This phase III trial enrolled patients with 
previously treated CLL to receive either Rituximab in combination with fludarabine and 
cyclophosphamide or fludarabine and cyclophosphamide alone. The study showed that 
fludarabine and cyclophosphamide in combination with Rituximab improved the outcome of 
patients with previously treated CLL (Robak et al. 2010). 
3.2 DNA Extraction from Cell Pellets and Cell Lysates 
Peripheral blood mononuclear cells were isolated routinely by Ficoll® density gradient 
centrifugation. After enrichment of lymphocytes, monocytes and macrophages, cell counts 
were obtained by a Sysmex Microcell Counter (Sysmex, Germany). Either aliquots of 5 x 106 
cells were pelleted and frozen at -80 °C or the cells were lysed in 300 µl RLT buffer (Qiagen, 
Hilden, Germany; the exact composition is confidential) and stored at -80 °C.  
DNA from frozen patient mononuclear cells was prepared with QIAamp DNA Mini Kit (Qiagen, 
Hilden, Germany) for the purpose of screening, validation and exome sequencing. Pelleted 
cells were resuspended in PBS (2.4) to a final volume of 200 µl. Aliquots from RLT lysates were 
halved, one half was stored again at -80 °C and the other half was diluted with PBS to a final 
volume of 200 µl for further processing. Then 20 µl of Proteinase K was added and mixed well. 
For cell lysis, 200 µl of buffer AL was added and vigorously mixed on a vortexer and incubated 
for 10 minutes at 56 °C. AL is a guanidine based lysis buffer. For cells lysed in RLT buffer this 
step can be omitted, 200 µl of ethanol was added to the lysate and transferred to a QIAamp 
Mini spin column placed in a 2 ml collection tube and centrifuged for 1 minute at 8000 rpm. 
The flow through was discarded and the bound DNA was washed with 500 µl AW1 buffer and 
500 µl AW2 buffer by centrifugation at 8000 rpm for 1 minute and 14000 rpm for 3 minutes, 
respectively. The flow through was discarded at each step. Thereafter the column was placed 
into a 1.5 ml microcentrifuge tube, 100 µl of AE buffer (2.4) was added and incubated at room 
temperature for 5 minutes. The DNA was eluted from the column by centrifugation at 
8000 rpm for 1 minute and stored at -20 °C. 
44                                                                                                            3  Methods and Patient Samples 
 
 
3.3 Shearing of DNA by Ultrasound 
For the fragmentation of double stranded DNA (dsDNA) a sonicator (Bioruptor® Standard, 
Diagenode, Liège, Belgium) was employed, which sheares DNA by ultrasound at 20 kHz 
frequency. The principle of DNA shearing by ultrasound is based on the expansion and 
contraction of a liquid, when sound with a certain wavelength passes through it. During 
expansion, a cavity is formed which implodes at high energy and the resulting shearing forces 
fragment the DNA. For shearing, 3 µg of DNA was dissolved in 100 µl TE (2.4) buffer in a 0.5 µl 
hard plastic tube (Qubit assay tubes). Using a hard plastic tube is important to achieve the 
appropriate conditions for ultrasound transmission. Tubes were placed in the tube holder of 
the sonicator located in a water bath cooled with ice. The DNA was sheared at low power 
levels (160 W) for 3 x 15 minutes with an alternating 30 seconds “on” and 30 seconds “off” 
rhythm to prevent overheating of the samples. After 15 minutes of shearing, the ice in the 
water bath was changed to maintain the temperature. The tubes were centrifuged between 
ice changes to ensure that all the liquid was collected at the bottom of the tube. 
3.4 Quantitative and Qualitative Analysis of Sheared DNA 
3.4.1 Quantification of DNA by UV Spectrophotometry 
Using UV spectrophotometry (Nano Drop® ND 1000 spectrophotometer), the concentration of 
DNA can be measured. Nucleic acids have their absorption maximum at 260 nm. The measured 
absorbance (A) can be used to calculate the DNA concentration using the Lambert-Beer 
equation. The absorbance of 280 nm of a DNA sample gives an estimation of protein 
contamination. The ratio of A[260]/A[280] reflects the purity of the sample, which is around 
1.8 for pure DNA. As reference, buffer or ddH2O was used depending on the solution the DNA 
was dissolved in. This method was mainly used to quantify DNA for validation or screening. 
With the Nano Drop instrument, dsDNA cannot be distinguished from single stranded DNA. 
Such a distinction is sometimes critical (see next paragraph). 
3.4.2 Fluorescence-based Measurement of Double Stranded DNA Concentration 
For exome sequencing it is important to know the exact concentration of dsDNA as the DNA is 
to be sheared to short dsDNA fragments for library construction. For this purpose, a 
fluorescence-based dsDNA quantification assay on a Qubit® Fluorometer (Life Technologies, 
GmbH, Darmstadt, Germany) was used. The fluorescent dyes are specific for dsDNA and be-
come intensely fluorescent when bound to dsDNA. To measure the exact amount of dsDNA of 
a sample, the fluorometer is calibrated by two standards. The amount of dsDNA is directly 
proportional to the fluorescent signal. For each measurement, 2 µl of DNA solution was 
analyzed according to the manufacturer’s instructions. 
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3.4.3 Gel Electrophoresis 
The quality of the DNA was also analyzed using agarose gel electrophoresis. DNA is a 
negatively charged molecule. In an electric field, DNA molecules move towards the anode and 
are separated according to their size when moving through a gel matrix. The concentration of 
the agarose gel was chosen depending on the DNA size. For fragments from 50 bp up to 
3000 bp, 1.8 % (w/v) of agarose was dissolved in 1x TBE (2.4). Gels were prepared in an 
Erlenmeyer flask and boiled in a microwave oven until the solution was completely clear. 
After cooling to ≈50 °C, 10 µl GelRED™ from a 10,000 x stock solution was added to 100 ml 
of gel and transferred to a gel electrophoresis chamber. The gel is polymerized after 
approximately 20 min. Loading dye from a 5 x concentrated stock solution (2.4) was added 
to the samples before they were loaded on the gel. For sizing, a DNA ladder (2.4) was 
added. The DNA fragments were separated in the gel chamber containing 1x TBE 
electrophoresis buffer at 120 - 130 Volts (the distance between the electrodes was about 
25 cm). After 20 - 60 min, the gels were analyzed under UV light. GelRED™ is a fluorescent 
dye, which interacts with the DNA backbone and can be seen under UV light. All gels were 
analyzed and photographed with the Intas Gel Get Imager. 
3.4.4 Qualitative Analysis of DNA Libraries Using the Bioanalyzer 
To determine the size distribution of small DNA samples, 1 µl sheared DNA or genome/exome 
library was analyzed on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). The principle of separating charged DNA molecules by size in the Bioanalyzer is the same 
as described before using agarose gel electrophoresis. The major difference is that in the 
Bioanalyzer this is performed on a chip, which is a micro-channel based electrophoretic cell. 
Like an agarose gel electrophoresis, the chip is filled with a gel mixed with fluorescence dye. 
Electrodes provide an electric field, in which small molecules migrate faster than large ones 
through the gel matrix. The fluorescently labeled DNA is detected by a laser. In addition to the 
target DNA, a size standard with known DNA concentration is loaded in parallel. Additionally, 
two markers named “upper” and “lower” are loaded together with the sample DNA onto the 
chip as internal standards. The sample concentration is determined by the “upper” marker, 
which is of known concentration. The data are displayed as an electropherogram or as a gel-
like image. The advantage of this method is the very small amount of DNA needed for sample 
characterization. The Agilent DNA 1000 Assay (Agilent Technologies, Santa Clara, CA, USA) 
analyzes DNA in the size range between 25 - 1000 bp down to a concentration of ≈0.1 ng/µl. 
The DNA 1000 chips were used for sheared DNA and adapter ligated libraries. Exome libraries 
were analyzed on an Agilent High Sensitivity chip (Agilent Technologies, Santa Clara, CA, USA), 
which is sensitive to concentrations between 5 and 500 pg/µl. For each measurement, 1 µl of 
sample (sheared DNA or library) was analyzed with a Bioanalyzer according to the user 
manual. This method is very well suited to determine the fragment size after DNA shearing and 
the shift in size after adapter ligation and amplification.  
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3.5 Enzymatic Manipulation of DNA 
3.5.1 Polymerase Chain Reaction 
PCR is a well-established technique to exponentially amplify segments of DNA flanked by two 
regions of known sequence. Synthetic oligonucleotides (primers) bind complementary to the 3’ 
ends of a dsDNA fragment that is to be amplified. The first step of a PCR is the denaturation of 
dsDNA. Thereafter, the temperature is lowered for annealing so that the primers can bind to 
their targets. The annealing temperature is typically 2 - 4 °C below the melting temperature 
(Tm) of a primer, which can be calculated as follows: Tm = 4 °C x (G+C) + 2 °C x (A+T). The new 
strand is synthesized with a heat stable polymerase in the presence of dNTPs. A standard PCR 
reaction was performed using a PCR master mix (Taq PCR Master Mix Kit, Quiagen, Hilden, 
Germany) containing a Taq polymerase without proofreading activity. 
PCR reagents Volume  Final Concentration 
Taq PCR Master Mix (2x): 
5 units Taq DNA Polymerase 
2x PCR buffer 
400 µM of each dNTP 
3 mM MgCl2 
12.5 µl  
0.2 units Taq DNA Polymerase 
1x PCR buffer 
200 µM of each dNTP 
1.5 mM MgCl2 
10 µM Forward primer 1 µl 0.4 µM 
10 µM Reverse primer 1 µl 0.4 µM 
Q-Solution (5x) optional 5 µl 1x 
25 mM MgCl2 optional 1-2.5 µl 1 -2.5 mM 
Template DNA 10 - 50 ng/µl 1 µl  - 
ddH2O ad 25 µl - 
For GC rich fragments or fragments with a high degree of secondary structure for which the 
standard protocol failed, Q-solution or (Qiagen, Hilden, Germany) MgCl2 was optionally added. 
The main component of Qiagen’s Q-solution is betaine (N, N, N-trimethylglycine). This 
component changes the melting behavior of DNA in a way that GC and AT base pairs become 
equally stable (Rees et al 1993). If Q-Solution did not result in amplification, more MgCl2 was 
added to a final concentration of up to 2.5 mM. MgCl2 facilitates the binding between primers 
and template, which increases the chance to amplify difficult templates. The standard PCR 
protocol was cycled through a temperature program in a thermocycler as described below. 
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Steps Temperature (°C) Time (min:sec) No. of cycles 
Initial denaturation 95 05:00 1 
Subsequent denaturations 95 00:30 
30 - 35 
Annealing 55 – 58 00:30 
Elongation 72 00:30 
Final Elongation 72 05:00 1 
The annealing temperature depends on the melting temperature of the primers, and the 
elongation time is dependent on the product size and extension rate of the polymerase. The 
Qiagen Master Taq, which was most frequently used for DNA amplification, extends approxi-
mately 2 - 4 kb/min. For other polymerases the extension time was individually adjusted.  
In many cases, a touchdown PCR was performed where the annealing temperature decreases 
from a high level down to its optimum. Starting with a high annealing temperature reduces 
unspecific products due to unspecific primer binding. The basic touchdown protocol was 
performed in a thermocycler as follows: 
Steps Temperature (°C) Time (min:sec) No. of cycles 
Initial denaturation 95 05:00 1 
Denaturation 95 00:30 
2 
Annealing 63 -2 °C per 2 cycles 00:30 
Elongation 72 01:00 
Denaturation 95 00:30  
25 - 30 Annealing 58 00:30 
Elongation 72 00:30 
Final Elongation 72 05:00 1 
3.5.1.1 Purification of PCR Products by Ultrafiltration  
The resulting PCR products were cleaned on NucleoFast 96 PCR Plates (Macherey-Nagel, 
Düren, Germany) based on ultrafiltration technique. Each well contains a filter membrane 
through which the PCR fragments (≥150 bp) cannot pass, whereas primers, dNTPs and salts 
pass through the filter during centrifugation. For that procedure, PCR products were diluted 
with ddH2O to a final volume of 100 µl and transferred to a NucleoFast® plate placed on top of 
a waste plate. The plates were centrifuged at 4000 x g for 20 minutes. Thereafter, the 
membrane was washed with 100 µl ddH20 and centrifuged again under the same conditions. 
The purified PCR products were recovered by adding 25 µl ddH2O or AE buffer onto the 
membrane. The purification plates were shaken for 10 minutes at room temperature before 
the PCR products were removed from the plates and stored at -20 °C.  
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3.5.1.2 Purification of DNA and PCR Products using Magnetic Beads 
A polyethylene glycol (PEG) solution containing magnetic beads coated with a special solid 
phase is an alternative for PCR and DNA purification. PCR products and enzymatically treated 
DNA obtained during exome preparation are purified with Agencourt AMPure XP (Beckman 
Coulter GmbH, Krefeld, Germany) magnetic beads. DNA >100 bp is selectively bound to the 
coated paramagnetic particles. The concentration of salt and PEG in the bead solution 
determines the size of DNA bound to the beads. The higher the PEG concentration the smaller 
is the size of the bound DNA (Lis and Schleif 1975). DNA and magnetic beads are mixed at a 
ratio of 1:1.8 and incubated for 5 minutes. On a magnetic stand, the beads with the bound 
DNA are separated from contaminants, which remain in solution. After two washing steps with 
500 µl of 70 % ethanol, the beads are dried at 37 °C in a thermoblock and resuspended in 
nuclease free water. The purified DNA can then be separated from the beads on a magnetic 
stand. 
3.5.2 DNA Sequencing with Capillary Electrophoresis 
The capillary sequencing method is based on the chain-determination method, which was 
developed by Sanger and colleagues in 1977 (Sanger et al. 1977). It is often called Sanger 
(dideoxy) sequencing. This method is based on the ability of the polymerase to incorporate 
nucleotides which lack the 3’ hydroxyl group. Extension of DNA fragments is inhibited at the 
time a dideoxynucleotide is incorporated. For cycle sequencing, fluorescently labelled 
dideoxynucleotides are used. One reaction contains fluorescently labeled dideoxynucleotides 
(ddNTPs), template DNA, deoxynucleotides (dNTPs), a DNA polymerase, primer and buffer. For 
the cycle sequencing reaction, 1 - 2 µl purified PCR product, 0.3 µM primer, 2 µl 5x sequencing 
buffer (Applied Biosystems, Foster City, CA, USA) and 1.5 µl BigDye® Terminator v1.1 Ready 
Reaction mix (contains dNTPS, fluorescently labeled ddNTPS and a DNA Polymerase, Applied 
Biosystems, Foster City, CA, USA) are mixed in a final volume of 10 µl. The optimal extension 
activity of the polymerase provided by the kit is 60 °C. The reaction was cycled through a 
temperature profile in a thermocycler with the following program: 
Steps Temperature (°C) Time (min:sec) No. of cycles 
Initial denaturation 94 03:00 1 
Subsequent denaturation 94 00:30 
25 
Annealing 58 00:30 
Elongation 60 03:00 
Final Elongation 60 05:00 1 
3.5.2.1 Purifying Cycle Sequencing Products by Ethanol Precipitation 
Ethanol precipitation is a low cost method for purifying cycle sequencing products but it takes 
some time. The cycle sequencing products were acidified with 1/5 volume of 3 M NaAc and 
precipitated with 5 volumes of ethanol. After vigorous vortexing the precipitates were 
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centrifuged for 20 minutes at 4000 x g. The pellets were washed with 100 µl of 70 % ethanol 
and centrifuged again for 20 min at 4000 x g. After air drying, the pellets were resuspended in 
20 - 30 µl ddH2O. Thereafter, the purified cycle sequencing products were run on a capillary 
sequencer ABI PRISM 3100 (Applied Biosystems, Foster City, CA, USA). The resulting 
sequencing data was analyzed with the Sequencher (www.genecodes.com) software. 
3.5.2.2 Purifying Cycle Sequencing Products using Centri-Sep™ Columns 
Centri-Sep™ columns (Princeton Seperations, NJ, USA) were also used for purifying cycle 
sequencing products. This method is costly but very fast. The columns contain a hydrated 
polysaccharide matrix to remove excess dye terminators from the cycle sequencing reactions. 
The excess buffer of each column needs to be removed by an initial centrifugation step of 
3 min at 750 x g. Thereafter, the cycle sequencing products can be loaded on the columns and 
unused material is removed in a second centrifugation step at 750 x g for 3 minutes. Excess 
dye terminators stay in the matrix and the cleaned products are directly collected in a fresh 
sequencing plate. The products can be directly loaded onto the sequencer. 
3.5.3 Enzymatic DNA Manipulation for Exome Sample Preparation 
The enzymatic manipulation of sheared DNA for exome sequencing was performed according 
to, the instructions of Agilent’s (Agilent Technology, Santa Clara, California, USA) user guide: 
“SureSelect Target Enrichment System for Illumina Paired-End Sequencing Library” (Version 
2.0.1, May 2010).  
3.5.3.1 Generating Blunt Ends and Phosphorylation of 5’ Ends 
As a result of physical DNA shearing heterogeneous ends are produced, like overhanging 3 
prime and 5 prime ends or blunt ends. Therefore, the fragmented DNA needs to be 
enzymatically treated to generate blunt ends for later adapter ligation. To generate blunt ends, 
the fragmented DNA is treated with Klenow enzyme (part of DNA Polymerase I) which fills up 
5’ overhangs with its 5’→3’ polymerase activity in the presence of dNTPs and 3’overhangs are 
removed by its 3’→5’ exonuclease activity. Additionally, T4 DNA polymerase is added to the 
mix which has the same properties but with a much higher exonuclease activity. The end re-
pair mix also contains T4 polynucleotide kinase which catalyzes the transfer of a gamma 
phosphate from ATP to the 5’ hydroxyl terminus of the fragmented DNA to ensure 
phosphorylated 5 prime ends, which are necessary for adaptor ligation later on. The end repair 
mix was prepared as follows: 
Reagent Volume for 1 exome library Final concentration 
DNA sample (100 ng/µl) 30 µl 30 ng/µl 
10x Phosphorylation Reaction Buffer 
(NEB)  
10 µl 1x 
10mM each dNTP mix (NEB) 4 µl 0.4 mM 
T4 DNA polymerase 3U/µl (NEB) 5 µl 0.15 U/µl 
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Reagent Volume for 1 exome library Final concentration 
Klenow Fragment 5U/µl (NEB) 1 µl 0.05 U/µl 
T4 PNK 10U/µl (NEB) 5 µl 0.5U/µl 
Nuclease free water ad 100 µl - 
The samples were incubated for 30 minutes at 20 °C in a thermocycler without closing the lid. 
Afterwards the blunted DNA was purified using Agencourt AMPure XP beads (Beckman Coul-
ter, Brea, CA, USA). The DNA was eluted from the magnetic beads in ≈ 30 µl of nuclease free 
water. 
3.5.3.2 Adenylation of 3 Prime Ends 
The process in which one nucleotide A-overhangs are added to the 3’ ends of blunted DNA is 
called tailing. In the following step the fragments can be ligated to Illumina’s sequencing 
adapters as the sequencing primers have corresponding “T” overhangs on their 3 prime ends. 
Furthermore, A-tailing prevents the formation of concatamers of template DNA fragments 
during adapter ligation. A-tailing is performed using a Klenow fragment without 3’→5’ 
exonuclease activity. For the reaction mix, 30 µl of end repaired DNA fragments, 5 µl of 10x 
NEBuffer2 for Klenow Fragment 3’→5’ exo- (New England Biolabs, UK), 10 µl of 1 mM dATP 
(New England Biolabs, UK) and 3 µl of Klenow Fragment 3’→5’ exo- were mixed together with 
nuclease free water to a final volume of 50 µl. The reaction mix was prepared as follows and 
incubated on a thermocycler at 37 °C for 30 minutes with open lid: 
Reagent Volumes for                                 
one exome library 
Final concentration 
End-repaired DNA fragments (100 
ng/µl) 
30 - 32 µl 60 ng/µl 
10x NEBuffer2 for Klenow Fragment 5 µl 1x 
1 mM dATP (NEB) 10 µl 0.2 mM 
Klenow Fragment (3’→5’ exo-) (NEB) 3 µl 0.15 U/µl 
Nuclease free water ad 50 µl - 
The tailed DNA fragments were purified with magnetic beads and resuspended in nuclease 
free water.  
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3.5.3.3 Adapter Ligation 
Adapter and DNA fragments are covalently linked during ligation. The molar ratio of adapters 
to DNA fragments was 10:1. Illumina provides forked adapters, which are ligated to the sticky 
ends of the target DNA. Due to the sticky and phosphorylated ends of the target DNA and the 
adapters, they are ligated in a manner that the resulting products have distinct sequences on 
their 3’ and 5’ ends shown in red and blue, respectively, in the illustration below. This is 
important, as in a subsequent PCR reaction (3.5.3.4) an anchor DNA sequence is added by 
using primers with a 5’ extension. Figure 4 shows the adapter sequences (grey/blue and 
grey/red) and the genomic DNA fragment (black): 
 
Figure 4 Illustration of Y-shaped adapters. A) The Y-shape of the adapters ensures that each fragment has different 
overhangs on both ends. B) Adapter sequence; Oligonucleotide sequences © 2007-2012 Illumina, Inc. All rights 
reserved. 
For the adapter ligation, 14 µl of A-tailed DNA was mixed with 25 µl 2x DNA ligase buffer (New 
England Biolabs, UK), 6 µl paired-end Adapter oligo mix (Illumina, San Diego, California, USA) 
and 5 µl T4 DNA ligase (New England Biolabs, UK). The mix was incubated for 15 minutes at 
20 °C on a thermocycler without using a lid. The ligated fragments were cleaned using 
magnetic beads and eluted in 50 µl nuclease free water. The adapters do not contain the 
anchor sequences for the flow cell. These sequences are introduced via PCR with specific 
primers binding to the overhangs of the adapters (the blue and red sequences in Figure 4). 
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3.5.3.4 Amplifying Adapter-ligated Libraries 
After adapter ligation, a PCR was performed with Illumina primers PE 1.0 and PE 2.0. As 
mentioned earlier, these primers have specific 5’ extensions so that the final amplification 
product can be bound and sequenced on a flow cell. The tails of the primers contain the P5 
and P7 capture sequences, which bind to the complementary capture oligonucleotides on the 
flow cell.  
The primer sequences as shown below were obtained from the “Illumina Adapters Sequences 
Letter” at www.illumina.com/support                        
(file name: 2012-09-18_IlluminaCustomerSequenceLetter.pdf). 
 
Figure 5 Sequence of illumina primers. Oligonucleotide sequences © 2007-2012 Illumina, Inc. All rights reserved. 
The sequence highlighted in orange and green are the P5 and P7 capture sequences, the 
adapter sequence is highlighted in blue/grey and red/grey with the terminal “T” in black. The 
underlined part represents the binding site of the sequencing primers.  
During this PCR reaction, fragments with different adapters on either end are enriched in 
contrast to fragments containing only one or no adapter. Fragments with only one adapter can 
bind to the flow cell but cluster formation and sequencing is not possible. Fragments without 
any adapter cannot be bound to the flow cell at all. Besides fragments without adapters, the 
mixture can also contain adapter dimers. The terminal “T” on the primers only binds to 
fragments containing the corresponding “A” which was introduced earlier during the A-tailing 
process. In contrast, adapter dimers do not have the corresponding “A” and cannot be 
enriched. For that purpose, illumina designed special primers that are completely resistant to 
the 3’–5’ exonuclease activity of the polymerase (illumina paired end sample preparation 
guide, Catalog # PE-930-1001, Part # 1005063 Rev. E, February 2011). Only a few PCR cycles 
are performed to enrich the adapter-ligated fragments in order to avoid introducing a bias for 
some genomic regions. The adapter-ligated fragments (25 µl) were amplified with 1 µl of 
Herculase II Fusion DNA Polymerase (this Pfu-based polymerase is manufactured by Agilent 
Technologies), 1 µl of each Illumina PCR primer (PE 1.0 and PE 2.0) with a final concentration of 
0.25 µM, 0.5 µl of a 25 mM dNTP mix, 10 µl 5x Herculase II reaction buffer and nuclease free 
water in a 50 µl reaction. The PCR was performed in a thermocycler with an initial 
denaturation at 98 °C for 30 seconds, four cycles with 10 seconds denaturation at 98 °C, 
30 seconds with 65 °C annealing temperature and 30 seconds elongation at 72 °C and a final 
elongation step for 5 minutes at 72 °C. In later experiments, we extended the initial 
temperature to 1 min and the denaturation step at each cycle was prolonged to 20 seconds, 
we also increased the number of cycles to six. The final genomic library contains fragments 
with P5 and P7 attachment sites on opposite ends. To examine if the adapter ligation was 
successful, the library was analyzed on a High Sensitivity Bioanalyzer chip. Typically, a size shift 
PE PCR Primer 1.0 
5’   AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
PE PCR Primer 2.0 
5’CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
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from around 150 bp for the sheared DNA to a 250 - 300 bp peak for the adapter-ligated 
fragments was observed.  
3.6 Exome Capture by In-Solution Hybridization 
For exome enrichment, Agilent’s Sure Select human all exon RNA library kit (V3) representing a 
target of 50 Mbp of coding sequences was used. This kit targets about ~1.6 % of the human 
genome (51,607,577 bases). The kit was developed by Agilent and the Sanger institute and its 
bait library was derived from different databases with an annotation based on the GENCODE 
project (Harrow et al. 2006). The bait library represents 99.86 % of CCDS (Sept.2009), 90.74 % 
of the GenBank (June 2010) sequence database, 96.47 % of RefSeq Genes, 97.50 % of RefSeq 
Transcripts (June 2010) and 75.24 % of Ensemble genes. In addition, miRNAs from miRBase are 
represented (taken from Agilent Technologies). The enrichment was performed according to 
the Sure Select target enrichment protocol (Version 2.0.1 May 2010). 
The principle of enrichment is based on a system first described by Gnirke and colleagues 2009 
(Gnirke et al. 2009). It is a solution-based oligonucleotide hybridization and capture method. 
Biotinylated RNA oligonucleotides, also called baits, are used for in-solution enrichment. The 
Sure Select 50 Mb kit contains 635,250 baits with a length of ~120 nucleotides representing 
51.6 Mb of target sequence (Sulonen et al. 2011). The biotinylated baits are incubated 
together with the adapter ligated genomic library (see 1.5.7.4). The hybridized or captured 
fragments, representing the whole exome, were purified with streptavidin-coated magnetic 
beads.  
The sequencing library (adapter ligated genomic fragments as described above), quantified 
using the Qubit (3.4.2), was dried in a vacuum centrifuge at 40 °C and dissolved in nuclease 
free water to a final concentration of 147 ng/µl. An aliquot of 3.4 µl containing 500 ng of total 
genomic library was used for the hybridization process. In parallel, buffers for hybridization 
were prepared. For the hybridization buffer, 25 µl of SureSelect Hyb #1 (contains 20x SSPE), 
1 µl SureSelect Hyb #2 (contains 0.5 M EDTA), 10 µl SureSelect Hyb #3 (contains Denhardt’s 
solution for blocking) and 13 µl SureSelect Hyb #4 (contains 10 % SDS) were mixed for each 
library. The hybridization buffer mix was kept at room temperature. In the meantime, the 
SureSelect block mixture was prepared from 2.5 µl SureSelect Block #1 (contains Human 
Cot-1DNA to block repetitive elements), 2.5 µl SureSelect Block #2 (contains salmon sperm to 
reduce non-specific hybridization) and 0.6 µl SureSelect Block #3 (contains an oligo mix to 
block the adapters). To prevent RNA baits from being degraded by RNases, 1 µl of SureSelect 
RNase Block was diluted in 2 µl nuclease free water. For each exome capture, 2 µl of freshly 
prepared RNase block was mixed with 5 µl capture library (bait) in a 0.2 ml PCR tube and put 
on ice. Each genomic library (3.4 µl) was mixed with 5.6 µl block mix in a 0.2 ml PCR tube on ice 
prior to hybridization, which was performed in a thermocycler using the following program. 
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Steps Temperature (°C) Time (h:min) 
Preheating 95 Hold 
Denaturation 95 00:05 
Sample preparation 70 00:15 
Hybridization  70 -1°C per h 05:00 
Final hybridization 65 24:00 
All following sample preparation steps were performed on a heated thermocycler. First the 
genomic library (3.4 µl library and 5.6 µl block mix) was placed in the thermocycler at 95 °C to 
allow denaturation of the genomic library. Thereafter, the thermocycler was cooled down to 
70 °C, which is hot enough so that the library was not able to reanneal. Then 40 µl of 
hybridization buffer was placed in 0.2 ml PCR tubes in the thermocycler as well as the capture 
libraries. The lid of the thermocycler was closed to allow samples and buffers to reach the 
same temperature for 5 min. Then the lid of the thermocycler was opened and 13 µl of 
hybridization buffer was transferred to the capture library. Immediately after this, the entire 
genomic library (9 µl) was also transferred to the capture library and mixed by pipetting. The 
lid of the thermocycler was closed to start the hybridization process. The hybridization was 
performed at 65 °C for at least 24 h. The initial starting temperature of 70 °C was set to 
remove secondary structures from GC rich fragments. After the 24-hour hybridization step, the 
hot libraries were transferred to a solution of biotinylated beads (Dynal MyOne Streptavidin 
T1, Invitrogen) to separate the enriched, exonic DNA, which by now had annealed to the 
biotinylated baits, from the remaining genomic DNA. 
3.6.1.1 Enrichment of Captured Sequences using Biotinylated Beads 
The hybridized baits were enriched using streptavidin coated magnetic beads. The 
streptavidin-biotin interaction has one of the highest affinities of all non-covalent interactions. 
The washing solutions, elution and neutralization buffers were already included in the Agilent 
Sure Select human all exon RNA library kit (V3). For each hybridization, 50 µl of well-mixed 
Dynal magnetic beads were transferred to a 1.5 ml microzentrifuge tube. The beads were 
washed three times with 200 µl of Sure Select Binding buffer. Between the washing steps, the 
tube was put on a magnetic stand to remove the supernatant. The beads were resuspended in 
200 µl binding buffer to which the captured libraries were transferred and mixed on a rotator 
for 20 minutes at room temperature. Thereafter, the solution was resuspended in 500 µl Sure 
Select Wash Buffer #1 and incubated at room temperature for 15 minutes. Beads and buffer 
were separated on the magnetic stand and the beads were washed three times with 500 µl 
prewarmed Sure Select Wash Buffer #2. For each washing step, the mix was incubated for 10 
minutes at 65 °C in a thermoblock. For elution of the bound fragments, the beads were mixed 
with 50 µl Sure Select elution buffer and incubated for 10 minutes at room temperature. Beads 
and buffer were separated on a magnetic stand and the eluate was neutralized with 50 µl Sure 
Select neutralization buffer. The resulting exome library was concentrated from 100 µl to 30 µl 
using AMPure XP magnetic beads.  
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3.6.1.2 Amplifying Captured DNA by PCR 
To increase the concentration of the captured library fragments, a few PCR cycles were 
performed. Only half of the library, 15 µl, was used for amplification and quantified by Qubit 
fluorometry. If the amount was too low, the other half of the library was amplified as well. In a 
50 µl reaction, 15 µl of captured DNA was mixed with 10 µl Herculase reaction buffer, 1 µl of 
dNTPmix (25 mM each), 1 µl Herculase II Fusion DNA Polymerase, 1 µl Sure Select GA PCR 
Primers and nuclease free water. The PCR was performed on a thermocycler using the 
following program with optimized settings in parentheses. 
Steps Temperature (°C) Time (min:sec) Cycles 
Preheating 98 02:00 (03:00) 1 
Denaturation 98 00:20 (01:20)  
10 - 12 Annealing 60 00:30 
Elongation  72 00:30 
Final elongation 72 05:00 1 
Usually 10 PCR cycles were enough for adequate amplification. The quality and quantity of the 
library was analyzed on a Bioanalyzer using a High Sensitivity kit (3.4.4). If the concentration 
was too high and the chip was overloaded, the sample was either diluted and analyzed again 
or analyzed undiluted on a DNA 1000 kit. Alternatively, the molarity of a library can also be 
calculated from a Qubit concentration measurement if the molecular mass of the fragments is 
estimated. For this, the molecular mass for one base pair (≈ 650 g/mol) is multiplied with the 
median fragment length (250 - 300 bp). The molarity can be calculated by dividing the weight 
(g) by molecular mass (g/mol) and volume (L). A library concentration of around 2 ng/µl 
measured with Qubit Fluorometer equals 10 - 12 nM at a median fragment length of 250 – 300 
bp. 
3.7 Exome Sequencing on the Illumina Genome Analyzer IIx 
The exome libraries were sequenced on a Genome Analyzer IIx (Illumina, San Diego, CA, USA). 
The sequencing was performed in collaboration with the Laboratory of Functional Genome 
Analysis (LaFuGa) at the Gene Center in Munich. The following paragraphs describe the basic 
principles of cluster generation and paired-end sequencing on an Illumina Genome Analyzer. 
3.7.1 Cluster Generation on the cBot 
The exome libraries were adjusted to 2 nM in 10 mM Tris-HCl, pH 8.5 buffer with 0.1 % Tween 
20. The DNA was denaturated with 0.1 N NaOH in a 1:1 ratio and thereafter diluted with 
Illumina’s hybridization buffer to a final concentration of 10 pM. The denaturated template 
DNA is now ready to be bound to the capture oligonucleotides of the flow cell. The flow cell is 
an optically transparent slide with 8 individual channels or lanes with covalently attached 
oligonucleotide anchors on the bottom surface of each lane. The loading of the target 
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fragments and bridge amplification is performed on a cBot (Illumina, SanDiego, CA, USA) 
device. The cBot instrument contains a thermal stage on which the flow cell is placed, as well 
as stage for the reagents. A manifold positioned on the flow cell and connected with the 
reagent stage provides the flow through of reagents and loading of template DNA fragments. 
On the cBot, clonal clusters are generated by bridge amplification as shown in Figure 6. The 
resulting clusters (≈50 million/lane) contain around 1000 identical copies of a single DNA 
fragment. For each exome, one lane was used. In one of the 8 lanes, a PhiX library was loaded 
as internal control. The flow cell is placed onto a thermal stage for cluster generation. The 
principle of cluster generation is shown below (Figure 6). 
 
 
Figure 6 Schematic representation of cluster generation on the cBot. A) Double stranded templates with distinct 
adapter (P5 and P7) sequence on each end are denaturated prior to hybridization. B) The surface of the flow cell is 
coated with complementary adapters. C) Hybridization of fragments. D) Extension of bound molecules. E) The 
synthesized double strands are denaturated (formamide). The newly synthesized strand is covalently bound to the 
flow cell while the original strand is washed away. F) Single strands arch over to adjacent anchor molecules to form 
a bridge. After extension, the strands are separated. The whole process is repeated many times to form clonal 
clusters. G) Only one strand is sequenced in the first round. The other strand is cleaved enzymatically. H) The 
sequencing primers are bound and 3’ ends are blocked to avoid unspecific binding during sequencing. 
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After amplification, the double stranded DNA with P7 (green) and P5 (orange) overhangs (a) is 
denaturated with NaOH to obtain single stranded fragments. On the cBot instrument, the 
single stranded library DNA fragments are immobilized on the flow cell through binding of the 
Illumina adapters to complementary anchor nucleotides (b), which are covalently attached to 
the flow cell. The fragments all bind with same orientation to the complementary 
oligonucleotides (c). The oligonucleotides are extended to generate identical copies of the 
fragments (d). The copied fragments are now covalently attached to the flow cell (e). The 
original strands are washed away after denaturation. During the next step clusters are 
generated through bridge amplification of each bound fragment. By arching over to adjacent 
anchor oligonucleotides, each template DNA forms a bridge like structure (f), which forms a 
priming site for the next extension step. The bridge is denaturated again. The process of 
isothermal denaturation (by formamide) and amplification is repeated 35 times to create a 
clonal cluster of each fragment with over 2000 molecules (illumina cBot™Part# 15006165 Rev. 
K., October 2012). After the last extension step, the fragments are linearized again and the 
fragments bound with the P5 adapters are enzymatically cleaved prior (g) to the binding of 
sequencing primers (h). Furthermore, the 3’ ends are blocked (h) to avoid spurious DNA 
priming during sequencing. This whole process is fully automated and takes about 4 - 6 hours. 
After this, the flow cell is ready for sequencing on the genome analyzer.  
3.7.2 Sequencing of Cluster-Amplified Template DNA 
Illumina’s sequencing is based on sequencing by synthesis using a mixture of four distinct 
fluorescently labeled dNTPs. Each nucleotide also has reversible terminator to cap the 3’-OH 
group. In each reaction all four nucleotide analogs are added but the DNA polymerase 
incorporates only the nucleotide which is complementary to the template DNA. Thereafter, 
the non-incorporated nucleotides are washed away, before the camera detects the fluorescent 
emission of the incorporated nucleotides. Before the next cycle starts, the fluorophore and the 
3’-OH terminator are chemically removed.  
For a more efficient use of the library we performed paired end sequencing. In paired end 
sequencing, each fragment is sequenced from both ends. The principle of sequencing is shown 
in Figure 7. 
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Figure 7 Illustration of paired end sequencing after cluster generation. A) Sequencing by synthesis with 4 
fluorescent labeled nucleotides. As soon as the fluorescent terminators are incorporated (one per fragment) all 
clusters on the flow cell are imaged. Bound terminator and fluorescence is washed from the flow cell to start the 
next sequencing round. B) After the first read is completed, the strand synthesized by the sequencing reaction is 
removed and the covalently bound fragments arch over again to form bridges with adjacent anchors. C) Both 
anchor adapters on the flow cell are now covalently bound to the fragments. D) For the second read, all fragments 
with the P7 anchor are enzymatically cleaved. E) Blocking of 3’ ends. F) The sequencing primer binds for the second 
read to the other end of the fragment. 
After the cluster generation step on the cBot, the first of two sequencing rounds is started on 
the Genome Analyzer. Each cycle starts with the incorporation of a single, labeled nucleotide 
which has a blocking group at the 3’OH position (A). Excess enzyme and nucleotides are 
washed away and the fluorescence of the incorporated nucleotide is recorded with a camera. 
Then, the fluorescent dye and the blocking group are removed prior to the next sequencing 
cycle. After 76 - 80 cycles the first read is completed and the newly synthesized DNA strands 
are removed from the templates. The remaining covalently bound fragments form again 
bridges with anchor oligonucleotides and become extended (B). The resulting fragments are 
now attached to the flow cell in the opposite orientations (C). To ensure that all fragments are 
sequenced in the same direction, fragments are cleaved at the P7 adapter (D). After the 3’ 
ends are blocked (E) and sequencing primers have bound, the fragments are sequenced from 
the other end (F). The pictures that are acquired after each incorporation step are processed 
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@1:1:10629:1764:Y 
AAGTGGAGCCCCCTCGCTGTACACCAGTGCGCTCACCATCGACGTATTAATGATGGGCCAGTGAGGCA 
+1:1:10629:1764:Y 
EGG@GGGGDGHHHGDGGGGFGGGGGHHDHGDHHHHG8EGGGGGGGGHHBFHFHHGDEGEFEBEBGEEF 
to obtain the raw sequence of each cluster. For a paired end run, about 14 days were required. 
This long run time is mainly due to the time it takes for the CCD camera to acquire the images. 
Each lane is imaged in 120 tiles with 4 different filters for each of the four fluorescent dyes 
used. Thus a single, one nucleotide sequencing step results in the acquisition of 4x120x8 = 
3840 high resolution images.  
 
3.8 Analyzing Exome Data on Galaxy Cluster 
For large-scale data analysis an appropriate computer system is required. All data analysis was 
performed on a Unix computer cluster at the Gene Center accessible via a VPN client. The data 
was stored and processed on a Unix computer cluster (>5 nodes) with 25 terabyte of hard disk 
storage. We used Galaxy, an open-source, web-based application for NGS data analysis 
(Giardine et al. 2005; Goecks et al. 2010) locally installed and administered at the LaFuGa at 
the Gene Center in Munich. All open source based analysis tools used for analysis as described 
below were accessible from the Galaxy interface. This allows combining different analysis 
programs to generate individual workflows using a graphical user interface, instead of using 
the Unix command line interface.  
3.8.1 Processing of Image Files and Base Calling  
The raw images taken by the Genome Analyzer during a run contain all the sequencing 
information. The RTA1.9 software (www.illumina.com) performs the base calling on the 
primary image files in real time (while the run is in progress) and stores the resulting data in 
binary files. The raw images are deleted after base calling to conserve disk space. A single 76 
bp run on a Genome Analyzer produces about 2.5 terabytes of primary image files. Therefore, 
the base calling cannot be repeated. The binary base calling data files are then converted into 
FASTQ files before being transferred to the Galaxy cluster. The FASTQ file format contains 
sequence and quality information. 
Figure 8 Sample FASTQ file. This read originates from the first tile of lane one. The x and y coordinates define the 
cluster of this read, which is 10629:1764 in this example. In this case, the read passed the chastity filter (see Results) 
therefore it is flagged with Y (Yes). Reads that did not pass the chastity filter are marked with N (No). Line four 
describes the PHRED quality of each nucleotide by ASCII code.  
A FASTQ file uses four lines per sequence, in the first line a sequence identifier and description 
of the read is given starting with the “@” character, followed by the sequence in line 2, in line 
3 sequence identifier and description are optionally but the line always starts with the “+” 
character and line four contains the Phred quality value for each nucleotide in line 2 encoded 
in ASCII characters. In Figure 8 a read in FASTQ format from our own data is shown after base 
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calling and filtering with the CASAVA program. These FASTQ files are then used on the Galaxy 
server for downstream analyses. 
3.8.2 Downstream Analysis of Sequence Data 
3.8.2.1 Burrows Wheeler Aligner (BWA) 
The first step in our downstream analysis of the sequence data was the mapping of the reads 
to the reference human genome. We used hg18 (NCBI Build 36.1/hg18) assembled in March 
2006 by the International Human Genome Sequencing Consortium as the reference human 
genome sequence. This reference sequence has a total length of 3,104,054,490 bases.  
There are many short read aligners available for the mapping of short paired-end reads based 
on different indexing strategies. Conventional alignment algorithms like BLAST are too 
computationally intensive to perform the alignment of millions of short reads to a reference 
genome in an acceptable time frame. The Burrows Wheeler Alignment tool is designed to 
rapidly map short reads to a reference sequence. It is based on the Burrows Wheeler 
transformation (Li and Durbin 2009). With this tool an index from the human genome DNA 
sequence is generated, comparable to an index of a book. With the use of the index, short 
reads can be mapped to the human genome. In contrast to other short read aligners, BWA 
allows mismatches and gaps. We used default settings for read mapping. The output format is 
SAM (Sequence Alignment/Map): 
Column Field Description 
1 QNAME Query (pair) NAME 
2 FLAG bitwise FLAG 
3 RNAME Reference sequence NAME 
4 POS 1-based leftmost mapping POSition 
5 MAPQ MAPping Quality (Phred-scaled) 
6 CIGAR extended CIGAR string 
7 MRNM Mate Reference sequence NaMe  
('=' if same as RNAME) 
8 MPOS 1-based Mate POSition 
9 ISIZE/TLEN Inferred insert SIZE/ Template LENgth 
10 SEQ query SEQuence on the same strand as the reference 
11 QUAL query QUALity  
(ASCII-33 gives the Phred base quality) 
12 OPT variable OPTional fields in the format TAG:VTYPE:VALU 
Table 1 SAM alignment format. The SAM format is a Tab delimited format and each line in the SAM format 
represents an alignment of a read. Each line consists of eleven mandatory fields and an additional optional field 
which is created by BWA. Description is taken from http://samtools.sourceforge.net/samtools.shtml.  
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1:1:5215:1359:Y 83 Chr3 17028520 60 79M = 17028333 -266 
GCCTTTCTGTGAGAAAAGGGAAGAAATCCAGGGAATATGCATCTTTGAGAACACTGTGGATTAAAACCGTGGATGAGGT 
=67554?BB:@;EEEBF9E>AB@GBB>GHGGGEGBEGGHHHHEGGEGGGBHHHHHHHHHG@HHHHFGHHGGGGEBGGDG 
XT:A:U NM:i:0 SM:i:37 AM:i:25 X0:i:1 X1:i:0 XM:i:0 XO:i:0 XG:i:0 MD:Z:79 
The SAM format was developed in 2009 by Li and colleagues (Li et al. 2009). This format stores 
alignments from different sequencing platforms and read aligners in a generic file format, 
which can be used as input for further downstream analysis programs. By default, the output 
of BWA program is the alignment in a SAM file. 
Figure 9 Sample SAM alignment format. 
It contains an optional header section (not shown) and an alignment section. The alignment 
section contains the information for each read (Figure 9). It tells us where the read maps to the 
reference genome and the quality of the read. All this information is given in the 11 mandatory 
fields of the alignment section.  
FIELD Example 
QNAME 1:1:5215:1359:Y 
FLAG 83 
RNAME Chr3 
POS 17028520 
MAPQ 60 
CIGAR 79M 
MRNM = 
MPOS 17028333 
ISIZE/TLEN -266 
SEQ GCCTTTCTGTGAGAAAAGGGAAGAAATCCAGGGAATATGCATCTTTGAGAACACTGTGGA… 
QUAL =67554?BB:@;EEEBF9E>AB@GBB>GHGGGEGBEGGHHHHEGGEGGGBHHHHHHHHHG… 
OPT XT:A:U NM:i:0 SM:i:37 AM:i:25 X0:i:1 X1:i:0 XM:i:0… 
Table 2 Fields of the SAM format are assigned with an example of our own data. 
In this example the cluster coordinates of a read on the flow cell is also the query name 
(QNAME). Each read of a pair has the same query name. A FLAG is used to describe the 
alignment, see also Table 3. In this example the RNAME is equivalent with the chromosome 
name where the read is located. The read we looking at, starts hat Chr3 position 17028520 
with a mapping quality (MAPQ) of 60. CIGAR (compact idiosyncratic gapped alignment report) 
gives alignment information (see also http://samtools.sourceforge.net/SAMv1.pdf). The letter 
M in the CIGAR string denotes an alignment match which can be a sequence match or 
mismatch. In our example all 79 bases of the read align with the reference. The number of 
matches and mismatches is not given in this field. The equal sign denotes that the mate's 
reference sequence name (MRNM) is the same as the RNAME. The leftmost position of the 
mate is 17028333 (MPOS). The distance between the read pair calculated from the leftmost 
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position to the rightmost position is 266 bases (ISIZE/TLEN). The SAM format also contains the 
entire sequence (SEQ) of a read and the corresponding base quality in ASCII-33 format (QUAL). 
In the last field (OPT) there can be many optional tags (the NM tag for example gives the 
number of mismatches as an integer (i), (http://bio-bwa.sourceforge.net/bwa.shtml). In our 
example the number of mismatches is zero. 
Bit Description 
(http://samtools.sourceforge.net/samtools.shtml) 
Example  
FLAG: 83  
0x0001 the read is paired in sequencing 1 
0x0002 the read is mapped in a proper pair 1 
0x0004 the query sequence itself is unmapped 0 
0x0008 the mate is unmapped 0 
0x0010 strand of the query (1 for reverse) 1 
0x0020 strand of the mate 0 
0x0040 the read is the first read in a pair 1 
0x0080 the read is the second read in a pair  
0x0100 the alignment is not primary  
0x0200 read did not pass quality controls  
0x0400 optical or PCR duplicate  
Table 3 Bitwise FLAG. Each bit has assigned information about the alignment. The FLAG in the example is 83 
(decimal) in the binary system it would be 1010011. When reading the binary number from right to left the 
information assigned to each bit can be read from the table. In our example, the read has the following properties 
(indicated by 1): paired, mapped in a proper pair, read is from the reverse strand and it is the first read in a pair.  
3.8.2.2 SAMtools 
The SAM format stores alignments from different sequencing platforms and read aligners in a 
generic file format, which can be used as input for further downstream analysis programs. The 
SAM format is the human readable version, there is also a binary version called BAM which 
contains the same information. The SAMtools software package allows the manipulation of 
alignments in the SAM/BAM format (Li et al. 2009). The SAMtools software package was used 
to generate BAM files and sorted BAM files. In addition, it was used to remove PCR duplicates 
and to generate pileup and flagstat files. Flagstat files provide information on total mapped 
and paired reads for example. The pileup file describes the alignment information at each 
chromosomal position. The pileup, later mpileup (SAMtools 0.1.14), file was used as input for 
the variant caller software VarScan as described below.  
SAMtools version 0.1.14 and higher includes a tool called BAQ: base alignment by quality. This 
tool helps to remove false positives variants close to an InDel. This option is turned on by 
default. As this default option is often too stringent, it was turned off for analyses and the less 
stringent variant calling routine integrated in SAMtools called extended BAQ was used instead. 
As later versions of SAMtools allow combining multiple SAM/BAM files into one pileup file, the 
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output is called mpileup instead. In addition, SAMtools provides a simple text alignment 
viewer, which allows visualizing reads mapped to a reference sequence. 
3.8.2.3 VarScan and VarScan 2 
Variant calling was performed using VarScan and VarScan 2 an open source tool (Koboldt et al. 
2009; Koboldt et al. 2012). VarScan is specifically designed for short reads like the ones 
produced by the Illumina platform. Two different workflows were established for variant 
calling. 
3.8.2.4 Reference files  
As mentioned earlier, the output of each exome sequencing experiment was restricted to 
coding exons and known SNPs were excluded. This was achieved by working with BED 
(Browser Extensible Data) files containing the position of coding exons and SNPs. A BED file is a 
tab delimited text file, which is commonly used to represent genomic features. It has three 
required fields per line and nine optional fields (http://genome.ucsc.edu/). The first required 
field contains the chromosome name, the second and third lines contain start and end 
coordinates of a chromosome feature. To limit the sequencing data to known coding exons, a 
BED file from the UCSC table browser (http://genome.ucsc.edu/cgi-bin/hgTables) was 
downloaded in May 2012 containing all human RefSeq genes based on the human genome 
assembly from March 2006 (NCBI Build 36/hg18). To exclude known SNPs from the exome 
data the dbSNP build 130 BED file from the UCSC table browser was downloaded as well. 
3.8.3 BEDtools 
BEDtools is also an open source software tool, which allows manipulating and comparing 
genomic features contained in different BED files (Quinlan and Hall 2010). We used BEDtools 
to perform coverage calculations across the whole exome and for individual genes.  
3.8.4  Picard 
Summary statistics were calculated with the Picard program (http://picard.sourceforge.net). 
BAM files were analyzed for general alignment metrics (summary alignment metrics) and 
exome hybridization metrics (hybrid selection specific metrics). 
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4 Results 
4.1 Whole Exome Sequencing of 25 CLL Patient Samples 
To identify disease-causing mutations in malignant diseases, next-generation sequencing is the 
method of choice. The terms next-generation sequencing or second-generation sequencing 
refers to techniques and machines that allow the generation of mega- or gigabases of 
sequence information in a single experiment. All next-generation sequencing methods are 
based on the massive parallelization and miniaturization of sequence reactions. Several 
sequencing systems are commercially available and include the 454 pyrosequencing 
technology (Roche) developed by Jonathan Rothberg (454 Life Sciences), ligation based 
sequencing in the SOLID system (ABI) or Illumina’s sequencing by synthesis strategy. With 
constant improvements in these technologies, sequencing costs per megabase are decreasing 
tremendously. With the latest next-generation sequencing technology whole genomes or 
targeted regions can be analyzed and either mapped to a reference or assembled de novo in a 
very short time. However, whole human genome sequencing is still costly and requires the 
manipulation of substantial data quantities. For many problems the sequencing and the 
analysis of the coding regions of a genome, the so-called exome, is quite sufficient to gain 
insight into disease pathology. To perform whole exome sequencing (WES) one can choose 
between different exome enrichment strategies.  
We performed WES of 25 CLL patient samples and their matched normal controls using an in 
solution exon enrichment strategy (Agilent SureSelect). In CLL several prognostic markers, like 
the deletion of certain genomic regions as assayed by FISH, the mutational status of the IGHV 
locus or the expression levels of ZAP-70 have been identified. However, the predictive power 
of these markers is limited and they cannot fully explain the heterogeneity and the great 
variability in the clinical course of disease seen in CLL patients. The use of the monoclonal 
anti-CD20 antibody (Rituximab) in conjunction with chemotherapy has significantly improved 
progression-free survival of CLL patients even in second line therapy (Robak et al. 2010). The 
aim of this project was to identify new, potentially predictive markers in previously treated 
patients that had reached complete remission after second-line treatment with fludarabine 
and cyclophosphamide (FCR) or with fludarabine and cyclophosphamide (FC) alone. 
4.1.1 Biological and Clinical Characteristics of the CLL Patient Cohort 
The CLL patient samples used in this project were obtained from the REACH study patient 
cohort. The primary objective of the REACH study was to compare progression free survival in 
previously treated CLL patients, treated with rituximab and fludarabine and cyclophosphamide 
(FCR) with patients treated only with fludarabine and cyclophosphamide (FC) (Clinical Study 
Protocol BO17072F). This study was an international, multicenter, open-label, phase III trial. It 
was conducted at 88 centres. Between July 2003 and August 2007, 552 patients were 
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randomized to the FC or the FCR arm (Robak et al. 2010). The Laboratory for Leukemia 
Diagnostics at the university hospital Grosshadern in Munich performed the routine dia-
gnostics for these samples. The routine diagnostic tests included morphology, FISH analysis 
using a panel of 5 FISH probes, measurement of ZAP-70 expression levels and determination of 
the IGHV mutational status.  
The CLL patient samples for WES were selected from the REACH study cohort (n=552). Patient 
samples were selected based on the availability of a remission sample from the same patient 
and a negative minimal residual disease (MRD) status. In total, 25 CLL patient samples and 
their matched normal controls fulfilled these criteria. Table 4 shows a comparison of the 
clinical and biological characteristics of the patients available for WES with the complete 
REACH study cohort. Note that the data of the 25 WES patients are included in the REACH 
cohort data.  
Characteristics 
Number of patients, n 
REACH cohort WES subgroup  P-value* 
Sex, n 546 25  
   Female 181 (33 %) 8 (32 %) 1.0 
   Male 365 (67 %) 17 (68 %)  
Age, n 546 25  
   Mean (sd) 61.8 (9.0) 62.1 (9.8) 0.85 
   Median (range) 63 (35-83) 61 (38-79)  
Binet stage, n 546 25 0.023 
   A 55 (10 %) 6 (24 %)  
   B 321 (59 %) 16 (64 %)  
   C 170 (31 %) 3 (12 %)  
Beta-2 microglobulin (mg/L), n 531 25 0.35 
   Mean (sd) 3.4 (2.2) 3.41 (1.3)  
   Median (range) 3.47 (0.003-17.1) 3.0 (1.8-6.5)  
Lymphocytes (10
9
/L), n 544 25 0.26 
   Mean (sd) 64.5 (68.3) 45.5 (41.6)  
   Median (range) 42.0 (0.54-431.0) 25.4 (5.2-148.0)  
B-Symptoms, n 546 25 0.66 
   No 391 (72 %) 17 (68 %)  
   Yes 155 (28 %) 8 (32 %)  
ECOG performance status, n 545 25 1.0 
0 325 (60 %) 15 (60 %)  
1 220 (40 %) 10 (40 %)  
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Characteristics 
Number of patients, n 
REACH cohort WES subgroup  P-value* 
IGHV mutational status, n 517 25 0.033 
   Mutated 191 (37 %) 15 (60 %)  
   Unmutated 326 (63 %) 10 (40 %)  
ZAP-70, n 408 21 0.04 
   Negative 236 (58 %) 17 (81 %)  
   Positive 172 (42 %) 4 (19 %)  
CD38, n 324 16 0.31 
   Negative 154 (47.5 %) 10 (62.5 %)  
   Positive 170 (52.5 %) 6 (37.5 %)  
Del17p, n 529 25 0.25 
   No 487 (92 %) 25 (100 %)  
   Yes 42 (8 %) 0 (0 %)  
Del13q, n 531 25 0.68 
   No 225 (42 %) 12 (48 %)  
   Yes 306 (58 %) 13 (52 %)  
Trisomy 12, n 530 25 0.55 
   No 462 (87 %) 21 (84 %)  
   Yes 68 (13 %) 4 (16 %)  
Previous Chemotherapy, n 537 25 0.82 
   Alkylator refractory  145 (27 %) 6 (24 %)  
   Alkylator sensitive 302 (56 %) 16 (64 %)  
   Fludarabine 90 (17 %) 3 (12 %)  
Treatment at 2
nd
 line, n 546 25 0.22 
   FCR 272 (50 %) 9 (36 %)  
   FC 274 (50 %) 16 (64 %)  
Time from last progression 
(days), n 
544 25 0.17 
   Mean (sd) 98.8 (145.4) 53.6 (42.4)  
   Median (range) 50 (1-1406) 41 (4-171)  
Table 4 Clinical and biological characteristics. Clinical and biological characteristics of the WES patients (n=25) 
compared with the total REACH cohort. These data were kindly provided by F. Hoffmann-La Roche. There are 
significant differences in ZAP-70 status, IGHV mutational status and Binet stage between both cohorts. * P-values 
were calculated for various clinical and biological variables applying the Mann–Whitney U test or Fisher's exact test 
respectively for continuous and categorical variables (*, P <0.05).  
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The fact that the REACH study included only patients at relapse is the reason for the adverse 
clinical and biological characteristics of this cohort. Most of the REACH patients had an 
intermediate Binet stage at diagnosis. More than 60 % of the patients had an unmutated IGHV 
status, which is associated with poor prognosis (Damle et al. 1999; Hamblin et al. 1999). The 
WES subgroup of patients, in contrast, has more favorable prognostic markers. The WES 
patients had significantly better IGHV status, 60 % had a mutated and only 40 % an unmutated 
status. There was also a significant difference in the expression levels of ZAP-70, a surrogate 
marker of IGHV mutational status, with most WES patients being ZAP-70 negative. According 
to the Binet staging system patients selected for whole exome sequencing had a significantly 
better prognosis compared to the entire REACH study cohort. Obviously there is a selection 
bias in the exome cohort towards patients with better prognosis.  
4.1.1.1 FISH Status and Content of CD19 Positive Cells in Tumor Samples 
The deletion of certain genomic regions as assayed by FISH is one of several markers of 
prognostic relevance in CLL. Patients harboring a 13q deletion as sole abnormality have the 
most favorable prognosis. In contrast patients harboring a 17p deletion have the worst 
prognosis, as the TP53 locus is affected. Patients with 11q deletions affecting the ATM locus 
have a slightly better prognosis. Patients with no abnormality in the FISH screen or with a 
trisomy 12 have an intermediate prognosis (Dohner et al. 2000). 20 of the 25 WES samples had 
a single genomic alteration when analyzed with FISH probes for the following genomic regions: 
6q, 13q, 11q, 17p and centromere 12 (for the detection of trisomy 12) (Table 5). 
 del (13q) No aberration Trisomy 12 del (11q) del (6q) 
Samples (#) 13 5 4 2 1 
Samples (%) 52 20 16 8 4 
Table 5 Chromosomal aberrations in REACH exome cohort. The most frequent abnormality in the REACH exome 
cohort is the 13q deletion in n=13 patients, followed by normal karyotype (n=5), trisomy 12 (n=4), 11q (n=2) and 6q 
(n=1). 
Most patients in the WES group harbored a 13q deletion as sole aberration (52 %). There was 
no significant difference in the proportion of patients with 13q deletion compared to the total 
REACH cohort. No FISH aberration, trisomy 12, 11q deletion and 6q deletion were found in 20, 
16, 8 and 4 percent of the WES patients, respectively. There were no WES patients with a 
deletion of the short arm of chromosome 17. This is due to the fact that the WES patients had 
to have a remission sample. Patients with a 17p deletion affecting the TP53 tumor suppressor 
gene have a low chance of achieving remission.  
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Table 6 Overview of FISH markers and percentage of CD19 positive cells as measured by flow cytometry for each 
tumor sample. For patients P02 and P18 no flow cytometry data was available (NA = not analyzed).  
 
Figure 10 Proportion of CD19 positive cells as measured by flow cytometry. For 23/25 samples data was available 
at diagnosis. 
To estimate the proportion of CLL cells in the leukemic samples derived from peripheral blood, 
routinely obtained flow cytometry data were analyzed. Flow cytometry data was available for 
23 of the 25 WES samples. As B cell derived cells, most B-CLL cells express the CD19 antigen on 
their cell membrane. The proportion of CD19 positive cells in our WES samples ranged from 49 
to 94 %. As CD19 is also found on normal B-cells the exact proportion of CLL cells cannot be 
determined. An enrichment of CD19 positive cells was not performed.  
4.1.1.2 Disease Free Remission Samples as Defined by MRD and FISH Status 
The 25 CLL samples and matched remission samples for WES were selected from the REACH 
study cohort. As we used the remission sample from the same patient as non-tumor control, 
we had to ensure that there were only very low levels of residual CLL cells in the remission 
sample. All non-tumor samples for which sufficient material was available (>5 µg of gDNA) 
were selected according to MRD level and FISH status. The remission status was determined by 
measuring the level of the patient-specific IGHV rearrangement using realtime quantitative 
PCR. These measurements were performed routinely for all samples of the REACH study 
cohort. Disease free remission was defined as MRD levels of less than 1x10-3 as measured using 
the disease-specific IGHV rearrangements.  
P01 P02 P03 P04 P05 P06 P07 P08 P09 P10 P11 P12 P13 P14 P15 P16 P17 P18 P19 P20 P21 P22 P23 P24 P25
IGVH  mutated
IGVH  unmutated
no FISH marker
Trisomy 12
del(13q)
del(11q)
del(17p)
del(6q)
CD19 positive cells (%) 89.50 NA 88.53 80.95 93.50 84.05 88.69 90.13 79.83 69.42 77.05 53.99 72.02 84.39 93.14 87.80 86.56 NA 93.98 69.31 70.53 92.84 48.59 82.99 71.87
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Remission 
Sample 
MRD  
Level 
MRD 
Sensitivity 
MRD 
Quantitative Range 
MRD  
Interpretation 
P00 <5x10-5 5x10-5 1x10-4 Negative 
P01 <1x10-4 1x10-4 1x10-4 Negative 
P02 <1x10-4 1x10-4 1x10-4 Negative 
P03 <1x10-4 1x10-4 1x10-4 Negative 
P06 <1x10-3 1x10-4 1x10-3 Oqrpos 
P07 <1x10-4 1x10-4 1x10-4 Negative 
P08 <1x10-4 1x10-4 1x10-4 Negative 
P09 4.75x10-4 1x10-4 1x10-4 Iqrpos 
P12 <1x10-4 1x10-4 1x10-4 Negative 
P13 <1x10-4 1x10-4 1x10-4 Negative 
P16 7.7x10-4 1x10-4 1x10-4 Iqrpos 
P19 <1x10-4 1x10-4 1x10-3 Negative 
P20 <1x10-4 1x10-4 1x10-4 Negative 
P21 <1x10-4 1x10-4 1x10-4 Negative 
P23 <5x10-5 5x10-5 1x10-4 Negative 
P24 <1x10-4 1x10-4 1x10-3 Negative 
Table 7 MRD levels as determined by quantitative realtime PCR. MRD levels were routinely measured using 
disease specific IGHV rearrangements by realtime quantitative PCR. Disease free remission was defined by MRD 
levels of less than 1x10
-3
. Oqrpos: out of quantitative range positive; iqrpos: in quantitative range positive. 
MRD levels of 16 of the 25 patients of the WES cohort had MRD levels of less than 1x10-3. Of 
these 16 patients n=2 had an MRD level of <5x10-5, n=11 had an MRD level of <1x10-4 and n=3 
had an MRD level of <1x10-3. To increase the number of samples available for WES we also 
included samples with a FISH negative remission sample. FISH screening was routinely 
performed on all patient samples. We estimate that the maximum proportion of remaining CLL 
cells in a remission sample is no more than 10 % if the FISH abnormality present at diagnosis 
can no longer be detected. Nine additional samples from the REACH cohort fulfilled this 
requirement (Table 8).  
Remission 
Sample 
MRD  
Level 
MRD 
Sensitivity 
MRD 
Quantitative Range 
MRD  
Interpretation 
P04 1.25x10-3 1x10-4 1x10-3 Iqrpos 
P05 7.44x10-3 1x10-4 1x10-4 Iqrpos 
P10 6.09x10-3 1x10-4 1x10-4 Iqrpos 
P11 1.16x10-3 1x10-4 1x10-4 Iqrpos 
P14 0.02 1x10-4 5x10-4 Iqrpos 
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Remission 
Sample 
MRD  
Level 
MRD 
Sensitivity 
MRD 
Quantitative Range 
MRD  
Interpretation 
P15 0.02 1x10-4 1x10-4 Iqrpos 
P17 0.04 5x10-5 5x10-5 Iqrpos 
P18 0.31 1x10-4 1x10-4 Iqrpos 
P25 0.02 1x10-4 1x10-4 Iqrpos 
Table 8 MRD levels of the samples selected on the basis of a negative FISH marker in the remission sample (n=9). 
MRD levels were routinely measured by realtime quantitative PCR. Iqrpos: in quantitative range positive. 
Out of these nine samples, n=4 had fewer than 0.74 % CLL cells according to MRD measure-
ments, n=4 had fewer than 4 % CLL cells. There is only one remission sample, which was FISH 
negative but had an MRD level of 0.31 (30 %).  
4.1.2 Target Enrichment, Sequencing and Low Level Data Analysis Including Read 
Mapping and Quality Metrics 
We used the Agilent SureSelect Human All Exon 50 Mb platform (later referred to as Agilent 
50 Mb kit) to enrich the coding regions, or exome, of each CLL sample. The Agilent 50 Mb kit 
consists of a biotinylated RNA library of fragments with a length of 120 nucleotides, the so-
called baits, which are complementary to the coding regions of the human genome. The 
enrichment is based on an in-solution hybridization step. To enrich the patients’ exome, 
genomic DNA is converted into a sequencing library, which is composed of fragments of about 
150 bp in length. Then, those fragments from the genomic library are enriched that contain 
exonic sequences (3.6). This process takes at least 24 h. The enriched fragments are amplified, 
purified and diluted to an appropriate concentration for sequencing. The exome libraries were 
sequenced on a Genome Analyzer IIx (Illumina) and the data were analyzed on a Galaxy server. 
The sequencing and the data analysis were performed at the Laboratory for Functional 
Genome Analysis (LaFuGa) at the Gene Center of the University of Munich. 
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Figure 11 Gel like images and electropherograms of two Bioanalyzer runs. A) Sheared DNAs from five different 
samples run on a Bioanalyzer DNA 1000 chip with fragments of around 150 bp in length represented as gel like 
pictures (left) and as electropherogram (right) of one patient sample (P12). The amount of DNA is calculated from 
the area below the curve. B) The second gel like picture represents the same patient samples but after adapter 
ligation and post-hybridization amplification. There is a clear shift visible from 150 bp to 250 bp. The shift can be 
also seen in the electropherogram. In addition, there is a small peak visible at around 71 bp representing excess 
primers. Concatamers can be seen at around 1000 bp.  
Figure 11 shows the results after DNA shearing of genomic DNA (A) and the shift after adapter 
ligation and amplification (B). 
  
A 
B 
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4.1.2.1 Low Level Data Analysis  
The base calling from the raw image files and the generation of the FASTQ files was performed 
by the Genome Analyzer IIx during the sequencing run. Thereafter FASTQ files were 
transferred to the Galaxy server. The low level data analysis on the galaxy server is 
summarized in Figure 12, briefly: at the beginning, reads that did not pass illumina’s chastity 
filter need to be removed, in the following the reads can be mapped to the reference genome 
and a generic file is generated which is the basis for further downstream analysis including 
SNV-, InDel-calling and calculation of coverage.  
 
Figure 12 Flowchart of the initial sequence analysis steps. The images acquired during the sequencing run were 
processed in real time on the Genome Analyzer (cluster detection, base calling etc.) and FASTQ files were 
generated, which were transferred to the Galaxy server. With the FASTQ Quality Filter, reads that did not pass 
chastity filter were removed. Reads were mapped to the human reference genome with BWA default settings. 
SAMtools was used to remove duplicated reads and reads with a mapping quality of <10. To generate the mpileup 
file, which is the input format for downstream analysis, the minimum base quality for a base to be considered was 
set to 13 and the “extended BAQ computation” option was selected.  
The chastity filter identifies clusters with a low signal to noise ratio. Frequently, adjacent 
clusters are too close to each other or even overlapping and their signals cannot be measured 
independently.  
The chastity of a base call is defined as: ℎ =
	 	( 	 	 	 	 )
	 	
  
A cluster passes the chastity filter if not more than one base call has a chastity of <0.6 in the 25 
first bases of a cluster. A chastity of ≥0.6 means that the signal of the base is at least 1.5 fold 
stronger than the signal of the second most intense base at that position. The chastity filter 
information is encoded as comment in the first line of each FASTQ file. Reads are either 
marked with “Y” (Yes) or “N” (No) for reads that passed or failed the chastity filter, 
respectively. As reads that did not pass the filter are only flagged and not deleted, we used the 
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‘FASTQ Quality Filter’ an in house tool, to remove all reads which did not pass the chastity 
filter. At this point, the reads can be mapped to the reference genome. Mapping is a 
challenging and very time intensive step of NGS data analysis. An enormous number of short 
reads need to be mapped to a reference genome to create an alignment file. We decided to 
use the BWA mapping tool, its algorithm is designed to align short reads up to 100 bp and it 
allows mismatches and gaps (Li and Durbin et al 2009). For mapping, the FASTQ files are 
needed as input. We used the default settings of BWA for mapping of paired-end reads.  
The SAM (Sequence Alignment Map) format is the final output of BWA. Output and settings of 
the alignment tool are described in more detail in the material and methods section 3.8.2.1. 
For further analysis, SAMtools (Li et al 2009) was used to filter reads based on mapping quality 
and to remove PCR duplicates. In addition, SAMtools generates a pileup file which is a generic 
file format (3.8.2.2) and is used for downstream analyses.  
BWA calculates the mapping quality scores for each alignment, which is the Phred-scaled 
probability of an alignment being incorrect. Phred quality values were originally developed by 
Phil Green and coworkers (Ewing et al. 1998). They integrated quality scores in a base calling 
program for automated sequencing traces. The principle of describing the quality of a base call 
was adopted for mapping qualities or SNP variants of next-generation sequencing data. The 
quality score Q is calculated from the probability P that the mapping or base is incorrect by the 
following formula: Q = -10 log10P. For example: a mapping score Q of 20 means that there is a 
1 % chance that the mapping is incorrect. A Q score of 30 denotes a 0.1 % probability that the 
mapping is incorrect, or, with other words, the mapping is 99.9 % correct. 
The Phred quality values are rounded to the nearest integer. In our workflow we removed 
reads with a mapping quality <10 using SAMtools. A mapping quality of 10 denotes an error 
probability of 0.1, so a mapping quality of 10 means that one out of 10 reads with that quality 
would be mapped to a wrong position. We also removed duplicate reads (SAMtools) 
introduced by PCR during library construction. SAMtools also detects reads with identical outer 
coordinates. In this case, only the read with the highest quality is retained. It is not possible to 
distinguish between duplicates resulting from PCR amplification or duplicates resulting from 
the same template by chance.  
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Figure 13 Filter settings and mapping quality for the reads from the 50 exomes. A) Total number of raw reads, 
reads filtered by chastity, mapped reads, mapping quality and reads after duplicate filtering. Unique reads mapped 
with a quality ≥10 were used for downstream analysis. Out of these the total number of reads with mapping quality 
≥13, ≥20 and ≥30 is shown. ● Number of total reads to be further filtered.  Number of total reads used for 
downstream analysis, separated by mapping quality. B) Mean (sd) percentage of reads mapped with the different 
filter settings, calculated for all 50 exomes. About 81.6 % of the reads passed the chastity filter. Further than that 
filter options for mapped reads and reads mapped with a quality of ≥10 were applied, resulting in 79.7 % and 71.8 % 
of the raw reads remaining, respectively. After removal of PCR duplicates 63.7 % of raw reads are remaining which 
were used for downstream analysis. 63.5 % of all reads mapped with a quality ≥13, 62.8 % mapped with quality ≥20 
and 58.5 % had a mapping quality of 30 or better. MQ: mapping quality; M: million 
On average 18.4 % of all reads were discarded by Illumina’s chastity filter due to low signal to 
noise ratio (Figure 13). Reads passing this filter were mapped to the human genome reference 
by BWA. More than 97 % of all reads that passed the chastity filter could be mapped to a 
unique position in the genome. Mapping qualities were assigned to each read by the BWA 
program. A mapping quality of 0 indicates that a read can be mapped to more than one locus 
in the reference genome or is not mapped at all. These reads were discarded by the software. 
After mapping with BWA, the reads were further analyzed by SAMtools. The SAMtools’s filter 
for mapping quality was set to ≥10 to retain reads mapped to the correct position with a 
probability of greater than 90 %. Between 8.9 to 10.8 % of the mapped reads did not fulfill this 
quality requirement. In addition, we removed on average 11 % duplicates from the reads after 
mapping quality filtering. Duplicate reads have exact the same 5´-end mapping coordinates. A 
duplicate read can either be the result of two PCR generated copies of the same genomic 
fragment being sequenced twice in different locations of a flow cell or it can be an optical 
duplicate when one cluster on the flow cell is erroneously identified as two adjacent clusters.  
  
A B 
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 Raw 
reads 
(M) 
Passed chastity 
filter 
(M)                   (%) 
Passed mapping quality 
(MQ≥10) 
(M)                     (%) 
Duplicate 
removal 
(M)                (%) 
Mean 
(sd) 
 94 (20)  77 (14) 82  68 (12) 72  60 (11) 64 
Median 
(range) 
 99 
(45-126) 
 83 
(42-93) 
84  73 
(38-83) 
74  64 
(36-75) 
65 
Table 9 Number of reads after each filtering step. The percentage of reads remaining after the filtering steps was 
calculated based on the raw reads obtained. The minimum mapping quality was set at 10. The numbers shown are 
the mean and medians of all 50 exomes sequenced. MQ: mapping quality; M: million; sd: standard deviation  
The mean (including the standard deviation: sd) and median (including the range) number of 
reads remaining after the different filtering steps is summarized in Table 9. The number of 
bases sequenced and used for downstream analysis was about 4.8 Gb per exome assuming a 
mean read length of 80 bp and considering all bases regardless of base quality.  
For the reads, which were selected for downstream analysis, the distribution of mapping 
qualities was evaluated. The mapping quality tells us the probability that a read is mapped 
correctly. Table 10 shows the distribution of mapping qualities (after duplicate removal) for 
the 50 exomes sequenced in this project.  
Mapping quality 
(# reads passed 
filter) 
≥MQ10 
(M) 
≥MQ13 
(M) 
≥MQ20 
(M) 
≥MQ30 
(M) 
Mean (sd) 60.2 (11.2) 60.0 (11.1) 59.2 (11.0) 55.2 (11.2) 
Median (range) 64.5 (36.1-74.6) 64.3 (36.0-74.4) 63.5 (35.6-73.6) 59.9 (32.0-69.2) 
Mapping quality 
(Percentage of 
reads)  
≥MQ10                  
set to 100 %  
≥MQ13 
(%) 
≥MQ20 
(%) 
≥MQ30 
(%) 
Mean (sd) - 99.7 (0.0) 98.5 (0.2) 91.5 (4.3) 
Table 10 Reads that passed the various filter criteria for mapping quality. The average number of reads per 
exome, which passed the filter with a certain mapping quality, is shown in the upper part of the table. In the lower 
part, the average percentage of reads (per exome) with a mapping quality ≥ 13, 20 and 30 was calculated from all 
the reads that reached a mapping quality of ≥ Q10. A total of 50 exomes were sequenced. M: million; MQ= Mapping 
Quality; sd: standard deviation 
On average, 60.2 million reads per exome were available for downstream analysis. These reads 
remained after chastity and mapping quality filtering and after duplicate removal. To evaluate 
the mapping quality, we divided the mapped reads into those with a mapping quality ≥13, 20 
and 30, which correspond to reads mapped with an error probability of less than 5, 1 and 
0.1 %, respectively. On average, 60.0 million reads per exome had a mapping quality of 13 or 
higher and 59.2 million had a mapping quality of 20 or higher. More than 90 % of reads had a 
mapping quality of 30 or higher. A mapping quality of 30 indicates that there is a 1 in 1000 
chance that the read is mapped to the wrong location. 
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4.1.2.2 Enrichment Efficiency of the Agilent’s SureSelect Kit 
Agilent’s SureSelect kit consists of 120-mer biotinylated RNA baits for capturing genomic DNA 
fragments corresponding to exons. The proportions of reads or bases that map to target 
regions are a measure for the enrichment efficiency of the capture kit. We used the Integrative 
Genome Viewer (IGV) (Robinson et al. 2011; Thorvaldsdottir et al. 2012) to visualize the read 
mapping on the reference sequence. BAM files and tracks in the Bed file format can be loaded 
into the viewer and displayed in different tracks. The mapping data from one sample (P19) as 
well as the target regions of the Agilent 50 Mb kit and the hg18 RefSeq genes are shown as a 
screenshot of the IGV window in Figure 14.  
 
Figure 14 IGV screen shot. The data displayed in IGV shows the mapping of the reads from CLL sample P19 at the 
TP53 locus. The coverage is displayed as a histogram in the upper portion of the “CLL sample P19” track and as 
individual reads in the lower portion of the track. Note that not all reads could be displayed because of lack of 
space. The annotation for the human genome is shown in dark blue and the Agilent SureSelect 50 Mb target regions 
in light blue. The RefSeq coding exons are displayed as green boxes in the bottom track. 
The IGV program displays the mapping data in its genomic context and allows the user to zoom 
in and scroll over chromosomes. A chromosome ideogram is positioned at the top of the 
window, and the current position on the chromosome is indicated by a red box. In Figure 14, 
the mapped exome sequencing data of CLL sample P19 was loaded into the viewer, and the 
region around the TP53 gene was magnified. The mapped reads are displayed as grey arrows 
indicating the sequencing direction of each individual read. The coverage is displayed as 
histogram in the upper portion of the window. The colored bars in the right histogram of the 
window indicate heterozygous SNPs (blue and orange). The human RefSeq gene track shown in 
dark blue with exons represented as boxes is displayed by default when the human genome is 
selected as reference. The Agilent 50 Mb targets (light blue) were uploaded. This track shows 
the position of the baits. The hg18 RefSeq coding exons are shown in the bottom track. By 
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moving the mouse pointer over the display additional information is shown in pale yellow text 
boxes. 
The target positions of the Agilent 50 Mb kit (light blue boxes in Figure 14) overlap the exon 
boundaries of the RefSeq gene annotations. As a result of the position of the baits and the 
random fragments of DNA in the sequencing library, there are reads that map only partially or 
not at all to the targets. Some reads also map to intergenic regions due to sequence 
homologies or inefficient capturing. The performance of the Agilent 50 Mb kit for capturing the 
target regions was analyzed using a BED file provided by Agilent Technologies containing all 
target regions of the kit based on the NCBI Build 36 (hg18) annotation. However, for 
downstream analysis we used the human RefSeq genes as downloaded in May 2012 from the 
UCSC table browser (http://genome.ucsc.edu/cgi-bin/hgTables). The RefSeq genes are based 
on the human genome assembly from March 2006 (NCBI Build 36/hg18). Only the RefSeq 
genes (34,380,348 bases) were considered to be the target in the downstream analysis if not 
otherwise specified. 
 
Figure 15 Quality of exome enrichment. On target metrics calculated at the single nucleotide level for the Agilent 
50 Mb targets (blue). On average, 79.56 % of the bases map to or near to the target (± 250 nucleotides), 57.05 % 
mapped on the target and 22.51 % near to the target. When the RefSeq genes were considered as targets, fewer 
bases map on or near the target (72.72 %), on average 39.25 % map on target and 33.01 % close to the target 
(green). On average target metrics (including standard deviations) were calculated for all 50 exomes.  
We used the Picard program (http://picard.sourceforge.net) to calculate on target metrics at 
the base level. We calculated the percentage of bases from mapped reads that mapped to 
target regions (on target) or within 250 nucleotides off target (near target). The percentage of 
on or near target bases when the RefSeq genes were used as target is with 72.72 % only a few 
percentage points lower than the 79.56 % when we used the Agilent 50 Mb kit as target. This 
difference is due to the fact that the Agilent 50 Mb bait library contains additional targets like 
miRNAs and transcripts annotated in other databases (CCDS, Ensembl and GenBank).  
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4.1.2.3 Mean and Median on Target Coverage  
Coverage is defined as how many times a given genome position was sequenced. We 
calculated the coverage for the bases of the hg18 RefSeq genes. The coverage was calculated 
from a file generated by BEDtools, which contained the coverage at each nucleotide position 
of the target. 
 
Figure 16 Mean and median on target coverage calculated for all 50 exomes. Each dot represents the mean or 
median coverage of one exome. The black line represents the mean. 
For all 50 exomes, the average target coverage ranged between 32x and 73x with a mean of 
57x (±11.7). The median coverage ranged from 26x to 60x with a mean of 47x (±9.8). The 
median coverage represents the data more accurate, as single positions with extraordinarily 
high coverage will not influence the median to the same extent as the mean.  
4.1.2.4 Percentage of Target Positions Sequenced  
It is of great interest to know how complete the exome target was sequenced. About 95 % of 
all target positions had a coverage of at least one. However, to be able to identify mutations or 
variants with a certain degree of confidence, a 10-fold coverage is required. A 10-fold coverage 
was achieved for about 85 % of all target positions in all 50 exomes. Half of all target positions 
had a coverage of more than 40x (Figure 17). 
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Figure 17 Coverage of target positions (hg18 RefSeq genes). A) Target positions genes covered x-fold or higher. B) 
Target positions covered ≥10x, 1-9x or not at all. The graph shows the coverage data for all 50 exomes, error bars 
represent standard deviation. 
On average 5 % of all target regions were not covered at all in our 50 exome sequence 
samples. These targets were most likely not enriched during exome capture. On average, 10 % 
of all hg18 RefSeq positions were covered but were not covered by at least ten reads, which 
was our threshold for variant calling.  
4.1.3 Downstream Analysis for the Detection of Single Nucleotide Variants (SNVs) 
and Insertion/Deletions (InDels) 
One of the most important goals in the analysis of tumor genomes or exomes is the 
identification of tumor-specific genetic lesions. As a first step in this process, heterozygous 
positions in the sequence and positions where the sequence is different from a reference 
sequence have to be found. 
Since 2009, a large number of variant detection programs have become available for the 
analysis of next-generation sequencing data. One of these is VarScan, which was developed by 
Dan Koboldt and colleagues (Koboldt et al. 2009). This tool is compatible with the output of 
short read aligners like BWA. There are two ways to use VarScan to detect tumor-specific 
variants: 1) in the so-called subtraction workflow, variants are first detected separately in the 
tumor and the remission sample, and then the remission variants are subtracted from the 
tumor variants: 2) in the so-called “somatic” workflow a built-in routine in VarScan 2, called 
somatic, is used, which directly identifies somatic mutations, loss of heterozygosity and copy 
number alterations in the sequencing data of paired tumor-normal samples (Koboldt et al. 
2012). The results of the two workflows were compared to each other. From 2012 onward, we 
also used VarScan 2 for the subtraction workflow. VarScan 2 has an option to reduce false 
positive calls close to InDels. Many false positive calls occur adjacent to InDels as a result of 
faulty alignment because introducing a gap is much more “costly” than a mismatch. 
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4.1.3.1 Subtraction Workflow to Detect CLL-specific Variants  
In the subtraction workflow, SNVs and InDels were called separately in the mapped read data 
for the CLL and the corresponding remission sample from the same patient. We used much 
more stringent filter settings for the variant calling in the CLL sample than in the remission 
sample. For the CLL sample a minimum coverage of 10 at the position of a putative variant was 
required. The minimum variant frequency was set to 20 %, and at least 3 variant reads had to 
be present. Since we attempted to validate all variants by Sanger sequencing, we assumed that 
a minimum variant frequency of 20 % would be the lowest detectable level using Sanger 
sequencing. Using these settings also implied that variants with a 20 % frequency would not be 
called at positions with a coverage between 10- and 14 fold since at least 3 variant reads were 
required. In other words, variants at a position with 10-14 fold coverage need at least a variant 
frequency of 21 % for a variant to be called.  
In contrast to the CLL samples, the remission samples were analyzed with extremely relaxed 
filter settings. The coverage and the number of variant reads were both set at 1. We used a 
minimum variant frequency of 1 % in the high stringency (HS) setting and 5 % variant 
frequency in the low stringency (LS) setting (Figure 18). After variant calling, the variant lists 
from the tumor and normal sample were compared and only the variants present in the tumor 
sample and not in the remission sample were retained. To reduce the number of putative 
tumor-specific variants even further, all variants that were at the position of a known 
polymorphism (dbSNP130) and variants that were not located in the RefSeq coding exons were 
also excluded. We also discarded variants that were only supported by sequences from one 
strand and variants with a p-value >0.05 (Fisher’s exact test). Custom filter settings retained 
only variants with at least four reads. 
In a first step to identify those variants that might be so-called driver mutations, we annotated 
the effect of the CLL specific variants on the protein level using the snpEff program (Cingolani 
et al. 2012) to identify those variants that would result in a missense or nonsense mutation 
(nonsynonymous variants). InDels and nonsynonymous tumor-specific variants were manually 
inspected using the IGV browser. This inspection of candidate variants helped to further 
reduce the number of false positives calls resulting, for example from misalignments adjacent 
to germline InDels.  
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Figure 18 Flow chart 1 Subtraction workflow with high and low stringency filter settings using VarScan 2. Number 
of SNVs are given exemplary for P3. Among the nine and ten SNVs which remained after custom filter settings, six 
and seven were nonsynonymous for the HS and LS settings respectively. REM: remission sample; LS: Low Stringency 
filter settings; HS: High Stringency filter settings. 
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4.1.3.2 Somatic Workflow to Detect CLL-specific Variants 
In the somatic workflow, using the VarScan 2 somatic subroutine, aligned sequencing data 
from a CLL and the corresponding remission sample were compared directly (Koboldt et al. 
2012). At each position, the genotype is determined in the CLL and remission sample based on 
user-defined thresholds for base quality, coverage and variant frequency. The genotypes at 
each position are compared between tumor and normal sample. A variant is called 
homozygous when the reads supporting the variant are >75 % of the total reads at this 
position. If the variant genotypes of the CLL and the remission sample match at a given 
position, the variant is called germline (inherited). If the remission sample matches the 
reference and the tumor contains a variant, this position is called “somatic” indicating that this 
variant was probably somatically acquired. If the remission control is heterozygous at a given 
position and the tumor sample homozygous, this position is called “loss of heterozygosity” 
(LOH). 
The following parameter settings were used for the somatic subroutine of VarScan 2: minimum 
coverage 10 for both tumor and remission sample minimum variant frequency for a 
heterozygous position to be called in the tumor sample was set to 20 %. Only variants 
supported by at least four reads were considered. A 20 % allele frequency and a minimum of 
four reads in the tumor sample means that variants at a position with 10-19 fold coverage 
need at least a variant frequency of 21 % for a variant to be called. High confidence variants 
were called with the following custom settings: (1) the maximum variant allele frequency in 
the remission sample was set to 5 %, (2) variants were required to have a p-value of <0.05 
(Fisher’s exact test) (3) and reads from both strands of the tumor sample needed to be present 
at that position. Variant annotation and effect prediction were performed in the same way as 
in the subtraction workflow. In addition, all nonsynonymous variants were manually inspected 
by IGV before validation. 
In contrast to the subtraction workflow, the somatic workflow also allows the user to enter the 
estimated purity of the tumor and normal sample. The LOH positions called by this workflow 
were manually inspected by IGV but not validated by Sanger sequencing. Due to time 
constraints these variants could not be analyzed in detail in this project.  
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Figure 19 Somatic workflow using VarScan 2. REM: remission sample 
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4.1.3.3 Validation by Sanger Sequencing 
To examine the rate of true positive calls, we performed Sanger sequencing (3.5.2) of all non-
synonymous SNVs and InDels, which were called by our analysis pipeline. We set the minimum 
variant frequency to 20 % in our exome analysis pipeline, high enough to ensure that those 
candidates were detectable by Sanger sequencing if they were true positives. With a minimum 
variant frequency of 20 %, we also expect not to underestimate the number of true positive 
calls as we would not be calling possible mutations below the sensitivity of conventional 
sequencing. Besides data analysis, validation was one of the most laborious parts of the 
project. At the beginning we were uncertain which minimum requirements a true positive 
variant should fulfill. Therefore, we validated variant positions with different numbers of total 
reads, variant reads, various p-values and positions with variant reads from one or both 
strands. In total, we validated around 300 nonsynonymous SNVs and InDels. With this testing 
we became more familiar with the performance of the various filter settings and we then set 
the strict requirements for a variant to be validated as follows: p-value <0.05, ≥4 variant reads 
from both strands. For each amplicon we designed primers with a melting temperature of 
about 60 °C so that we could amplify multiple targets in one PCR run using a touch-down PCR 
protocol. The amplicon size ranged between 152 and 1065 bp for all variants that could be 
validated. To conserve genomic DNA from the original samples, we first tested the primers on 
DNA isolated from a cell line. In the next step we performed the PCR on the CLL as well as 
remission sample. In total, we performed around 600 PCR reactions on patient DNA. Starting 
from these amplicons, we further prepared twice the number of sequencing reactions for 
bidirectional Sanger sequencing.  
4.1.3.4 Comparing Subtraction Workflows with High and Low Stringency Settings  
To evaluate the differences between low and high stringency setting in the subtraction 
workflow we compared the number of CLL-specific SNVs that were detected in all 25 CLL 
exome samples with low vs. high stringency filter settings. The SNVs had to be supported by a 
minimum of four reads and a p-value <0.05. In addition, we only included nonsynonymous 
SNVs into this comparison, which were also resequenced by Sanger sequencing. We did not 
Sanger sequence candidate SNVs that did not result in a missense or nonsense mutation. 
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Figure 20 Comparing VarScan 2 subtraction workflows. A) In total n=199 validated mutations were detected using 
the high stringency filter and n=236 with low stringency filter settings. The number of SNVs that were false positives 
(non-confirmed) also increased from n=20 to n=27. B) All confirmed mutations detected with high stringency filter 
settings were also detected by the low stringency filter. HS: high stringency; LS: low stringency 
The number of true positive nonsynonymous SNVs increased when we allowed the SNV to 
have a variant frequency of 5 % in the non-tumor sample (low stringency setting). This 
effectively means that we permitted cases, in which there were still some (less than about 
10 %) CLL cells present in the remission sample. For the 25 CLL exomes the number of 
validated SNVs increased from n=199 to n=236 (Figure 20 A) when the low stringency settings 
were used. All SNVs detected by the high stringency (HS) filter settings were also detected by 
the low stringency (LS) filter (Figure 20 B). The number of variants that could not be confirmed 
by Sanger resequencing increased from n=20 to n=27 when the low stringency settings were 
applied (Figure 20 A). The SNVs, which could not be confirmed, were either false positives or 
SNVs which were also present in the remission sample. Some of the SNVs could already be 
excluded at the manual inspection stage with the IGV browser before Sanger sequencing. By 
increasing the variant frequency in the non-tumor sample to 5 %, the number of true positive 
of missense and nonsense mutations increases by 16 %, but the number of false positives 
increased by 35 %.  
4.1.3.5 Comparing the Subtraction Workflow with the Somatic Workflow 
We also compared the results of the somatic workflow and the low stringency subtraction 
workflow. For both workflows we only compared SNVs that could be confirmed by Sanger 
sequencing with a minimum of four variants in the tumor sample and a p-value of <0.05. The 
minimum variant frequency in tumor samples was set to 20 % in both workflows.   
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Figure 21 Comparison between the somatic and subtraction LS workflow. A) In total n=237 SNVs could be 
confirmed with the somatic filter settings, n=15 could not be confirmed. For the low stringency filter settings n=236 
SNVs were confirmed, whereas n=27 proved to be false positives (not confirmed). B) Seven SNVs affecting seven 
genes could only be detected by the somatic workflow and six mutations in six genes were only identified with the 
low stringency subtraction workflow.  
Almost equal numbers of true mutations were detected with the somatic and LS subtraction 
workflow, with n=237 and n=236 mutations, respectively (Figure 21). Although the amount of 
variants is similar, the variety of genes is higher. Seven genes were only observed within the 
somatic output and six were specific for the subtraction LS workflow (Figure 21). There were 
fewer false positive variants (n=15) with the somatic workflow compared to the LS subtraction 
workflow (n=27). It is important to note that three false positives SNVs in the LS subtraction 
workflow were called because of a low coverage (<10x) in the remission sample. This resulted 
from the minimum coverage setting of 1-fold in the LS subtraction workflow. The somatic 
workflow required a minimum coverage of 10 in the remission samples.  
4.1.3.6 Confirmed Missense and Nonsense Mutations in CLL  
Nonsynonymous SNVs resulting in a missense or nonsense mutation, which were obtained 
using the three different workflows, are summarized in Figure 22. All mutations shown were 
confirmed by Sanger sequencing of the CLL and remission sample (3.5.2). When we assign the 
nonsynonymous variants to the corresponding patient samples we see some variation in the 
number of mutations per sample. There were between 2 and 17 mutations per sample.  
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Figure 22 Missense and nonsense mutations detected in 25 CLL REACH exome samples. CLL patient samples from 
P01 – P25 and the number of their confirmed somatic mutations detected by the three workflows are plotted. HS: 
High stringency (minimum variant frequency in non-tumor sample 1 %); LS: Low stringency (minimum variant 
frequency in non-tumor sample 5 %) 
Only mutations affecting the hg18 RefSeq genes (BED file) were analyzed and are shown here. 
Confirmed InDels are not included here. In all workflows, only SNVs with a p-value of <0.05 
were considered for validations and the minimum variant frequency in the tumor sample was 
set to 20 %. The minimum coverage for a nucleotide position in a tumor sample was set to 10 
in all workflows. In total, we were able to confirm 243 mutations with Sanger sequencing from 
all three workflows (199 in the Subtraction HS workflow; 236 in the Subtraction LS workflow; 
237 in the Somatic workflow). The mutations detected with the low stringency settings 
included all mutations found with the high stringency setting (Figure 20 B). When we used the 
HS subtraction workflow we obtained between 1 and 14 mutations per patient. The mean was 
8 (±3.8) mutations per patient. The LS subtraction workflow increased the mean number of 
mutations to 9 (±4.0) with a range of 2 and to 16 mutations. The somatic workflow produced 
similar results. The number of mutations ranged between 2 and 17, with a mean of 9 (±4.1). As 
mentioned earlier, about 15 % of all target positions could not be analyzed, as they did not 
reach the minimum coverage requirements for a SNV to be called. Therefore, the mutations 
described are derived from only 85 % of the target (i.e. the RefSeq hg18 genes). This implies 
that the true number of missense and nonsense mutations in each sample is about 17 % 
greater.  
4  Results                                                                                                                                                     89 
 
 
4.1.3.7 Rate of True Positive Mutations in the Different Workflows 
Due to different filter settings and algorithms of the three workflows the rate of true positive 
missense and nonsense mutations varied between workflows. Of course, this “confirmation 
rate” is also dependent on the sensitivity of Sanger sequencing, which we used as the 
validation method. The proportion of true positives was calculated with respect to all non-
synonymous variants detected with a given workflow. Some positions were excluded in 
advance, as they did not pass visual inspection using the IGV browser. The following graph 
represents the true positive rate of confirmed nonsynonymous variants for all three workflows 
from the 25 CLL samples (Figure 23).  
 
Figure 23 Frequency of variants confirmed by Sanger sequencing. The rate of true positive nonsynonymous calls 
was calculated from all nonsynonymous SNVs detected for each workflow after exclusion of low quality positions by 
visual inspection. 
The highest confirmation rate (>94 %) was obtained with the somatic workflow followed by 
the high and low stringency subtraction workflows with a true positive rate of almost 91 % and 
90 %, respectively (Figure 23). To calculate the confirmation rate for each workflow we only 
considered positions, which fulfilled strict criteria. Only variants supported by a minimum of 
four reads, a p-value of <0.05 and variants found on reads from both strands were considered. 
As our filter settings did not remove variants (but sort them), which did not fulfill these 
criteria, we also validated some of these SNV calls in the beginning of our project. Some of 
these could be confirmed but we did not consider them for this calculation, since we did not 
systematically validate SNVs, which did not fulfill these criteria in all samples. The validation 
rate for SNVs that did not pass these criteria was very low. The confirmation rate for InDels 
was also very low and was not calculated. 
4.1.4 Somatic Mutations in CLL  
In the 25 CLL samples that were whole exome sequenced, 271 mutations, which lead to an 
alteration at the protein level or affected a splice site region, were confirmed by Sanger 
sequencing. These mutations included mainly single nucleotide exchanges but also insertions 
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and deletions. These 271 mutations affected 260 different genes. The total number of 
mutations detected (n=271) is larger than reported in the preceding paragraphs because we 
also validated some putative SNVs by Sanger sequencing, which did not fulfill the strict 
requirements (p-value <0.05, ≥4 variant reads, both strands). These putative SNVs often had 
only three variant reads or reads from one strand only. The majority of these variants proved 
to be false positives. We mainly carried out this validation in the initial stages of the project to 
become familiar with the performance of the various filter settings in our workflows.  
Missense Nonsense InDel Read through Splice site 
237 (87.45 %) 19 (7.01 %) 13 (4.80 %) 1 (0.37 %) 1 (0.37 %) 
Table 11 Mutations detected by exome sequencing and confirmed by Sanger sequencing. Total mutations n=271.  
Among the validated variants, 87 % were missense mutations (n=237), 7 % nonsense 
mutations and 5 % insertions or deletions and 1 % read through and splice site mutations. Only 
one patient had a read through mutation in a stop codon. The splice site mutation was 
discovered by chance. We did not systematically look for splice site mutations.  
Case Gene 
Name 
Gene 
ID 
Annotation Chr Position Type of 
Mutation 
cDNA 
change 
Protein 
change 
Var. 
Freq. 
P01 GRHPR 9380 NM_012203.1  9 37420571 Missense c.662C>T p.A221V 40 % 
P01 CHD2 1106 NM_001271.3 15 91335751 Missense c.3455G>A p.R1152Q 41 % 
P01 FAR2 55711 NM_018099.4  12 29361161 Missense c.1076C>A p.A359D 41 % 
P01 DMP1 1758 NM_004407.3  4 88799614 Missense c.143G>A p.S48N 56 % 
P01 IL28A 282616 NM_172138.1  19 44451977 Missense c.280C>T p.R94C 46 % 
P01 C1orf27 54953 NM_017847.5  1 184626488 STOP c.497G>A pW166* 54 % 
P01 ARHGEF17 9828 NM_014786.3  11 72756343 Missense c.6062G>A p.R2021K 21 % 
P01 FOLR4 390243 NM_001199206.1 11 93679364 Missense c.176C>T p.T59M 37 % 
P01 PCDHGA4 56111 NM_018917.2  5 140715774 Missense c.823G>A p.G275R 46 % 
P01 RUFY1 80230 NM_001040451.2 5 178961575 Missense c.1514T>A p.M505K 49 % 
P01 ABCC10 89845 NM_033450.2  6 43525728 Missense c.4316G>A p.R1439H 67 % 
P02 PAPD5 64282 NM_001040284.2  16 48807491 Missense c.769A>T p.I257F 38 % 
P02 TCHHL1  126637 NM_001008536.1  1 150325863 Missense c.919C>A p.P307T 41 % 
P02 CDH12  1010 NM_004061.3  5 22114366 Missense c.177T>A p.N59K 55 % 
P02 ACOX2  8309 NM_003500.3  3 58492480 Missense c.683A>G p.Q228R 56 % 
P02 ADAMTS12 81792 NM_030955.2  5 33624604 Missense c.2722G>A p.V908M 39 % 
P02 CREBBP 1387 NM_004380.2  16 3869873 STOP c.46A>T p.K16* 73 % 
P02 SRD5A1 6715 NM_001047.2  5 6716025 Missense c.659C>G p.A220G 49 % 
P02 METRNL 284207 NM_001004431.1  17 78636203 Missense c.271G>A p.V91I 47 % 
P02 OR4A47 403253 NM_001005512 11 48467438 Missense c.518A>T p.D173V 32 % 
P02 ZNF227 7770 NM_182490.1  19 49432420 Missense c.1997G>A p.G666E 40 % 
P02 RB1 5925 NC_000013.11 13 47845541 Splice Site G>A - 79 % 
P03 SCUBE2 57758 NM_020974.2  11 9067848 Missense c.238G>A p.E80K 28 % 
P03 MAGI2 9863 NM_012301.3  7 78920440 Missense c.133G>T p.G45W 37 % 
P03 ATXN2L 11273 NM_148415.2  16 28754870 Missense c.3011C>T p.A1004V 46 % 
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Case Gene 
Name 
Gene 
ID 
Annotation Chr Position Type of 
Mutation 
cDNA 
change 
Protein 
change 
Var. 
Freq. 
P03 RPS6KA3 6197 NM_004586.2  X 20121613 Missense c.506A>G p.D169G 29 % 
P03 MED12 9968 NM_005120.2  X 70255979 Missense c.131G>A p.G44D 20 % 
P03 C2orf67/ 
KANSL1L 
151050 NM_152519.2  2 210727383 Missense c.169A>C p.T57P 26 % 
P03 XPO1 7514 NM_003400.3  2 61572976 Missense c.1711G>A p.E571K 20 % 
P03 EBF2 64641 NM_022659.3 8 25771883 Missense c.1397C>T p.T466M 46 % 
P04 ADAMTS20 80070 NM_025003.3  12 42132649 Missense c.1877A>T p.N626I 54 % 
P04 CYFIP2 26999 NM_014376.2 5 156718645 Missense c.2728C>T p.P910S 39 % 
P04 XPO1 7514 NM_003400.3  2 61572975 Missense c.1712A>G p.E571G 53 % 
P04 EMR2 30817 NM_013447.3  19 14744226 Missense c.283G>A p.V95M 37 % 
P04 CSF2RB 1439 NM_000395.2  22 35664221 Missense c.2425C>G p.Q809E 48 % 
P04 GRM6 2916 NM_000843.3  5 178341401 Missense c.2497G>A p.G833S 50 % 
P04 RBPMS2 348093 NM_194272.1  15 62830842 Missense c.136G>A p.E46K 64 % 
P04 SF3B1 23451 NM_012433.2  2 197975079 Missense c.2098A>G p.K700E 36 % 
P04 CCDC111 201973 NM_152683.2  4 185840404 Missense c.1016A>T p.D339V 38 % 
P04 CYB5D1 124637 NM_144607.4  17 7702519 Missense c.234A>C p.R78S 50 % 
P04 PPP1R1B  84152 NM_032192.3  17 35045433 Missense c.493C>T p.R165C 34 % 
P05 PCLO 27445 NM_033026.5  7 82422083 Missense c.6122A>C p.E2041A 40 % 
P05 KAT5 10524 NM_006388.3  11 65240801 Missense c.1018G>A p.V340I 59 % 
P05 CAPZA3 93661 NM_033328.2  12 18783343 Missense c.874A>C p.S292R 27 % 
P05 IFT52 51098 NM_016004.2  20 41682917 Missense c.706G>T p.V236F 35 % 
P05 MYH7 4625 NM_000257.2  14 22969669 Missense c.939C>G p.I313M 42 % 
P05 TIAM2 26230 NM_012454.3  6 155492528 Missense c.479G>A p.R160Q 29 % 
P05 BRDT 676 NM_207189.2  1 92219832 Missense c.1934G>A p.S645N 40 % 
P05 ARHGEF5 7984 NM_005435.3  7 143706861 Missense c.4605C>G p.D1535E 46 % 
P05 MYH2 4620 NM_001100112.1  17 10384070 Missense c.1047G>T p.K349N 32 % 
P05 TRIML1 339976 NM_178556.3  4 189305147 Missense c.1034T>A p.V345E 40 % 
P06 KIAA18437 285175 NM_032504.1  2 210495332 Missense c.5444G>A p.R1815H 44 % 
P06 KLRC4 8302 NM_013431.2  12 10452793 Missense c.271A>G p.I91V 23 % 
P06 GRK7 131890 NM_139209.2  3 142982234 Missense c.941A>G p.Y314C 29 % 
P07 ANKS1B 56899 NM_001204081.1  12 97747087 Missense c.80C>A p.A27D 55 % 
P07 FRAS1 80144 NM_025074.6  4 79590478 Missense c.6424G>T p.G2142C 44 % 
P07 ROBO1 6091 NM_002941.3  3 78799773 Missense c.1916C>T p.A639V 50 % 
P07 KIAA2022 340533 NM_001008537.2  X 73877566 Missense c.3551G>C p.S1184T 54 % 
P07 KLHL6 89857 NM_130446.2  3 184755925 Missense c.211C>G p.L71V 59 % 
P07 BAZ1A 11177 NM_013448.2  14 34313286 Missense c.2995A>G p.K999E 52 % 
P07 MARCH6 10299 NM_005885.3  5 10458769 STOP c.1432C>T p.R478* 38 % 
P07 UNC13C 440279 NM_001080534.1  15 52094479 Missense c.2087A>T p.E696V 55 % 
P07 LRP1B 53353 NM_018557.2  2 141424319 Missense c.3091T>G p.C1031G 50 % 
P07 OTUD7B 56957 NM_020205.2  1 148182861 Missense c.2051G>T p.R684M 40 % 
P07 BMP2K 55589 NM_198892.1  4 80012800 Missense c.1617G>T p.Q539H 37 % 
92                                                                                                                                                   4  Results 
 
 
Case Gene 
Name 
Gene 
ID 
Annotation Chr Position Type of 
Mutation 
cDNA 
change 
Protein 
change 
Var. 
Freq. 
P07 NBPF4 148545 NM_001143989.2  1 108573289 Missense c.1436C>T p.A479V 28 % 
P07 LIMD1 8994 NM_014240.2  3 45611380 Missense c.5A>G p.D2G 38 % 
P07 KLHL6 89857 NM_130446.2  3 184692708 Missense c.1567G>T p.G523W 36 % 
P07 C12orf51/ 
HECTD4 
283450 NM_001109662.3 12 111130155 STOP c.7635G>A p.W2545* 48 % 
P07 COL18A1 80781 NM_030582.3  21 45731807 Missense c.2392G>A p.G798R 50 % 
P07 NOX1 27035 NM_007052.4  X 99991879 Missense c.1050C>A p.F350L 58 % 
P08 TTN 7273 NM_133378.4  2 179154538 Missense c.58999 
G>A 
p.V19667I 49 % 
P08 LRRC7 57554 NM_020794.2  1 70278036 Missense c.3827G>A p.R1276K 43 % 
P08 TNFAIP3 7128 NM_006290.3  6 138234147 Missense c.90T>A p.F30L 48 % 
P08 PASD1 139135 NM_173493.2  X 150593064 Missense c.1925C>T p.P642L 52 % 
P08 DOCK10 55619 NM_014689.2  2 225366381 Missense c.5192C>T p.A1731V 30 % 
P08 TNS3 64759 NM_022748.11  7 47406532 Missense c.902C>T p.T301M 57 % 
P08 GRIA2 2891 NM_000826.3  4 158500511 Missense c.2057C>T p.A686V 44 % 
P08 LRFN5 145581 NM_152447.3  14 41430859 Missense c.2042G>A p.R681H 28 % 
P08 MYO6 4646 NM_004999.3  6 76607703 Missense c.704T>A p.I235N 22 % 
P08 FREM2 341640 NM_207361.4  13 38331672 Missense c.7464T>A p.N2488K 31 % 
P08 CELSR3 1951 NM_001407.2  3 48658567 Missense c.7423C>T p.R2475W 43 % 
P08 RBM46 166863 NM_144979.4  4 155939514 Missense c.750A>C p.E250D 29 % 
P08 DIO2 1734 NM_013989.4  14 79747441 Missense c.128G>A p.R43H 48 % 
P08 ANKFN1 162282 NM_153228.2  17 51881489 Missense c.1159G>T p.V387F 25 % 
P08 PDE1C 5137 NM_001191058.1  7 31885200 Missense c.539G>A p.R180K 53 % 
P09 TOP2A 7153 NM_001067.3  17 35810749 Missense c.2543T>C p.V848A 47 % 
P09 MRO 83876 NM_031939.3  18 46581740 Missense c.562G>T p.D188Y 42 % 
P09 ASH1L 55870 NM_018489.2 1 153714418 Missense c.4868G>A p.G1623S 48 % 
P09 ARSK 153642 NM_198150.2  5 94962507 Missense c.1297G>A p.A433T 41 % 
P09 SKIV2L2  23517 NM_015360.4  5 54684790 Missense c.1469A>G p.N490S 32 % 
P09 SIPA1L1 26037 NM_015556.1  14 71125565 Missense c.1223A>T p.N408I 47 % 
P09 PTPRT 11122 NM_007050.5  20 40414194 Missense c.1706G>A p.S569N 28 % 
P09 ADAM8 101 NM_001109.4  10 134934461 Missense c.1478A>G p.E493G 50 % 
P09 SCD5 79966 NM_001037582.2  4 83845516 Missense c.307C>T p.R103W 28 % 
P09 ADAMTS14 140766 NM_080722.3  10 72138406 Missense c.736G>A p.D246N 31 % 
P09 AMHR2 269 NM_020547.2  12 52104426 Missense c.137G>T p.G46V 39 % 
P09 SCRN2 90507 NM_138355.3  17 43270693 Missense c.1061G>A p.R354H 48 % 
P09 DNAH5 1767 NM_001369.2  5 13894872 Missense c.5413C>T p.R1805C 35 % 
P09 MYH2 4620 NM_001100112.1  17 10389453 Missense c.440A>G p.K147R 45 % 
P10 RANBP2 5903 NM_006267.4  2 108766484 Missense c.9370G>A p.G3124R 38 % 
P10 ERCC8 1161 NM_000082.3  5 60231264 Missense c.665G>A p.C222Y 43 % 
P10 AKR1C4 1109 NM_001818.3  10 5232219 Missense c.160T>A p.L54I 29 % 
P10 PRKCA 5578 NM_002737.2  17 62169255 Missense c.1439C>T p.A480V 25 % 
P10 COL5A2 1290 NM_000393.3  2 189616186 Missense c.3407G>A p.R1136Q 39 % 
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P10 KLRC2 3822 NM_002260.3  12 10477782 Missense c.358G>A p.E120K 75 % 
P10 KIF9 64147 NM_001134878.1  3 47261974 Missense c.1321C>T p.R441C 27 % 
P11 ZFP161/ 
ZBTB14 
7541 NM_003409.4  18 5281893 Missense c.314T>A p.V105D 39 % 
P11 ARMC4 55130 NM_018076.2  10 28265762 Missense c.2151G>C p.K717N 36 % 
P11 MRE11A 4361 NM_005591.3  11 93836981 Missense c.1171A>T p.N391Y 23 % 
P11 NRBP1 29959 NM_013392.2  2 27509813 STOP c.169G>T p.E57* 52 % 
P11 KCNJ5 3762 NM_000890.3  11 128291514 Missense c.938G>A p.G313D 32 % 
P11 FAM179A 165186 NM_199280.2  2 29103242 Missense c.1873C>T p.R625W 46 % 
P11 ATM 472 NM_000051.3  11 107741297 Missense c.9023G>A p.R3008H 22 % 
P11 GPR61 83873 NM_031936.4  1 109887409 Missense c.242A>G p.H81R 44 % 
P11 EGR2 1959 NM_001136178.1  10 64243338 Missense c.1066G>A p.E356K 39 % 
P11 SLC2A2 6514 NM_000340.1  3 172207696 Missense c.547G>A p.A183T 44 % 
P12 KIAA0240 23506 NM_015349.1  6 42905325 Missense c.1276C>G p.Q426E 31 % 
P12 RNASE2 6036 NM_002934.2 14 20494104 Missense c.334C>T p.L112F 43 % 
P12 LGR5  8549 NM_003667.3  12 70233271 Missense c.580G>T p.A194S 42 % 
P12 ABCA9 10350 NM_080283.3  17 64543452 Missense c.886G>A p.V296I 49 % 
P12 KIAA1586  57691 NM_020931.2  6 57026109 Missense c.853C>T p.R285C 41 % 
P12 KIAA1712/ 
CEP44 
80817 NM_001145314.1 4 175462073 Missense c.485G>A p.G162D 36 % 
P12 CDH12 1010 NM_004061.3  5 21890556 Missense c.627C>A p.F209L 51 % 
P12 ADAM17 6868 NM_003183.4  2 9562809 Missense c.1481T>G p.M494R 44 % 
P12 PAM 5066 NM_000919.3  5 102338007 Missense c.1451G>A p.G484D 36 % 
P12 RIMS2 9699 NM_001100117.2  8 105095968 STOP c.3283C>T p.R1095* 28 % 
P12 PTPRU 10076 NM_133178.3  1 29457762 Missense c.364C>T p.R122C 48 % 
P12 FLNB 2317 NM_001457.3  3 58084289 Missense c.3556A>C p.K1186Q 41 % 
P12 CASP6 839 NM_001226.3  4 110831463 Missense c.635T>A p.V212D 37 % 
P12 PACS2 23241 NM_015197.3  14 104904619 Missense c.448G>A p.G150S 46 % 
P12 CTAGE5 4253 NM_005930.3  14 38833003 Missense c.544T>C p.S182P 40 % 
P12 PRPS1L1 221823 NM_175886.2  7 18033893 Missense c.38A>G p.Q13R 20 % 
P12 ACSM2B 348158 NM_182617.3  16 20465291 Missense c.1105A>T p.T369S 48 % 
P13 OR5W2 390148 NM_001001960.1 11 55437838 Missense c.797A>G p.Y266C 57 % 
P13 BHLHB9 80823 NM_001142525.1  X 101891757 Missense c.1178C>A p.S393Y 49 % 
P13 GANC 2595 NM_198141.2  15 40419269 STOP c.1954C>T p.R652* 43 % 
P13 GTSF1 121355 NM_144594.2  12 53145216 Missense c.19G>A p.D7N 39 % 
P13 HPSE 10855 NM_001098540.2  4 84453395 Missense c.569C>T p.A190V 39 % 
P13 C20orf54/ 
SLC52A3 
113278 NM_033409.3  20 694403 Missense c.16C>T p.H6Y 36 % 
P13 IGFN1 91156 NM_001164586.1  1 199461632 Missense c.10544C>T p.T3515M 30 % 
P13 MYL12A 10627 NM_006471.2  18 3243964 Missense c.259A>G p.T87A 53 % 
P13 FAM32A 26017 NM_014077.2  19 16162758 Missense c.331A>G p.T111A 39 % 
P14 PLS1 5357 NM_001145319.1  3 143872568 Missense c.278G>A p.R93Q 44 % 
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P14 OR2L8 391190 NM_001001963.1  1 246179686 STOP c.904C>T p.R302* 42 % 
P14 SLC6A5 9152 NM_004211.3  11 20616662 Missense c.1951G>A p.G651R 48 % 
P14 OR5J2 282775 NM_001005492.1  11 55701154 Missense c.485G>A p.S162N 39 % 
P14 SLC6A11 6538 NM_014229.1  3 10949837 Missense c.1372G>T p.G458C 39 % 
P14 FLNC 2318 NM_001458.4  7 128284512 Missense c.7666C>T p.P2556S 46 % 
P14 FUBP1 8880 NM_003902.3  1 78217236 STOP c.41C>G p.S14* 37 % 
P14 CCDC85A 114800 NM_001080433.1  2 56273648 Missense c.809G>A p.R270H 38 % 
P14 ZNF512B 57473 NM_020713.1  20 62061926 Missense c.2438G>T p.R813L 54 % 
P14 ADAMTS3 9508 NM_014243.2  4 73373443 Missense c.2938G>A p.V980M 50 % 
P14 ARSD 414 NM_001669.3  X 2835439 Missense c.1655G>A p.R552Q 50 % 
P14 CCDC56 28958 NM_001040431.2  17 38204198 Missense c.28C>A p.L10M 26 % 
P14 COL4A3 1285 NM_000091.4  2 227850418 Missense c.2030G>A p.G677E 22 % 
P14 GRIK1 2897 NM_000830.3  21 29988086 Missense c.286G>A p.A96T 40 % 
P14 SMCHD1 23347 NM_015295.2  18 2678396 Missense c.643C>A p.H215N 46 % 
P14 XPO1 7514 NM_003400.3  2 61572976 Missense c.1711G>A p.E571K 7 % 
P15 DNAH7 56171 NM_018897.2  2 196428797 Missense c.8578G>T p.A2860S 47 % 
P15 SLIT2 9353 NM_004787.1  4 19867412 Missense c.199A>T p.I67F 54 % 
P15 XPR1 9213 NM_004736.3  1 179061080 Missense c.1111C>T p.R371W 40 % 
P15 KRT20 54474 NM_019010.2  17 36292425 Missense c.398A>G p.D133G 53 % 
P15 L2HGDH 79944 NM_024884.2  14 49838577 Missense c.316G>A p.E106K 41 % 
P15 MYEF2 50804 NM_016132.3  15 46237482 Missense c.985C>T p.R329C 45 % 
P15 RBM25 58517 NM_021239.2  14 72613953 Missense c.280A>T p.I94F 49 % 
P15 KRT4 3851 NM_002272.3 12 51487873 Missense c.1168G>A p.G390S 42 % 
P15 XPO1 7514 NM_003400.3  2 61572976 Missense c.1711G>A p.E571K 30 % 
P15 FLJ32682/ 
FAM194B 
220081 NM_182542.2  13 45059211 Missense c.844G>A p.D282N 67 % 
P15 SF3B1 23451 NM_012433.2  2 197975066 Missense c.2111T>A p.I704N 42 % 
P15 ITIH4 3700 NM_002218.4  3 52832920 Missense c.1312C>T p.R438W 65 % 
P15 PCLO 27445 NM_033026.5  7 82419594 Missense c.8611C>T p.P2871S 43 % 
P16 DST 667 NM_015548.4  6 56528572 Missense c.6797G>A p.R2266Q 41 % 
P16 ARHGAP18 93663 NM_033515.2  6 129996915 Missense c.581T>G p.L194R 42 % 
P16 DEFB114 245928 NM_001037499.1  6 50036079 Missense c.95G>A p.R32H 47 % 
P16 DOCK1 1793 NM_001380.3 10 129121682 Missense c.4997G>T p.G1666V 26 % 
P16 OBSCN 84033 NM_001271223.2 1 226588071 Missense c.18892G>T p.A6298S 39 % 
P16 ASMTL 8623 NM_001173474.1  X/Y 1482164 Extension c.1816T>G *606G 100 % 
P16 LAMA5 3911 NM_005560.3  20 60327354 Missense c.6982G>A p.A2328T 30 % 
P16 AKR1B1 231 NM_001628.2  7 133785062 STOP c.379G>T p.E127* 42 % 
P17 DNAJC13 23317 NM_015268.3  3 133661884 Missense c.1550C>A p.S517Y 39 % 
P17 ICAM5 7087 NM_003259.3  19 10263792 Missense c.755A>G p.D252G 36 % 
P17 LAMA1 284217 NM_005559.3  18 6955337 Missense c.7145A>G p.Y2382C 40 % 
P17 GRIN2A 2903 NM_001134407.1  16 9939789 Missense c.535G>A p.G179S 33 % 
4  Results                                                                                                                                                     95 
 
 
Case Gene 
Name 
Gene 
ID 
Annotation Chr Position Type of 
Mutation 
cDNA 
change 
Protein 
change 
Var. 
Freq. 
P17 SLC26A5 375611 NM_198999.2  7 102838136 Missense c.667A>G p.T223A 46 % 
P18 GPC6 10082 NM_005708.3  13 93832730 Missense c.1214C>A p.T405N 22 % 
P18 DUSP13 51207 NM_001007272.1 10 76527551 Missense c.248G>A p.R83H 27 % 
P18 PDE2A 5138 NM_002599.4  11 71977494 Missense c.1052A>G p.N351S 22 % 
P18 SIAH3 283514 NM_198849.2  13 45255947 Missense c.382C>T p.R128W 25 % 
P19 APOB 338 NM_000384.2  2 21084498 Missense c.8747C>T p.A2916V 57 % 
P19 APOB 338 NM_000384.2 2 21084417 Missense c.8828A>G p.E2943G 57 % 
P19 MYO18B 84700 NM_032608.5  22 24753166 Missense c.7226G>A p.R2409H 42 % 
P19 STX17 55014 NM_017919.2  9 101753188 Missense c.215T>C p.I72T 42 % 
P19 FBXO47 494188 NM_001008777.2  17 34352567 Missense c.1073T>C p.F358S 57 % 
P19 FGF14 2259 NM_175929.2  13 101173307 STOP c.634C>T p.R212* 48 % 
P19 ADAMTS13 11093 NM_139025.3  9 135279277 Missense c.188C>T p.P63L 41 % 
P19 IL3RA 3563 NM_002183.3  X 1431348 Missense c.565G>A p.A189T 41 % 
P19 KRAS 3845 NM_004985.3  12 25289551 Missense c.35G>A p.G12D 42 % 
P19 CHPF 79586 NM_024536.5  2 220113433 Missense c.1244G>A p.R415H 29 % 
P19 TKTL2 84076 NM_032136.4  4 164613013 STOP c.1324C>T p.R442* 51 % 
P20 SF3B1 23451 NM_012433.2  2 197975618 Missense c.1984C>G p.H662D 48 % 
P20 HOOK1 51361 NM_015888.4  1 60102919 Missense c.1654G>A p.A552T 41 % 
P20 OR9Q1 219956 NM_001005212.3  11 57703997 Missense c.505T>C p.C169R 38 % 
P20 PCSK1 5122 NM_000439.4  5 95787327 Missense c.349G>A p.A117T 38 % 
P20 CDK20 23552 NM_001170640.1  9 89778764 Missense c.82G>A p.E28K 37 % 
P20 USP8 9101 NM_001128610.1  15 48569368 Missense c.1969A>G p.K657E 37 % 
P20 SF4/SUGP1 57794 NM_172231.3  19 19282002 Missense c.214A>G p.N72D 50 % 
P20 C3orf15/ 
MAATS1 
89876 
NM_033364.3  3 120945710 Missense c.1879G>A p.E627K 39 % 
P20 SCEL 8796 NM_003843.3  13 77082191 Missense c.1226G>A p.S409N 35 % 
P21 VEGFC 7424 NM_005429.2  4 177845450 Missense c.1030A>C p.K344Q 37 % 
P21 MLH3 27030 NM_001040108.1  14 74583229 Missense c.2883G>T p.E961D 37 % 
P21 TESK2 10420 NM_007170.2  1 45695996 STOP c.49G>T p.E17* 35 % 
P21 EYS 346007 NM_001142800.1  6 64488697 Missense c.9189T>A p.S3063R 21 % 
P21 DSP 1832 NM_001008844.1  6 7524576 Missense c.3154T>A p.C1052S 30 % 
P21 ZDHHC20 253832 NM_153251.3  13 20853671 Missense c.959C>G p.P320R 27 % 
P21 SCN10A 6336 NM_006514.2  3 38738783 Missense c.3477C>G p.I1159M 29 % 
P21 TRAF3 7187 NM_145726.2  14 102441342 Missense c.1100T>C p.L392P 33 % 
P21 TP53 7157 NM_000546.5  17 7518996 Missense c.578A>G p.H193R 38 % 
P21 FASTK 10922 NM_033015.3  7 150406598 Missense c.386C>T p.T129M 20 % 
P21 CXCR4 7852 NM_003467.2  2 136588955 STOP c.1013C>G p.Ser338* 20 % 
P21 HEATR3 55027 NM_182922.2  16 48691642 Missense c.1600T>C p.C534R 21 % 
P21 CHRD 8646 NM_003741.2  3 185587355 Missense c.2225T>C p.V742A 31 % 
P22 DOCK4 9732 NM_014705.3  7 111272105 STOP c.2686C>T p.R896* 54 % 
P22 CSMD1 64478 NM_033225.5  8 3253055 Missense c.1844T>C p.I615T 48 % 
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P22 DDX3X 1654 NM_001356.3  X 41090557 Missense c.1447G>A p.A483T 97 % 
P22 COL11A1 1301 NM_001854.3  1 103261064 Missense c.1067A>T p.E356V 47 % 
P22 TSHZ2 128553 NM_001193421.1  20 51304068 Missense c.655G>A p.A219T 69 % 
P22 FAT3 120114 NM_001008781.2 11 92255907 Missense c.12637C>T p.R4213C 40 % 
P22 AHSG 197 NM_001622.2  3 187821328 Missense c.1019G>A p.R340H 46 % 
P22 KMO 8564 NM_003679.4  1 239794923 Missense c.629C>G P210R 33 % 
P22 KRAS 3845 NM_004985.3  12 25289548 Missense c.38G>A pG13D 52 % 
P22 UCHL1 7345 NM_004181.4  4 40960052 Missense c.513C>G p.H171Q 26 % 
P22 WDR33 55339 NM_018383.4  2 128182867 Missense c.3635C>G p.A1212G 22 % 
P22 SETD2 29072 NM_014159.6  3 47114571 STOP c.5020G>T p.E1674* 58 % 
P23 NRAS 4893 NM_002524.4  1 115060267 Missense c.38G>T p.G13V 29 % 
P23 CACNB1 782 NM_000723.4  17 34585240 Missense c.1529C>G p.S510C 35 % 
P23 MCC 4163 NM_002387.2  5 112448828 Missense c.907C>T p.R303C 31 % 
P23 PRMT1 3276 NM_198318.4  19 54877015 Missense c.175C>T p.R59C 27 % 
P23 TBCC 6903 NM_003192.2 6 42821000 Missense c.790C>T p.H264Y 20 % 
P23 HERPUD2 64224 NM_022373.4  7 35640449 Missense c.1057A>G p.M353V 29 % 
P23 DDX43 55510 NM_018665.2  6 74172247 Missense c.775A>C p.K259Q 23 % 
P23 UMOD 7369 NM_003361.2  16 20267895 Missense c.229T>A p.C77S 40 % 
P24 MURC 347273 NM_001018116.1  9 102380607 STOP c.361C>T p.Q121* 48 % 
P24 ZNF292 23036 NM_015021.1  6 88023170 Missense c.3104A>G p.N1035S 29 % 
P24 MSH6 2956 NM_000179.2  2 47886308 Missense c.3604A>T p.M1202L 34 % 
P25 FAT4 79633 NM_024582.4  4 126631124 Missense c.13697G>A p.G4566E 43 % 
P25 POT1 25913 NM_015450.2  7 124290902 Missense c.284G>T p.G95V 41 % 
P25 HMCN1 83872 NM_031935.2  1 184275588 Missense c.6134G>T p.W2045L 31 % 
P25 STC1 6781 NM_003155.2  8 23764905 Missense c.346A>T p.T116S 52 % 
P25 PKP2 5318 NM_001005242.2  12 32865686 Missense c.1884G>C p.K628N 48 % 
P25 ODZ1/ 
TENM1 
10178 NM_014253.3  X 123342366 STOP c.7879G>T p.G2627* 26 % 
P25 C1orf84/ 
SZT2 
23334 NM_015284.3  1 43680313 Missense c.7627C>T p.P2543S 52 % 
P25 VWF 7450 NM_000552.3  12 5951055 Missense c.7519C>T p.R2507W 42 % 
P25 ZC3H18 124245 NM_144604.3  16 87205192 STOP c.1222C>T p.R408* 60 % 
P25 CDAN1 146059 NM_138477.2  15 40809351 Missense c.2287T>C p.F763L 44 % 
P25 C13orf26/ 
TEX26 
122046 NM_152325.1  13 30441073 Missense c.698A>C p.Q233P 43 % 
P25 ERC2 26059 NM_015576.1  3 56305486 Missense c.675C>G p.I225M 39 % 
P25 CDC23 8697 NM_004661.3  5 137562054 Missense c.890T>C p.I297T 52 % 
Table 12 A complete list of somatic nonsynonymous point mutations and one splice site mutation from 25 
exomes. Var. Freq.: Variant Frequency 
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Case Gene 
Name 
Gene 
ID 
Annotation Chr Position cDNA change Protein 
change 
P03 NOTCH1 4851 NM_017617.3 9 138510470 c.7541_7542delCT p.(Pro2514Argfs*4) 
P04 DZIP1L 199221 NM_173543.2  3 139273257 c.1531_1533delinsCAT p.(Lys511His) 
P05 POLN 353497 NM_181808.2 4 2150892 c.1119delT p.(Cys373Trpfs*9) 
P10 RNF219 79596 NM_024546.3  13 78111006 c.503del p.(Asn168Metfs*7) 
P12 MBL2 4153 NM_000242.2 10 54200521 c.219dup p.(Gly74Trpfs*31) 
P12 MYST4/ 
KAT6B 
23522 NM_012330.3 10 76451845 c.3231_3232insCGAG
GAGGA 
p.(Asp1077_Glu107
8insArgGlyGly) 
P12 SPINK7 84651 NM_032566.2 5 147673148 c.87del p.(Val30Trpfs*42) 
P16 SUSD4 55061 NM_017982.3  1 221603325 c.63_65del p.(Gln22del) 
P16 MATN2 4147 NM_002380.3  8 99060403 c.1073del p.(Thr358Serfs*5) 
P21 OR4A16 81327 NM_001005274.1  11 54867315 c.70dup p.(Thr24Asnfs*63) 
P22 STAG2  10735 NM_001042749.1 X 123042954 c.2819_2828del p.(Arg940Ilefs*6) 
P22 CIB2 10518 NM_006383.3 15 76203112 c.73_75del p.(Lys25del) 
P22 DNAJC2 27000 NM_014377.1 7 102755417 c.351del p.(Lys117Asnfs*14) 
Table 13 A complete list of small somatic InDels from the 25 exomes. 
Point mutations can be divided into transitions and transversions. A mutation from one purine 
base to the other (A->G or G->A) or one pyrimidine base to the other (C->T or T->C) is called a 
transition. Transversions are base substitutions between purines and pyrimidines. We 
calculated the frequency of transitions and transversions in our data set. Transitions from a 
guanine base to an adenine or from a cytosine base to a thymine base, on the minus strand, 
were the most frequent base substitution, accounting for about 65 % of mutations observed. 
Transversions, on the other hand, were less frequently detected (35 %).  
 
Figure 24 Frequency of substitutions detected in 25 CLL exomes. There are six different types of single base 
substitutions. Most frequent is the transition G>A or C>T. Error bars represent standard deviation.  
The patients had about 11 (±4.3) mutations on average as detected by our exome sequencing 
pipeline. We only consider mutations here that lead to an amino acid change. The lowest 
number of mutations (n=3) was found in two patients. Both had trisomy 12. One had non-
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mutated and the other mutated IGHV genes. The highest number of mutations with n=20 was 
observed in a patient who had a mutated IGHV status and a 13q deletion.  
 
Figure 25 Total number of confirmed mutations per patient. The total number of mutations include: non-
synonymous point mutations, InDels and splice site mutations 
Although, we did not validate (Sanger resequence) putative mutations that would not lead to 
an amino acid change (synonymous mutations), we can estimate the number of true positive 
synonymous mutations from the confirmation rate obtained for the nonsynonymous 
mutations. If we use the data from the somatic workflow, we can estimate the number of true 
synonymous mutations using a confirmation rate of 94 % (Figure 23). Graur and Li computed 
the proportion of the different types of mutations from the genetic code with the assumption 
that all possible mutations occur with the same frequencies and that there is no codon 
preference (Sinauer Associates Graur and Li 2000). There are 549 possible point mutations that 
can occur in coding triplets (61x9). 134 or 25 % out of these 549 mutations do not lead to an 
amino acid change (silent or synonymous mutations). 415 (75 %) of the possible mutations 
lead to a change in the amino acid sequence either to a missense mutation (n=392, 71 %) or to 
a nonsense mutation (n=23, 4 %) (Sinauer Associates Graur and Li 2000). Based on the 
confirmation rate of 94 % (somatic workflow) and the fact that we detected 102 putative silent 
mutations in the 25 exomes (somatic workflow only) we estimate that there are about 96 true 
silent mutations. This is equivalent to about 27 % of all point mutations. Thus, we have 
approximately 73 % nonsynonymous (including 5 % nonsense mutations) and 27 % silent 
mutations in the coding sequences of our 25 CLL samples. This result is in good agreement 
with the theoretical calculations of Graur and Li and suggests that there is no obvious selection 
effect for nonsynonymous mutations in our 25 CLL samples. 
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4.1.4.1 Mutation Frequency in CLL Samples with Mutated vs. Unmutated IGHV Genes 
Somatic hypermutation may not only affect the immunoglobulin locus but also other genes 
(Wang et al. 2004). One would therefore assume that the number of mutations in our CLL 
samples with mutated IGHV genes should be greater than in patients with an unmutated IGHV 
status. 
 
Figure 26 Box plot showing the number of nonsynonymous mutations according to IGHV mutational status. There 
was no significant difference between the two groups, Mann-Whitney U test P= 0.4864. 
Although there seems to be a trend that patients with mutated IGHV harbor more 
nonsynonymous mutations (including InDels) the difference in mutation frequency did not 
reach statistical significance (Figure 26).  
  
100                                                                                                                                                   4  Results 
 
 
4.1.5 Discriminating Between Driver and Passenger Mutations 
A major challenge of large-scale mutation screens of tumors using next-generation sequencing 
is to distinguish between “driver” and “passenger” mutations. Passenger mutations are 
somatic mutations that just happened to be in the original, tumor-initiating cell. Passenger 
mutations do not have any functional consequences that affect the malignant phenotype of 
the cancer cells. Driver mutations, on the other hand, are mutations, which alter the function 
of genes in such a way that the consequences of these altered gene functions lead to or 
enhances the malignant phenotype. It is thus, very important to determine whether a given 
mutation is a passenger or a driver mutations. There are basically two approaches to 
distinguish between driver and passenger mutations: 1) functional validation by establishing 
for example a cell line model system for the mutation in question or 2) determining whether a 
gene is recurrently mutated. Of course a functional validation, even though it is the gold 
standard for identifying driver mutations, is very time-consuming and not practical for large 
numbers of mutations. Therefore identifying recurrently mutated genes in a given cancer 
subtype is the method of choice; even though genes can also be recurrently mutated by 
chance. As a first step to identify driver mutations we looked for recurrently mutated genes in 
our exome dataset. To extend our search for recurrently mutated genes we also compared our 
datasets with results from published CLL exomes and genomes. 
4.1.5.1 Recurrently Mutated Genes 
A recurrently mutated gene is a gene found mutated in more than one patient sample.  
Case Gene Chr Position cDNA AA 
change 
IGHV 
status 
FISH 
status 
Variant 
frequency 
P03 XPO1 2 61572976 G1711A E571K U-CLL normal 20 % 
P04 XPO1 2 61572975 A1712G E571G U-CLL 13q 53 % 
P14 XPO1 2 61572976 G1711A E571K U-CLL 13q   7 % 
P15 XPO1 2 61572976 G1711A E571K U-CLL 13q 30 % 
P04 SF3B1 2 197975079 A2098G K700E U-CLL 13q 36 % 
P15 SF3B1 2 197975066 T2111A I704E U-CLL 13q 42 % 
P20 SF3B1 2 197975618 C1984G H662D U-CLL normal 48 % 
P19 KRAS 12 25289551 G35A G12D M-CLL normal 42 % 
P22 KRAS 12 25289548 G38A G13D U-CLL 11q 52 % 
P02 CDH12 5 22114366 T177A N59K M-CLL normal 55 % 
P12 CDH12 5 21890556 C627A F209L M-CLL 13q 51 % 
P05 PCLO 7 82422083 A6122G E2041A M-CLL Tris12 40 % 
P15 PCLO 7 82419594 C8611T P2871S U-CLL 13q 43 % 
P05 MYH2 17 10384070 G1047T K349N M-CLL Tris12 32 % 
P09 MYH2 17 10389453 A440G K147R M-CLL 13q 45 % 
Table 14 Recurrently mutated genes in our 25 CLL sample cohort. MYH2: 1941 AA; PCLO: 4935 AA; CDH12: 794 AA; 
XPO1: 1071 AA; SF1B3: 144 AA; KRAS: 188 AA. AA: Amino Acid, M-CLL: mutated CLL, U-CLL: unmutated CLL
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The larger the coding region of a gene, the higher the likelihood it is recurrently mutated by 
chance. The most frequently mutated gene in our patient cohort was XPO1. XPO1 (exportin 1), 
also known as CRM1, encodes a 1071 amino acid long protein that mediates nuclear export 
signal (NES)-dependent protein export of proteins from the nucleus into the cytoplasm. XPO1 
was found mutated in 16 % (4/25) of our samples. One of these mutations was not initially 
detected by our exome sequencing analysis pipeline but only when we performed a larger 
Sanger sequencing screen of our cohort (4.2). The mutation evaded detection in the exome 
analysis pipeline due to a low variant frequency of just 7 % in the CLL sample. In Sanger 
sequencing a very small clone was detected that could retrospectively also be found in the 
next-generation sequencing data.  
As an example, the XPO1 mutation of patient P04 is shown in Figure 27. The grey bars 
represent reads aligned to the reference sequence. In the upper panel, representing the CLL 
sample, the variant at position 61,572,976 on chromosome 2 causing the amino acid change 
p.E571G is shown as blue Cs (Figure 27 A). Amino acid E571 is a mutational hotspot since it was 
mutated in all 4 of our samples. In the remission sample, in the lower panel, no variant was 
detected. Variant frequencies and total read counts are displayed in the small boxes. In 
addition, the number of reads derived from the plus and minus strand is indicated by a plus 
and minus sign, respectively. To confirm the result of the exome sequencing pipeline, the 
region was analyzed by Sanger sequencing (Figure 27 B). The upper chromatogram is derived 
from the CLL with the XPO1 mutation and the lower one is derived from the remission sample, 
which is wild type. 
 
Figure 27 XPO1 mutation in patient P04. A) Exome data shown as an IGV screenshot. The upper panel represents 
the CLL sample with the heterozygous mutation. No variant was detected in the remission sample in the lower 
panel. The variant counts are displayed in small boxes. B) Sanger sequencing of the confirmed mutation in the CLL 
sample (upper panel). In the remission sample (lower panel) the hotspot was wild type. 
Another gene, which was found to be frequently mutated in our CLL samples as well as in 
other hematological disorders (Papaemmanuil et al. 2011), is SF3B1, a gene which encodes the 
subunit 1 of the splicing factor 3b protein complex. With a frequency of 12 %, SF3B1 is the 
second most frequently mutated gene in our 25 CLL samples. In contrast to XPO1, the 
mutations in SF3B1 are not limited to a hotspot. Mutations in the CDH12 gene were also found 
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with a frequency of 8 %. This gene belongs to the cadherin superfamily and is involved in cell-
cell adhesion. We also detected mutations in the KRAS hotspot at amino acid 12 and 13 in 2/25 
cases (8 %). This protein is a member of the small GTPase superfamily. PCLO plays a role in 
synaptic vesicle trafficking. It was found mutated in 2/25 (8 %) of our CLL patients. We also 
found MYH2 mutations in 2/25 cases (8 %), this gene encodes the myosin 2 motor protein. It 
plays an important role in the contraction of skeletal muscles.  
4.1.5.2 Comparison of Mutations found in the Study Cohort with Published CLL Mutation 
Data  
To identify additional recurrently mutated genes, we compared the mutations we found in the 
exomes of our 25 CLL samples with published CLL whole exome and whole genome sequencing 
datasets. A total of 2399 genes with non-silent mutations affecting their protein coding regions 
have been described in three studies examining 200 CLL patient samples in total. The patients 
in these studies were predominantly analyzed at the time before their first treatment (Puente 
et al. 2011; Wang et al. 2011; Quesada et al. 2012). We compared the non-silent mutations in 
coding regions of the published datasets with the non-silent coding region mutations of our 
own dataset (n=270 mutations) which were found in 259 different genes.  
 Wang  Quesada  Puente  Wang  
Quesada 
Puente  
REACH 
Total number of  
non-silent coding 
mutations 
1730 1165 45 2935 270 
Total number of 
mutated genes  
1521 1027 44 2399 259 
Recurrently mutated 
genes: mutated in 2 or 
more sample 
139 96 0 194 (183) 6 
Genes which have two 
mutations in the same 
patient sample 
7 8 1 - 2 
Table 15 Summary of non-silent coding region mutations found in our study cohort and published CLL datasets. A 
recurrently mutated gene is a gene that was found mutated in more than one sample. A gene that is found mutated 
more than once but in the same sample is not considered as a recurrently mutated gene (see last row of the table). 
All three public data sets share 183 genes, 194 were recurrently mutated when mutated genes are added that were 
recurrently mutated in only one of the public datasets.  
Wang and colleagues analyzed n=91 patient samples with whole exome and whole genome 
sequencing and detected 1730 non-silent coding region mutations in 1521 genes, 139 genes 
were found recurrently mutated. Quesada and colleagues analyzed 105 patient and found 
1165 non-silent coding region mutations in 1027 different genes. Of these genes, 96 were 
recurrently mutated. By whole genome sequencing Puente et al detected 45 non-silent coding 
region mutations in 44 genes in four patient samples. None of them were recurrently mutated, 
the only mutation that occurred twice within the same gene was found in the same sample. 
When we consider all three studies, 194 of the 2399 genes were found mutated in more than 
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one CLL sample. All three studies together have 183 mutated genes that were found in more 
than one study. Ten genes were found mutated in all three studies (Figure 28 A).  
 
Figure 28 Mutated genes in CLL: Comparison of publicly available data sets with the data from our study. A) We 
selected three large CLL exome and genome sequencing studies: Wang et al (green), Quesada et al (orange) and 
Puente et al (purple). In these three studies n=91, n=105 and n=4 patients were examined, identifying n=1521, 
n=1027, and n=44 different genes with non-silent mutations in their coding regions, respectively. The Venn diagram 
shows the number of genes that were found to be mutated and the number of identical genes found in the three 
studies. B) When we compared our dataset of n=259 mutated genes (blue circle) with all mutated genes from the 
three studies (n=2399) there were 82 genes in common. 
When we compared the 2399 genes found mutated in these three studies with our set of 259 
mutated genes we found an overlap of 82 genes. Thus, our study (REACH) reports 177 
different genes that have been found mutated in CLL for the first time. Of the 82 genes found 
mutated both in the three studies and our study, 47 can only be identified as recurrently 
mutated when our dataset is taken into consideration. Thus, our study increases the number 
of recurrently mutated genes in CLL from 194 to 241. The 47 genes that our efforts add to the 
list of recurrently mutated genes and their full name are listed below.  
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Genes only identified as recurrently mutated when our dataset is taken into 
consideration.  
Gene ID Official Symbol Official Full Name (HGNC) 
338 APOB apolipoprotein B 
1010 CDH12 cadherin 12, type 2 (N-cadherin 2) 
1109 AKR1C4 aldo-keto reductase family 1, member C4 
1290 COL5A2 collagen, type V, alpha 2 
1301 COL11A1 collagen, type XI, alpha 1 
1387 CREBBP CREB binding protein 
1734 DIO2 deiodinase, iodothyronine, type II 
1767 DNAH5 dynein, axonemal, heavy chain 5 
1793 DOCK1 dedicator of cytokinesis 1 
1832 DSP desmoplakin 
2317 FLNB filamin B, beta 
2318 FLNC filamin C, gamma 
3762 KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5 
3845 KRAS Kirsten rat sarcoma viral oncogene homolog 
4620 MYH2 myosin, heavy chain 2, skeletal muscle, adult 
4893 NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 
5138 PDE2A Phosphodiesterase 2A cGMP-stimulated 
6336 SCN10A sodium channel, voltage-gated, type X, alpha subunit 
6903 TBCC tubulin folding cofactor C 
7369 UMOD Uromodulin 
8549 LGR5 leucine-rich repeat containing G protein-coupled receptor 5 
10076 PTPRU protein tyrosine phosphatase, receptor type, U 
10922 FASTK Fas-activated serine/threonine kinase 
11093 ADAMTS13 ADAM metallopeptidase with thrombospondin type 1 motif, 13 
11122 PTPRT protein tyrosine phosphatase, receptor type, T 
11177 BAZ1A bromodomain adjacent to zinc finger domain, 1A 
23036 ZNF292 zinc finger protein 292 
23334 SZT2 seizure threshold 2 homolog (mouse) 
23517 SKIV2L2 superkiller viralicidic activity 2 –like (S. cerevisiae) 
26059 ERC2 ELKS/RAB6-interacting/CAST family member 2 
26999 CYFIP2 Cytoplasmic FMR1 interacting protein 2 
64759 TNS3 tensin 3 
80070 ADAMTS20 ADAM metallopeptidase with thrombospondin type 1 motif, 20 
83873 GPR61 G protein-coupled receptor 61 
89857 KLHL6 kelch-like family member 6 
91156 IGFN1 immunoglobulin-like and fibronectin type III domain 
containing 1 
114800 CCDC85A coiled-coil domain containing 85A 
128553 TSHZ2 teashirt zinc finger homeobox 2 
131890 GRK7 G protein-coupled receptor kinase 7 
139135 PASD1 PAS domain containing 1 
165186 FAM179A family with sequence similarity 179, member A 
199221 DZIP1L DAZ interacting zinc finger protein 1-like 
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Genes only identified as recurrently mutated when our dataset is taken into 
consideration.  
Gene ID Official Symbol Official Full Name (HGNC) 
282775 OR5J2 olfactory receptor, family 5, subfamily J, member 2 
283450 HECTD4 HECT domain containing E3 ubiquitin protein ligase 4 
339976 TRIML1 tripartite motif family-like 1 
340533 KIAA2022 KIAA2022 
347273 MURC muscle-related coiled-coil protein 
Table 16 List of 47 recurrently mutated genes. With these genes our study increases the number of recurrently 
mutated genes in CLL from 194 to 241. HGNC: HUGO Gene Nomenclature Committee 
From the 82 genes that overlap between the public datasets and our dataset, 47 could be 
newly added to the recurrently mutated genes through the analysis of our CLL cohort (Table 
16). The remaining 35 genes were already known to be recurrently mutated from the three 
public datasets. Together with our dataset these genes are mutated in at least 3 out of 225 
patients (25 patients from our dataset and 200 patients from the three public datasets).  
Genes found mutated in our dataset and also known to be recurrently mutated in the 
public datasets  
Gene ID Official 
Symbol 
Official full name (HGNC) Cases/225 Frequency 
23451 SF3B1 splicing factor 3b, subunit 1, 155kDa 27/225 12 % 
7157 TP53 tumor protein p53 14/225 6 % 
4851 NOTCH1 notch 1 11/225 5 % 
472 ATM ataxia telangiectasia mutated 10/225 4 % 
27445 PCLO piccolo presynaptic cytomatrix protein 9/225 4 % 
7514 XPO1 exportin 1 (CRM1 homolog, yeast) 8/225 4 % 
667 DST Dystonin 7/225 3 % 
64478 CSMD1 CUB and Sushi multiple domains 1 7/225 3 % 
1106 CHD2 chromodomain helicase DNA binding 
protein 2 
6/225 3 % 
9968 MED12 mediator complex subunit 12 6/225 3 % 
25913 POT1 protection of telomeres 1 6/225 3 % 
53353 LRP1B low density lipoprotein receptor-related 
protein 1B 
6/225 3 % 
79633 FAT4 FAT atypical cadherin 4 5/225 2 % 
1654 DDX3X DEAD (Asp-Glu-Ala-Asp) box helicase 3,  
X-linked 
5/225 2 % 
1959 EGR2 early growth response 2 5/225 2 % 
7273 TTN Titin 5/225 2 % 
120114 FAT3 FAT atypical cadherin 3 5/225 2 % 
6091 ROBO1 roundabout, axon guidance receptor,  
homolog 1 (Drosophila) 
4/225 
 
2 % 
8880 FUBP1 far upstream element (FUSE) binding 
protein 1 
4/225 2 % 
9152 SLC6A5 solute carrier family 6 4/225 2 % 
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Genes found mutated in our dataset and also known to be recurrently mutated in the 
public datasets  
Gene ID Official 
Symbol 
Official full name (HGNC) Cases/225 Frequency 
(neurotransmitter transporter), 
member 5 
 
9353 SLIT2 slit homolog 2 (Drosophila) 4/225 2 % 
9699 RIMS2 regulating synaptic membrane 
exocytosis 2 4/225 
2 % 
9732 DOCK4 dedicator of cytokinesis 4 4/225 2 % 
1285 COL4A3 collagen, type IV, alpha 3 3/225 1 % 
5137 PDE1C phosphodiesterase 1C,  
calmodulin-dependent 70kDa 
3/225 
 
1 % 
7450 VWF von Willebrand factor 3/225 1 % 
10082 GPC6 glypican 6 3/225 1 % 
10178 TENM1/ 
ODZ1 
teneurin transmembrane protein 1 3/225 1 % 
23347 SMCHD1/ 
AP001011
.3 
structural maintenance of 
chromosomes flexible hinge domain 
containing 1 
3/225 
 
1 % 
55061 SUSD4 sushi domain containing 4 3/225 1 % 
83872 HMCN1 hemicentin 1 3/225 1 % 
84033 OBSCN obscurin, cytoskeletal calmodulin and 
titin-interacting RhoGEF 
3/225 1 % 
124245 ZC3H18 Zink finger CCH-type containing 18 3/225 1 % 
285175 UNC80/ 
C2orf21 
Unc-80 homolog (C.elegans) 
3/225 
1 % 
440279 UNC13C Unc-13 homolog c (C.elegans) 3/225 1 % 
Table 17 List of 35 recurrent genes. Genes that were found mutated in our gene set but were already known to be 
recurrently mutated within the three public datasets. HGNC: HUGO Gene Nomenclature Committee 
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4.1.5.3 Coverage of Frequently Mutated Genes in the CLL Exome Study Cohort 
SF3B1, ATM, MYD88, TP53 and NOTCH1 are among the most frequently mutated genes in CLL. 
However, we did not find a mutation in MYD88. To judge how well these genes were enriched 
by Agilent’s SureSelect 50 Mb capture kit we calculated the coverage per nucleotide of these 
five genes. We also calculated the per nucleotide coverage of XPO1, KRAS, PCLO, CDH12 and 
MYH2 which were also found recurrently mutated in our 25 CLL samples (Table 14). CDH12 is 
the only gene that had not been described as recurrently mutated in the three published 
datasets. 
 
Figure 29 Average coverage per nucleotide position of frequently mutated target genes in our CLL cohort. SF3B1, 
ATM, MYD88, TP53 and NOTCH1 are frequently mutated genes in CLL. XPO1, KRAS, CDH12, PCLO and MYH2 were 
found to be recurrently mutated in our study. CLL: denotes the reads in the leukemia samples; REM: denotes the 
reads in the remission samples 
Except for NOTCH1, all nucleotides in these 10 genes have a minimum coverage of ten reads, 
which is sufficient for SNV calling. Approximately half of all positions of NOTCH1 did not reach 
the minimum requirement of 10 reads in the tumor or remission samples. With a CG content 
of >60 %, the NOTCH1 cDNA has the highest GC content of all these genes. It should be noted 
that in some samples the mutations in more than one of these genes occur together. Patient 
P15 and P04 harbor both a XPO1 and a SF3B1 mutation and P03 has a XPO1 and a NOTCH1 
mutation.  
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4.1.5.4 Gene Category Analysis of Mutated Genes 
We identified mutations in 259 genes in our 25 CLL samples. As explained earlier, it is very 
difficult to distinguish driver from passenger mutations. There were 82 genes in our 25 
samples that were recurrently mutated if we take into consideration the whole exome and 
whole genome sequencing data from a total of 225 samples which include 200 CLL samples 
described in the literature. These 82 genes are quite likely to harbor driver mutations. 
However, there are 177 genes in our 25 CLL samples, which were only found mutated once. 
Not all of these genes would harbor driver mutations but some of them might. We would 
assume that driver mutations preferentially affect genes involved in certain cellular pathways. 
To estimate whether there was a preference for mutated genes to belong to certain groups we 
compared our mutated gene list to the Molecular Signature Database, a collection of 
annotated gene sets (MSigDB v.3.1) (Subramanian, et al. PNAS 2005). User-defined lists can be 
compared with the database and overlaps can be computed (Liberzon et al. 2011). In this way, 
it can be possible to find, that a large gene set contains mainly genes that are involved in a 
limited number of pathways.  
Table 18 REACH dataset clustered by gene families as analyzed by the MSigDB. Using the online tool at 
http://www.broadinstitute.org/gsea/msigdb/annotate.jsp we categorized the 259 mutated genes from our 25 CLL 
samples. All genes of the MSigDB are categorized into eight different gene categories, which are relevant in 
tumorigenesis. We loaded the list of 259 genes that we found mutated (coding mutations) in our own dataset into 
the search mask of MSigDB v.3.1 in order to compare the REACH dataset with the MsigDB v.3.1 database and 
categorize the genes by the given gene families. The output of this comparison is a table containing all genes of our 
own dataset that overlap with the MsigDB genes and could be grouped into one or more of the eight gene 
categories. A gene can also belong to more than one gene category at the same time. The eight different gene 
categories are listed within the grey boxes of the first row and also the first column of the table. Within the green 
boxes we find all genes belonging to one gene category. If a gene is also listed in one or more of the white boxes 
above, it belongs to more than one category. The grey boxes that define the position of the white boxes, tell us 
which category the gene belongs to. From this table one can see that the gene TP53 for example is a member of the 
tumor suppressor but it is also a member of the transcription factor gene category. The CREBBP is a transcription 
factor, translocated cancer gene and oncogene at the same time. 
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Cytokines and 
Growth Factors 
Transcription 
Factors 
Homeodomain 
Proteins 
Cell 
Differentiation 
Markers 
Protein 
Kinases 
Translocated 
Cancer Genes 
Oncogenes 
Tumor 
Suppressors 
Tumor 
Suppressors 
- TP53 - - ATM - - 
ATM, MSH6, SETD2, 
TNFAIP3, TP53 
Oncogenes - CREBBP - - - CREBBP, NOTCH1 
CREBBP, KRAS, 
NOTCH1, NRAS 
 
Translocated 
Cancer Genes 
- CREBBP - - - CREBBP, NOTCH1   
Protein 
Kinases 
- BRDT - - 
AMHR2, ATM, 
BMP2K, BRDT, FASTK, 
GRK7, NRBP1,OBSCN, 
PRKCA, RPS6KA3, 
TESK2, TTN 
   
Cell 
Differentiation 
Markers 
- - - 
ADAM17, CSF2RB, 
CXCR4, EMR2, 
IL3RA, KLRC2 
    
Homeodomain 
Proteins 
- TSHZ2 TSHZ2      
Transcription 
Factors 
- 
ASH1L, BAZ1A, BRDT, 
CHD2, CREBBP, EGR2, 
FUBP1, KAT5, MED12, 
OTUD7B, PACS2,TP53, 
TSHZ2, ZFP161 
      
Cytokines and 
Growth Factors 
FGF14, IL28A, 
RNASE2, SLIT2, STC1, 
VEGFC 
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Patient  Gene Name Accession Number Transcript Change Protein Change 
P1 CHD2 NM_001271.3 c.3455G>A p.(Arg1152Gln) 
P1 IL28A NM_172138.1 c.280C>T p.(Arg94Cys) 
P2 CREBBP NM_004380.2 c.46A>T p.(Lys16*) 
P3 RPS6KA3 NM_004586.2 c.506A>G p.(Asp169Gly) 
P3 NOTCH1 NM_017617.3 c.7541_7542delCT p.(Pro2514Argfs*4) 
P3 MED12 NM_005120.2 c.131G>A p.(Gly44Asp) 
P4 EMR2 NM_013447.3 c.283G>A p.(Val95Met) 
P4 CSF2RB NM_000395.2 c.2425C>G p.(Gln809Glu) 
P5 KAT5 NM_006388.3 c.1018G>A p.(Val340Ile) 
P5 BRDT NM_207189.2 c.1934G>A p.(Ser645Asn) 
P6 GRK7 NM_139209.2 c.941A>G p.(Tyr314Cys) 
P7 BAZ1A NM_013448.2 c.2995A>G p.(Lys999Glu) 
P7 OTUD7B NM_020205.2 c.2051G>T p.(Arg684Met) 
P7 BMP2K NM_198892.1 c.1617G>T p.(Gln539His) 
P8 TTN NM_133378.4 c.58999G>A p.(Val19667Ile) 
P8 TNFAIP3 NM_006290.3 c.90T>A p.(Phe30Leu) 
P9 ASH1L NM_018489.2 c.4868G>A p.(Gly1623Asp) 
P9 AMHR2 NM_020547.2 c.137G>T p.(Gly46Val) 
P10 PRKCA NM_002737.2 c.1439C>T p.(Ala480Val) 
P10 KLRC2 NM_002260.3 c.358G>A p.(Glu120Lys) 
P11 ZFP161  NM_003409.4 c.314T>A p.(Val105Asp) 
P11 NRBP1 NM_013392.2 c.169G>T p.(Glu57*) 
P11 ATM NM_000051.3 c.9023G>A p.(Arg3008His) 
P11 EGR2 NM_000399.3 c.1066G>A p.(Glu356Lys) 
P12 RNASE2 NM_002934.2 c.334C>T p.(Leu112Phe) 
P12 ADAM17 NM_003183.4 c.1481T>G p.(Met494Arg) 
P12 PACS2 NM_015197.3 c.448G>A p.(Gly150Ser) 
P14 FUBP1 NM_003902.3 c.41C>G p.(Ser14*) 
P15 SLIT2 NM_004787.1 c.199A>T p.(Ile67Phe) 
P16 OBSCN NM_001271223.2 c.18892G>T p.(Ala6298Ser) 
P19 FGF14 NM_175929.2 c.634C>T p.(Arg212*) 
P19 IL3RA NM_002183.3 c.565G>A p.(Ala189Thr) 
P19 KRAS NM_004985.3 c.35G>A p.(Gly12Asp) 
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Patient  Gene Name Accession Number Transcript Change Protein Change 
P21 VEGFC NM_005429.2 c.1030A>C p.(Lys344Gln) 
P21 TESK2 NM_007170.2 c.49G>T p.(Glu17*) 
P21 TP53 NM_000546.5 c.578A>G p.(His193Arg) 
P21 FASTK NM_033015.3 c.386C>T p.(Thr129Met) 
P21 CXCR4 NM_003467.2 c.1013C>G p.(Ser338*) 
P22 TSHZ2 NM_001193421.1 c.655G>A p.(Ala219Thr) 
P22 SETD2 NM_014159.6 c.5020G>T p.(Glu1674*) 
P23 NRAS NM_002524.4 c.38G>T p.(Gly13Val) 
P24 MSH6 NM_000179.2 c.3604A>T p.(Met1202Leu) 
P25 STC1 NM_003155.2 c.346A>T p.(Thr116Ser) 
Table 19 MSigDB Output. The 259 mutated genes were grouped into the following categories: tumor suppressors, 
oncogenes, translocated cancer genes, protein kinases, cell differentiation markers, homeodomain proteins, 
transcritption factors and cytokines/growth factors. 21 patient samples of our dataset had at least one mutation in 
a gene that could be grouped to one of these gene categories which are relevant for cancer development.  
We attempted to assign the 259 mutated genes (coding mutations) from our 25 CLL samples to 
gene categories that are known to play a critical role in cancer using MSigDB. The genes were 
grouped into eight categories: tumor suppressors, oncogenes, translocated cancer genes, 
protein kinases, cell differentiation markers, homeodomain proteins, transcription factors and 
cytokines/growth factors (Table 18). 43 of the 259 mutated genes belong to one of these 
categories. Interestingly, 21 of the 25 patients (84 %) had at least one mutation in one of these 
43 genes (Table 19 
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4.2 XPO1 Mutation Screening of 445 CLL Samples 
We paid special attention to Exportin 1 (XPO1), which was the most frequently mutated gene 
in our patient cohort. Using exome sequencing, we initially detected three samples with 
mutations affecting amino acid E571 of XPO1 in the 25 CLL samples of this study. All three 
XPO1 mutated samples had a non-mutated IGHV status, two had a 13q deletion and one had 
no aberration in our FISH screen. We then screened 445 CLL samples from the REACH cohort 
for XPO1 mutations using Sanger sequencing of almost the entire exon 16 (amino acids 529 to 
575). The 25 patient samples analyzed by whole exome sequencing were included in these 445 
samples.  
XPO1 Mutation any p.E571K p.E571G p.E571V p.E571Q p.E565I 
Cases 
N=445 
41 33 4 2 1 1 
Frequency 9.2 % 7.4 %     
Table 20 XPO1 mutations in n=445 REACH patient samples. Percentage not calculated if n<5. Note that all except 
one mutation affect codon 571.  
The analysis of these patients detected missense mutations in residue 571 in 40 (9 %) of the 
445 cases. One patient had a mutation in codon 565. Thus, the overall frequency of XPO1 
mutations is 9.2 % (41/445) in our CLL patients, who had all experienced a relapse. Among the 
mutated samples one was from the 25 samples of the exome sequencing group. This XPO1 
mutation, which was found in P14, was initially not detected by our exome sequencing and 
analysis pipeline as the number of mutated reads was only 7 %, which is below the detection 
threshold set at 20 %. 
 
Figure 30 Frequency of XPO1 mutations. Frequency of XPO1 mutations in CLL subgroups defined by FISH, IGHV or 
TP53 mutational status. Please note that these groups are not mutually exclusive. Thus the percentages add up to 
more than more than 9.2 %. 
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XPO1 mutations were slightly more frequent in patients with an unmutated IGHV status 
(13.5 %) and in patients with a 13q deletion (11.6 %).  
 
Figure 31 Distribution of XPO1 mutations. Distribution of IGHV mutational status, chromosomal aberrations 
detected by FISH and TP53 mutational status in previously treated CLL samples with wild type or mutant XPO1 
(Fisher’s exact test: ***, P <0.0001; *, P <0.05).  
In the group of 41 patients with an XPO1 mutation, 9.8 % had a mutated IGHV status, 73.2 % a 
13q deletion, 17.1 % an 11q deletion, 14.6 % a Trisomy 12, 7.3 % a 17p deletion and 3.1 % a 
mutated TP53 gene (one patient). 
In the group of patients with wild type XPO1 (for the exon 16 region) 40.2 % had a mutated 
IGHV status, 56.7 % a 13q deletion, 20.6 % an 11q deletion, 13.9 % a Trisomy 12, 8.2 % a 17p 
deletion and 12.9 % a mutated TP53 gene. Please note that these patient groups are not 
mutually exclusive, so the percentages add up to more than 100 %. Thus patients with an XPO1 
mutation were more likely to have a 13q deletion and less likely to have mutations of the IGHV 
genes than patients with a wild type XPO1 gene. 
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Figure 32 Heat map of the 445 CLL patients analyzed for XPO1 mutations and 6 other genetic alterations. The 
p-values were calculated for the correlation of the XPO1 mutational status with the IGHV mutation status, del(13q), 
del(11q), trisomy 12, del(17p), and TP53 mutation. For patient samples colored in black the IGHV status could not 
be clearly determined. ns: not significant 
The heat map in Figure 32 shows that mutations in XPO1 are significantly associated with a 
wild type IGHV status and the presence of 13q deletions. The association with an unmutated 
IGHV status suggests that the XPO1 mutations are acquired during early B-Cell development. 
Overall survival (OS) and progression free survival (PFS) of patients treated with FC or FC-R was 
kindly analyzed by F. Hoffmann-La Roche. There was no difference in OS or PFS between 
patients with wild type versus mutated XPO1 (data for OS, shown in discussion). Therefore, 
XPO1 is neither a prognostic nor a predictive marker for patients with previously treated CLL 
treated with FC or FC-R. 
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5 Discussion 
5.1 Next Generation Sequencing and its Applications 
Next generation sequencing has tremendously enhanced our ability to analyze cancer 
genomes and will help to improve cancer diagnostics and treatment decisions. Classical 
cytogenetics, a commonly used method in leukemia diagnostics, can detect chromosomal 
aberrations only down to about 10 Mb. FISH is more sensitive and aberrations of about 50 kb 
can be detected, but the targeted regions must be known and selected in advance. Array-
based comparative genomic hybridization (Array-CGH) techniques allow the detection of 
deletions and duplications across the entire genome at a higher resolution than FISH. 
However, balanced translocations cannot be detected using Array-CGH technology. In 
contrast, NGS technology allows the analysis of a whole genome at single base pair resolution. 
Roche’s 454 pyrosequencing technology, ABI’s SOLID ligation based sequencing and Illumina’s 
sequencing by synthesis are leading technologies in the field of next generations sequencing. 
These technologies enable us to study point mutations, insertions, deletions, copy number 
alterations or translocations in tumor genomes on a genome wide scale. WGS is the most 
comprehensive strategy to detect variants in tumor genomes but it is very expensive, and 
variants in non-coding regions, which constitute 98.5 % of the genome, are very difficult to 
interpret. Several whole cancer genomes have been reported so far. The first cancer genome 
published in 2008 was the genome of an AML patient (Ley et al. 2008). However, WES, which 
focuses on the 1.5 % of the genome coding for proteins, became more common within the last 
years as it is cheaper and faster than WGS. Using WES a much higher coverage of coding 
regions can be obtained with a considerable reduction of raw sequence production.  
Initially, the targeted sequencing of coding region of a genome was only possible by 
transcriptome analysis of cDNA derived from mRNA. Despite the tissue specific expression 
patterns of genes, mutation detection in many genes is possible using transcriptome 
sequencing (Greif et al. 2011). In contrast to WES or WGS, transcriptome sequencing provides 
additional information on gene expression levels, alternative transcripts and fusion transcripts. 
However, we were unable to obtain satisfactory results using whole transcriptome sequencing 
for CLL samples. We found that the RNA quality was inadequate resulting in poor 
transcriptome coverage and a high number of duplicated reads (data not shown). This problem 
might be due to the fragility of CLL cells (Macdonald et al. 2003) which might be the cause of 
poor mRNA quality. 
5.1.1 Whole Exome Sequencing of 25 Previously Treated CLL Patients 
In 2010, Agilent Technologies introduced the first commercial whole exome capture kit, which 
is based on an in-solution-hybrid-selection technology (Gnirke et al. 2009; Bainbridge et al. 
2010). DNA fragments containing exonic sequences are captured with biotinylated RNA baits. 
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We used the Agilent Human All Exon 50Mb platform to analyze a total of 50 exomes from 25 
CLL patient samples. For each patient, the exome from a blood sample at diagnosis (the CLL 
sample) and the exome from a blood sample at remission was captured and sequenced. As 
exome sequencing is based on genomic DNA, each gene is evenly represented. However, a bias 
can be introduced due to different capturing efficiencies across the exons. The patients we 
analyzed were treated on a clinical study designed and sponsored by F.Hoffmann-La Roche. In 
this trial, previously treated patients with CD20-positive B-cell CLL who had relapsed were 
treated with fludarabine, a purine analog, and cyclophosphamide, an alkylating agent, alone 
(FC arm) or together with rituximab (R-FC arm) to evaluate the efficacy and safety of the 
monoclonal antibody treatment in this setting (for further details see Roche protocol 
BO17072). Relevant prognostic markers in CLL, like the deletion of certain genomic regions 
and, the mutational status of the IGHV region, were evaluated in the laboratory for leukemia 
diagnostics at the University of Munich, Campus Grosshadern. We selected 25 of 552 patient 
samples at the time of relapse before second-line treatment and the corresponding disease 
free remission samples. Disease free remission was defined as minimal residual disease levels 
of less than 1x10-3 as measured by the disease specific IGHV rearrangements using quantitative 
PCR or FISH negativity if a marker was available. The analysis of a non-tumor (or germline) 
sample from the same patient is necessary to correctly identify somatic variants. Currently and 
for the forseeable future, single nucleotide polymorphism (SNP) data bases will not be 
comprehensive enough to contain every germline SNP in the population. There are about 1 to 
3 million SNPs differing between any two unrelated individuals accounting for about 0.1 % of 
the genome (Levy et al. 2007). The fact that a remission sample was required for proper 
analysis meant that we could only analyze patients that came into remission after treatment. 
We thus selected for samples from patients with a more favorable course of disease. Patient 
characteristics kindly provided by Hofmann-La Roche confirmed this assumption as our exome 
cohort represents patients with significantly better prognostic markers (IGHV, ZAP-70 and 
Binet stage) compared with the whole study group.  
After exome capturing paired-end sequencing was performed on an Illumina Genome 
Analyzer IIx. We obtained on average 94 million reads per lane and per exome, corresponding 
to more than 7 Gb of sequence assuming a 80 base pair read length. To align the sequence 
reads to the genome we chose the Burrows Wheeler Alignment tool, as it is designed to map 
short reads and allows mismatches and gaps for calling of small insertions and deletions (Li and 
Durbin 2009). The alignment output was in SAM and BAM format files, which can be 
manipulated by the SAMtools software package (Li et al. 2009). Before starting with variant 
calling, reads had to pass several quality filters. In a first step, reads derived from clusters on 
the flow cell with a low signal to noise ratio were discarded (chastity filter). On average, 18.4 % 
of the reads were discarded. More than 97 % of the remaining reads could be mapped to a 
unique position in the genome. We further filtered by mapping quality and removed PCR 
duplicates (11 % on average) since PCR introduced errors may result in false positive variant 
calls. This meant that we were able to use about 4.8 Gb of sequence data per patient for the 
downstream analysis. All custom scripts and data analysis workflows were executed on a 
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Galaxy server, an open source, web-based platform (Goecks et al. 2010). For this project we 
performed no quality trimming, realignment or base quality recalibration.  
5.1.2 Downstream Analysis 
Downstream analysis was performed using the human RefSeq genes as downloaded in May 
2012 from the UCSC table browser based on the human genome assembly from March 2006 
NCBI Build. The number of bases on or near target (±250 nucleotides) was about 72.72 %. For 
all 50, exomes the average on target coverage ranged between 32 and 73 fold. Off note, 
around 5 % of all targets were not covered at all and 10 % had a coverage of less than 10 fold. 
Thus, for 85 % of all target positions the coverage was at least 10-fold, sufficient for variant 
calling (SNVs and InDels). For variant calling, VarScan 2 was used with different settings. We 
obtained most variants with a minimal variant frequency of 5 % set in the remission sample. 
The best validation rate of 94 % (true positive variants) was obtained for our somatic 
workflow.  
In total, we could validate 271 variants in the 25 CLL samples including point mutations and 
small InDels. All variants were located in coding regions except for one splice site mutation 
affecting the RB1 gene. We identified, on average, 11 (±4.3) mutations per patient with a 
minimum of n=3 and a maximum of n=20.  
When we take into account that 15 % of all target positions could not be analyzed, as they did 
not reach the minimum coverage requirements for a SNV to be called, the mutations described 
are derived from only 85 % of the target (i.e. the RefSeq hg18 genes). This implies that the true 
number of missense, nonsense and InDel mutations in each sample is about 17 % greater. 
Considering the range of 3 to 20 mutations per sample, it is likely that between 0 and 3 
additional mutations are present in each sample.  
This result is in good agreement with published studies on CLL whole exome or whole genome 
sequencing (Puente et al. 2011; Quesada et al. 2012). Thus our data indicates that we 
successfully established whole exome sequencing in our laboratory, starting from library 
preparation to downstream computational analysis. As we created a solid foundation for 
whole exome sequencing analysis, we can now further optimize downstream analysis. In some 
regions for example there can be a great bias between forward and reverse reads. Therefore, 
only the forward or the reverse reads map to the reference sequence. This so-called strand 
imbalance is a result of the exome capturing mechanism (Guo et al. 2012). Variants that are 
derived from one strand only are commonly considered to be false positives due to sequencing 
artifacts, but Guo et al showed that strand imbalances, which derive as artifacts from the 
exome capturing mechanism, have little effect on genotype quality. In our dataset we were 
able to validate several mutations with the variant reads derived from one strand only, given 
that there was also a strand imbalance in the reference reads. Therefore variant reads derived 
from one strand only should not strictly be excluded.  
Most false positive calls occurred in the subtraction workflow when the minimum coverage 
required for the remission sample was set to one. With this setting we called many putative 
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somatic mutations in the tumor sample that later proved to be germline variants when 
analyzed with Sanger sequencing (false positives). In our somatic workflow, the minimal 
coverage requirement for calling SNVs in the remission control was set to ten therefore we 
faced less such problem to reduce the false positive rate.  
In general, a higher coverage will reduce false positive rates. Coverage is dependent on 
enrichment efficiency. Optimized sample preparation can positively affect coverage of sparsely 
covered targets. There are many reasons for some target regions to be sparsely covered. One 
of these reasons can be PCR amplification bias. Aird and colleagues have shown that PCR 
amplification bias can be reduced by using alternative polymerases and amplification settings 
(Aird et al. 2011). For one of our samples we changed amplification settings, we extended the 
initial elongation step and the denaturation step at each cycle for the amplification of the 
adapter ligated libraries. For the amplification of the captured DNA, we added two more PCR 
cycles (3.5.3.4 and 3.6.1.2). With these settings we could significantly increase the coverage for 
NOTCH1. In the 24 samples, where we did not optimize the PCR settings, the coverage for half 
of the nucleotide positions in NOTCH1 was below ten. In contrast, in the one sample where we 
used optimized PCR-settings, half of the NOTCH1 positions were covered 30-fold or higher and 
only 15 % of the positions were covered 10 fold or less. As NOTCH1 is a frequent mutational 
target in CLL we also analyzed NOTCH1 in all 25 samples by Sanger sequencing.  
In summary we had a very good validation rate, visual inspection of aligned reads further 
helped to reduce false positives. A change of downstream analysis settings may reduce the 
rate of false positive variants but can lead to an increase in the false negative rate, i.e. 
important somatic mutations will be discarded in the workflow. 
5.1.3 Sanger Sequencing as Validation and Screening Tool 
Sanger sequencing was used to validate all nonsynonymous mutations independently. 
Although Sanger sequencing is still the gold standard in diagnostics, its usefulness as an 
independent validation tool for mutations discovered with NGS approaches has its limitations. 
Firstly Sanger sequencing has a sensitivity of around 15 %, which means that heterozygous 
mutations present in clones that constitute less than 30 % cannot be reliably validated by 
Sanger sequencing. So true positive somatic mutations might be discarded after attempted 
Sanger sequencing validation. Secondly, Sanger sequencing is time consuming and labor-
intensive, taking several days from primer design to final sequence. Thirdly, one loses several 
nanograms of valuable patient DNA with each Sanger sequencing reaction. For our 
transcriptome project for example (Greif et al. 2011) we screened three candidate genes in 95 
patients for mutations. Altogether 46 amplicons per patient sample were amplified for a total 
of 4370 PCR-products. Sanger sequencing was performed bidirectional for all products 
resulting in over 8000 sequencing reactions that were performed and analyzed. This was not 
only laborious and costly, it also required about 1 µg of DNA per patient. Therefore, newer 
strategies using commercially designed gene panels and small scale NGS approaches are 
preferable for these focused screening approaches. With these strategies (e.g. the Haloplex 
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system from Agilent Technologies) several target genes and samples can be sequenced in 
parallel and with much higher sensitivity.  
5.2 Mutations Discovered in the 25 CLL Cases  
During the last years the identification of prognostically relevant mutations has not only 
improved the prediction of disease outcome in CLL but has also remarkable improved our 
understanding of CLL biology. Although the IGHV mutational status and cytogenetic markers 
are able to predict time to progression, time to therapy and overall survival in large cohorts of 
CLL patients, the clinical course of the individual patient is very difficult to predict. 
Furthermore, common FISH markers can be instable and the detection of the IGHV mutational 
status is very laborious and difficult and is not performed routinely in many laboratories. Thus 
the search for new, relevant biomarkers in CLL is an ongoing endeavor with exome sequencing 
having become a viable approach to identify somatic mutations in CLL.  
5.2.1 Frequency of Nonsynonymous Mutations in CLL 
In our study we evaluated 25 previously treated and relapsed CLL patients and discovered a 
total of 271 point mutations and InDels affecting 260 genes with a mean frequency of eleven 
mutations per patient. We and others find relatively few mutations per CLL patient in 
comparison to patients with solid tumors (Quesada et al. 2012; Kandoth et al. 2013; Vogelstein 
et al. 2013).  
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Figure 33 Number of somatic mutations in a variety of cancer types (taken from Vogelstein et al, 2013). A) 
Pediatric cancers (left) and adult cancers (right) with median number of nonsynonymous mutations per tumor in 
parentheses. A variety of cancer types with median number of nonsynonymous mutations represented as boxplots. 
MSI: microsatellite instability; SCLC: small cell lung cancers; NSCLC: non-small cell lung cancers; ESCC: esophageal 
squamous cell carcinomas; MSS: microsatellite stable; EAC esophageal adenocarcinomas.  
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Although leukemias are a heterogeneous group, AML (Welch and Link 2011; Greif et al. 2012) 
and CLL have a similar, average number of mutations in the coding regions. AML evolves from 
hematopoietic stem cells, which accumulate mutations that lead to increased proliferation and 
a block of differentiation. AML is characterized by rapidly proliferating cells and a rapid disease 
course. In contrast, the cell of origin in CLL is a more differentiated B cell, and disease arises 
mainly in elderly patients and is characterized by a protracted disease course with the slow 
accumulation of mature looking B cells (Chiorazzi et al. 2005). When we analyzed our first CLL 
exomes we were surprised that we found such a small number of mutations, especially in the 
cases with hypermutated IGHV genes where we expected more mutations in non-
immunoglobulin genes. Indeed, we found that the average number of somatic mutations was 
slightly higher in the IGHV mutated subgroup but the difference was not statistically significant 
most likely due to the small number of patients we analyzed. Other groups have shown a 
significant difference in the number of somatic mutations in non-immunoglobulin genes 
between mutated and unmutated CLL samples (Quesada et al. 2012). Landau and colleagues 
could also show that age is associated with a higher number of somatic mutations (Landau et 
al. 2013).  
5.2.2 Recurrently Mutated Genes 
If a gene is found mutated more often in cancer in general or in a particular cancer subtype 
than would be expected by chance, it can be assumed that such a gene harbors driver 
mutations. Among the 259 mutated genes (mutations in coding regions), we find six of them 
recurrently mutated in our 25 patients: XPO1 (16 %), SF3B1 (12 %), KRAS (8 %), CDH12 (8 %), 
PCLO (8 %), MYH2 (8 %). Due to our small sample size of only 25 patients and an average of 11 
mutated genes per sample, the likelihood that we would find the same gene mutated twice by 
chance in our cohort should be very low. However, calculating the likelihood of any gene being 
mutated more than once in a group of 25 patients is not trivial since one has to take into 
account the mutational target, i.e. the size of the gene that it presents to mutating agents. 
Thus very large genes like PCLO (4935 amino acids) and MYH2 (1941 amino acids) might be 
mutated twice in such a cohort by chance without being driver genes.  
When we assigned the 259 genes which had been found mutated in coding regions in our WES 
cohort using the online GSEA tool (http://www.broadinstitute.org/gsea/), we found mutated 
genes (n=43; 16 %) in all eight categories within this database: cytokines and growth factors, 
transcription factors, homeodomain proteins, cell differentiation markers, protein kinases, 
translocated cancer genes, oncogenes and tumor suppressors. A gene can also be assigned to 
more than one group. Out of the 43 genes, we most frequently see mutated transcription 
factors (33 %) and protein kinases (28 %). 84 % out of our 25 CLL samples had at least one gene 
mutated that belonged to one of these 8 categories (none of these genes were found mutated 
in Patients: P13, P17, P18 and P20). 
The nuclear export protein XPO1 was most frequently mutated in our WES cohort. This gene is 
a putative driver in CLL, which might be more common in relapsed patient samples due to the 
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preceding treatment. As we found XPO1 unexpectedly frequently mutated in 41 of 445 (9.2 %) 
patients, the role of XPO1 in CLL is discussed in a separate chapter.  
SF3B1 was found mutated in 3/25 samples (12 %) with various residues affected as shown in 
Table 14. All three samples had an unmutated IGHV status, two had a del(13q), and in one 
patient none of the FISH markers used showed an abnormality. The first next generation 
sequencing studies discovered that SF3B1 is frequently mutated in CLL and also in MDS 
(Papaemmanuil et al. 2011; Wang et al. 2011). Since these initial findings, much effort has 
been put into the evaluation of the role of SF3B1 mutations as a driver in CLL. SF3B1 is part of 
the spliceosome, which consists of several subunits of small nuclear ribonucleoprotein 
complexes, the so called snRNPs (U1, U2, U4, U5 and U6) and numerous splicing factors. The 
protein SF3B1 is part of one of the two heteromeric protein complexes of the U2 snRNP, 
namely SF3B, which also contains six other proteins (Wahl et al. 2009). Mutations in SF3B1 are 
predominantly clustered in the C-terminal region of the protein (Groves et al. 1999), which 
consists of 22 non-identical tandem HEAT repeats (HEAT named after the proteins Huntingtin, 
elongation factor 3, protein phosphatase 2A and TOR1 kinase), with K700E as the most 
frequent non-silent mutation. Analyses of diverse CLL cohorts have consistently shown that 
SF3B1 mutations are associated with more aggressive disease and poorer clinical outcome 
(Wang et al. 2011; Quesada et al. 2012; Oscier et al. 2013). Landau and colleagues observed 
that mutations in SF3B1 are predominantly subclonal and thus more likely to be involved in 
disease progression rather than disease initiation (Landau et al. 2013). This is consistent with 
the finding that fludarabine treatment refractory patients have a greater incidence of SF3B1 
mutations (≈17 %) than newly diagnosed patients (Rossi et al. 2011). Mutations of the SF3B1 
gene are frequently associated with deletions of the long arm of chromosome 11 (del(11q)). 
These findings suggest that mutations in SF3B1 and in ATM, which is affected by 11q deletions, 
might collaborate in CLL pathogenesis (Wang et al. 2011). Indeed a siRNA screen identified 
spliceosome components to be involved in DNA damage response being important for genome 
stability (Paulsen et al. 2009).  
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Figure 34 Spliceosome assembly as downloaded from the KEGG database (www.genome.jp/kegg/). Known 
mutational targets are highlighted in yellow. Blue depicts genes only found in our cohort not in the public CLL 
datasets (Wang et al, Puente et al and Quesada et al) and purple describes overlapping targets. This map was 
downloaded from Kyoto Encyclopedia of Genes and Genomes (KEGG) database. 
Even before SF3B1 was discovered to be frequently mutated in CLL and MDS (Papaemmanuil 
et al. 2011; Wang et al. 2011) SF3B1 had been shown to be a pharmacological relevant target. 
Spliceostatin A inhibits in vitro splicing and accumulation of pre-mRNA by binding to SF3B1 
(Kaida et al. 2007). Besides SF3B1, many other spliceosome components have been reported 
to be mutated in hematological malignancies.  
We also found RBM25 (also called S164) to be mutated. Mutations in RBM25 have not been 
previously been reported in CLL. Zhou and colleagues showed that the splice factor RBM25 
influences apoptosis through the regulation of different BCLX isoforms, which act as anti- or 
pro-apoptotic regulators (Zhou et al. 2008). An increase in RBM25 promotes the selection of 
the pro-apoptotic Bcl-xS (short form) isoform, and a reduction of RBM25 shifts the balance 
towards the anti-apoptotic isoform Bcl-xL (long form). The point mutation p.I94F affects the 
RRM (RNA recognition motif) domain of the RBM25 protein but it does not seem to be 
deleterious as phenylalanine and isoleucine both have hydrophobic side chains. The functional 
prediction tool PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) predicted the mutation to 
be benign. Mutations in RBM25 seem to have the potential to be drivers in CLL as it is a 
regulator of apoptosis. 
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The members of the RAS family of proto-oncogenes, which include HRAS, NRAS and KRAS are 
frequently mutated in human tumors (≈30 %). RAS proteins are small G-proteins and can 
switch between a GTP-bound and a GDP-bound state corresponding to the active and inactive 
state of the protein, respectively. RAS is a key regulator of many signaling pathways including 
cell growth, differentiation and apoptosis. Most mutations in RAS result in the abrogation of 
the normal GTPase activity resulting in a protein which is constitutively active. In our 25 exome 
samples we detected one NRAS mutation (p.G13V) in a case with unmutated IGHV status and 
Trisomy 12. In addition, two KRAS mutations were found: A KRAS G13D in a case with 
unmutated IGHV status and a del (11q) and a KRAS G12D mutation in a case with mutated 
IGHV status and no FISH marker. Thus, in our exome cohort RAS mutations had a frequency of 
12 %. RAS mutations have been reported to occur only infrequently in CLL (Browett et al. 1988; 
Gougopoulou et al. 1996; Domenech et al. 2012) compared with other hematological 
malignancies like AML where they are found with a frequency between 12 % and 27 % 
(Neubauer et al. 2008). As CLL is a very heterogeneous disease, the mutation frequencies for 
individual genes often vary a lot from study to study. The time point of mutational analysis 
(first diagnosis vs relapse) and treatment status are variables that have a great impact on the 
mutation frequency in different cohorts.  
We also found recurring mutations in the PCLO gene. The PCLO protein is part of the 
presynaptic cytoskeletal matrix where it is involved in establishing active synaptic zones and 
vesicle trafficking. The PCLO locus has been linked to major depressive disorder (Hek et al. 
2010). PCLO is a very large protein. Its longest protein coding isoform has 5142 amino acids. 
We found two non-silent mutations: p.E2041A in a CLL patient with trisomy 12 and mutated 
IGHV status, and p.P2871S in a case with del(13q) and unmutated IGHV status. According to 
the PolyPhen-2 prediction program, the E2041A mutation is probably damaging with a score of 
0.975, and the P2871S mutation is possible damaging with a score of 0.775. PCLO was found to 
be mutated at a frequency of 35 % in a series of 49 large B-cell lymphomas (DLBCL) (Lohr et al. 
2012). These results make it very likely that mutations in PCLO are important for tumorigenesis 
in lymphoid malignancies.  
The human type II classical cadherin-12 (CDH12) gene was recurrently mutated in two of our 
25 patient samples (N59K and F209L). CDH12 belongs to the cadherin superfamily of calcium 
dependent transmembrane proteins, which mediate cell-cell adhesion. Cadherins play a role in 
neural development and have been associated with neurological and psychiatric disorders 
(Redies et al. 2012). Mutations in cadherins have not been linked to leukemias so far. We did 
not analyze whether this gene is recurrently mutated in our 445 patient extended cohort. 
Several other cadherin gene family members have been found mutated in other CLL whole 
exome and genome sequencing studies (Wang et al. 2011; Quesada et al. 2012) 
MYH2, the myosin heavy chain II a gene, was mutated in two patients of our exome cohort. 
Since MYH2 presents a large mutational target encoding close to 2000 amino acids, it might be 
recurrently mutated out of chance. There are, to our knowledge, no reports in the literature 
that would suggest a functional link between MYH2 mutations and lymphoid malignancies. 
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Additional studies in larger collectives are warranted to determine the importance of MYH2 
mutations as drivers in CLL. 
We also extracted all nonsynonymous point mutations and InDels in coding regions from three 
large CLL genome and exome sequencing projects. 2399 different genes were found to be 
mutated in the 200 patients analyzed in these three studies (Puente et al. 2011; Wang et al. 
2011; Quesada et al. 2012). When we compared the 259 genes mutated (mutations in coding 
regions) in our 25 CLL samples we found that 82 of these 259 genes (32 %) were also found 
among the 2399 mutated genes of these three studies. One would have only expected about 
10 % of our mutated genes to be also found among these 2399 other genes, if the mutations 
were distributed randomly across the genome. This result suggests that about 2/3 of these 82 
genes are actually driver mutations. Of these 82 genes 47 could only be identified as 
recurrently mutated when our data was taken into consideration. With this finding, we 
increase the number of recurrently mutated genes in CLL from 194 to 241. These data 
emphasize that CLL is an extremely heterogeneous disease at the genetic level with many 
genes mutated recurrently but at a very low frequency. This is also becoming apparent when 
we look at the large number of genes (177) that have been found mutated in our small CLL 
cohort for the first time. For treatment approaches, it is necessary to know the genomic 
architecture of a disease. Therefore our data significantly increase our knowledge of CLL. 
About 241 recurrently mutated genes have been described in CLL up to now. However, only 3 
(SF3B1, TP53 and MYD88) of them are found mutated in more than 5 % of all the CLL samples 
of our study and the three public datasets. Other studies also find NOTCH1 and ATM 
frequently mutated (>5 %) in CLL. SF3B1, TP53, ATM, NOTCH1 and MYD88 are involved in well-
known cellular pathways and core processes in the cell. Notch is a transmembrane receptor 
which gave the name to the intercellular Notch signaling cascade, which plays a fundamental 
role in metazoan development. This signaling cascade controls many cellular processes 
including proliferation and differentiation. ATM is a serine-threonine kinase, which is involved 
in cell cycle checkpoint control. ATM is activated upon double strand breaks and 
phosphorylates proteins that are involved in cell cycle control, apoptosis and DNA repair. One 
of the target genes of ATM is the tumor suppressor TP53, which preserves genome integrity by 
regulating growth arrest and apoptosis. MYD88 is a cytosolic adapter protein, which is involved 
in Toll-like receptor and IL-1 signaling pathway and therefore it is regulating many 
proinflammatory genes.  
Mutations in SF3B1, NOTCH1, TP53 and ATM are associated with poor prognosis (Austen et al. 
2005; Zenz et al. 2010; Puente et al. 2011; Wang et al. 2011; Dufour et al. 2013). In our 
samples, the mutational hotspot (p.P2515Rfs*4) in NOTCH1 was found mutated in only one 
patient with an unmutated IGHV status and no FISH abnormalities. There was also only one 
patient (P21) with a TP53 mutation (p.H193R). This patient was normal on FISH and had 
mutated IGHV genes. As our cohort represents mostly patients with a favorable prognosis, this 
result was not surprising.  
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5.3 The Relevance of XPO1 in CLL  
XPO1, a transport receptor of the karyopherin-β family, was mutated frequently in our CLL 
cohort (41/445, 9.2 %). XPO1 and other transport proteins share an N-terminal RanGTP-
binding motif and interact with NPCs (nuclear core complex). The RanGTPase system plays a 
major role in nuclear transport, as it ensures the directionality of transport. Exportins like 
XPO1 bind their cargo in the nucleus, together with RanGTP and the cofactor RanBP3 
(activated Ran guanine exchange factor) and move into the cytoplasm where the complex 
dissociates upon activation of Ran through RanGAP1, the GTPase activating protein, and 
RanBP1 the coactivator of RanGAP (Sorokin et al. 2007). Compared to these, importins 
(heterodimer of importin-α and importin-β) bind their cargo in the cytoplasm and move them 
through the NPC into the nucleus where the cargo is released upon binding to RanGTP. The 
RanGTP/importin complex leaves the nucleus through the NPC without cargo and enters the 
cytoplasm where RanGTP is removed from the importin (Gorlich and Kutay 1999). The 
translocation process is most likely based on facilitated diffusion. The directional transport is 
regulated by Ran.  
The human XPO1/CRM1 protein has 1071 amino acid residues and a molecular weight of 112 
kDa (Fornerod et al. 1997b). This protein is very well characterized and transports a large 
number of proteins and certain RNA species from the nucleus into the cytoplasm (Fornerod et 
al. 1997a; Stade et al. 1997). XPO1 binds to its cargo either directly via Leu rich NESs (nuclear 
export signals) or indirectly via adapter proteins (Guttler and Gorlich 2011). The entire nuclear 
export complex has been well characterized by X-ray crystallography (Monecke et al. 2013).Till 
now, more than 200 NES-containing CRM1 cargos have been identified. The CRM1 cargos can 
be found in a database developed by Xu and colleagues (Xu et al. 2012). The consensus 
sequence of NES was defined by several mutational and computational studies as: φ-X2-3-φ-X2-
3-φ-X-φ, where φ is Leu, Val, Ile, Phe or Met and X can be any amino acid, which is repeated 2-
3 times as denoted by the subscript (Bogerd et al. 1996; la Cour et al. 2004; Dong et al. 2009). 
The tumor suppressor protein TP53 is also among the XPO1 cargos (Freedman and Levine 
1998).  
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Figure 35 Nuclear Export and Import (taken from Gohrlich and Kutay, 1999). Nuclear export factors (Exp) like XPO1 
bind their cargo in the nucleus together with RanGTP and move through nuclear pores into the cytoplasm. When 
localized in the cytoplasm the low intrinsic GTPase activity of the Ran-Protein is enhanced by RanGAP, which is 
activated by RanBP1. The complex dissociates, the cargo is now localized in the cytoplasm and the export protein 
returns into the nucleus. Importins (Imp), in contrast, leave the nucleus while bound to RanGTP. In the cytoplasm 
RanGAP and RanBP1 accelerate the dissociation of RanGDP from the complex. The free importin can now bind to its 
cargo and move it into the nucleus. Both transport mechanisms lead to a cytoplasmatic RanGDP enrichment. NTF2, 
the import receptor of Ran, relocates RanGDP into the nucleus where RCC1, the guanine nucleotide exchange 
factor, replaces GDP by GTP. 
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By WES we initially detected three samples (3 of 25, 12%) with XPO1 mutations, which all 
affected codon 571. Other studies had detected mutations in codon 571 of XPO1 as well but 
with an overall frequency of only 2.4 % (Puente et al. 2011). Therefore, we set out to explore 
this hotspot mutation in a larger group of REACH study patients (n=445) by Sanger sequencing 
and detected an overall frequency of 9.2 % of XPO1 mutation (41/445). Of these 41 XPO1 
mutations, 40 affected codon 571. As the screening group also included the 25 exome 
samples, we detected one additional XPO1 mutation (E571K) in our exome cohort, which 
initially went undetected during WES due to the low variant allele frequency of only 7 %. In the 
screening cohort, we detected a handful of XPO1 mutations at low variant allele frequency 
suggesting a later event in CLL evolution. The high frequency of XPO1 mutations in our cohort 
could be due to the fact that this cohort contains only relapsed and refractory CLLs. 
Despite its function as export receptor, XPO1 was initially identified as a protein involved in 
higher order chromosome structure, which was affected in XPO1 mutants in fission yeast. 
Therefore the protein was originally termed CRM1 for chromosome region maintenance 
protein (Adachi and Yanagida 1989). Subcellular localization studies showed that the protein is 
not only found in and around the nucleus but also at centrosomes and kinetochors explaining 
the mitotic phenotype of CRM1 mutants (Forgues et al. 2003; Arnaoutov and Dasso 2005). 
XPO1 ensures that proteins that are involved in centrosome duplication and kinetochore 
attachment are correctly positioned. A dysfunction in centrosomes syntheses (centrosome 
overduplication) and an impaired assembly of microtubules to form the mitotic spindle 
between kinetochore and the spindle poles may lead to aneuploidy. 
5.3.1 Nucleocytoplasmatic Transport and Cancer  
The nucleocytoplasmic transport process can be altered in different ways, some of which may 
promote uncontrolled cell growth, e.g. altered NPCs, modifications in cargo or transport 
receptors. Alteration of any of these processes may alter the subcellular localization of tumor 
suppressors, oncoproteins or transcription factors resulting in uncontrolled proliferation. 
Different fusion proteins have been described in AML that involve nucleoporins, like the 
translocation t(7:11)(p15;p15.5) resulting in the NUP98-HOXA9 fusion protein or the 
translocation t(6;9)(p23;q34) leading to a fusion between NUP214, also called CAN, and the 
nuclear binding protein DEK (Soekarman et al. 1992). Many studies focus on the cargo proteins 
of nucleocytoplasmic transport but not on the nuclear transport machinery itself. However, 
there is mounting evidence that disruption of the nucleocytoplasmatic transport plays an 
important role in several cancers. XPO1 was found to be overexpressed in ovarian cancer, 
cervical cancer, and osteosarcoma. (Noske et al. 2008; van der Watt et al. 2009; Yao et al. 
2009). In all three studies, increased XPO1 expression was associated with an unfavorable 
prognosis. Interestingly, van de Watt and colleagues found that inhibition of XPO1 through 
Leptomycin B, which covalently binds to the NES-binding groove of XPO1, significantly reduces 
proliferation of cancer cells but not of normal cells, indicating that certain cancers are 
dependent on XPO1 to maintain increased proliferation. Several XPO1 mutations are listed in 
the COSMIC database (catalogue of somatic mutations in cancer, http://www.sanger.ac.uk). In 
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CLL, XPO1 mutations have been identified as driver mutations based on the frequency of XPO1 
mutations and the mutational pattern of XPO1 (Landau et al. 2013). Interestingly, the highly 
conserved residue E571 is almost exclusively mutated. Such mutational hotspots are the 
hallmarks driver mutations that confer an additional function or lead to the formation of 
dominant negative proteins. The ring-shaped XPO1 protein consists of approximately 20 HEAT 
repeats and HEAT domains 11 and 12 form the hydrophobic NES-binding groove where residue 
E571 is located (Dong et al. 2009; Sun et al. 2013).  
5.3.2 Frequency of XPO1 Mutations in Primary and Relapsed CLL Cases 
Mutations in XPO1, which is located at chr2p15, are found recurrently in CLL but with a low 
frequency in the range of 1 to 3 % in cohorts with predominantly de novo CLL cases (Puente et 
al. 2011; Wang et al. 2011; Balatti et al. 2012; Quesada et al. 2012). Within our REACH exome 
cohort (n=25) we initially discovered three XPO1 mutations. This pointed to a surprisingly high 
frequency of XPO1 mutations of 12 %. Therefore we set out to screen this gene in a larger 
cohort of 445 patient samples. We restricted the screening to the known mutational hotspot in 
XPO1, amino acid E571, as most mutations in XPO1 have been found only at this position. In 
total, we discovered 41 XPO1 mutations (9.2 %), 40 mutations at E571 and 1 at E565 (n=33 
with E571K, n=4 with E571G, n=2 with E571V, n=1 with E571Q, and n=1 with E565I). 
Surprisingly, the frequency of 9.2 % XPO1 hotspot mutations in CLL was much higher than 
previously described. We may have even underestimated the frequency of XPO1 mutations as 
some minor clones might have gone undetected because they were below the detection 
threshold of our method. A small variant peak in a chromatogram can be either caused by a 
subclone or be due to a small proportion of tumor material in the sample. The latter possibility 
could be excluded because we knew the proportion of CD19 positive cells as well as the 
proportion of FISH marker positive cells (if FISH makers were available in a case). All patients 
who had a small heterozygous peak in the chromatogram had a high percentage of CD19 
positive cells and almost all cells analyzed by FISH were positive if a marker was available. The 
high percentage of patients with XPO1 mutations in our cohort, which was not seen in 
previous reports, might be due to the fact that the other studies analyzed mainly patient 
samples before administration of treatment. XPO1 mutations might be associated with disease 
progression and a more aggressive CLL. All cases with mutated XPO1 in the other WGS and 
WES studies had also an unmutated IGHV status (Puente et al. 2011; Wang et al. 2011; Kulis et 
al. 2012). In contrast we found XPO1 mutations to be significantly associated with 13q 
deletions, and 13q deletions are associated with a good prognosis.  
It should be kept in mind that we looked at a very selected group of patients: CLL patients who 
had relapsed after treatment. Therefore, the high incidence of XPO1 mutations in our group 
could be related to the fact that CLL with XPO1 mutations are more prone to relapse or that 
the treatment used in our cohort selected for pre-existing minor clones with XPO1 mutations. 
The latter scenario suggests that the frequency of XPO1 mutations might be greatly 
underestimated in pre-treatment patients, as the NGS analyses were not sensitive enough to 
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detect such small clones. As mentioned earlier, the presence of subclonal drivers at diagnosis 
predict a high probability of relapse in CLL (Landau et al. 2013).  
5.3.3 Relevance of Mutated XPO1 in CLL 
To our knowledge, there is no data available whether XPO1 mutations have an impact on the 
prognosis. We have analyzed overall survival in our XPO1 screening cohort and did not see a 
difference between patients with mutations in XPO1 (including only mutations at codon E571) 
and those without in the two treatment arms of our study.  
 
Figure 36 Overall survival of CLL cases with mutated or wild type XPO1 in both treatment arms of the study. 
Neither in the FC nor in the R-FC arm was a statistically significant difference in overall survival between patients 
with and without XPO1 mutations. Prognostic value in FC treated patients: Log-rank test P=0.4259. Data were kindly 
provided by F. Hoffmann-La Roche.  
From these data we can conclude that mutated XPO1 is not prognostic for overall survival in 
patients who have not been treated with Rituximab. Furthermore, there was no difference in 
overall survival for patients with mutated or wild type XPO1 status when additionally treated 
with Rituximab. Therefore XPO1 mutational status was also not predictive for a treatment 
benefit when adding Rituximab. As XPO1 might be a marker for disease progression we might 
not have seen a difference in overall survival within our cohort which represents patients with 
progressive disease. As mentioned earlier, XPO1 is the main nuclear export factor of the cell, 
but it is also important for centrosome duplication and attachment of spindle fibers to 
kinetochores during mitosis. The functional consequences of the mutations at position 571 in 
XPO1 are not known yet. In most mutated samples the wild type residue at position 571, 
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namely the negatively charged glutamic acid is replaced by lysine, which carries a positive 
charge. Since this charge exchange occurs in the cargo binding pocket of XPO1, the binding of 
cargo proteins might be affected. An impaired separation of chromatides or centrosome 
overduplication could be the consequence of these mutations and might result in aneuploid 
tumor cells. During interphase, however, the predominant role of XPO1 as nuclear export 
factor might be disturbed and therefore many proteins including tumor suppressors and proto-
oncogenes might be mislocalized. It has been also shown that XPO1 is involved in U snRNA 
(small nuclear RNAs with high amount of uracil) export to build up U snRNPs in the cytoplasm. 
U snRNPs are reimported into the nucleus via snurportin 1. Snurportin 1 itself is recycled to the 
cytoplasm by XPO1 (Paraskeva et al. 1999). However, without experimental data it is highly 
speculative to predict the functional consequences (gain or loss of function) of mutations 
affecting residue E571 of XPO1.  
In an experiment in Saccharomyces cerevisiae with conditional temperature sensitive xpo1 
mutants, generated by random mutagenesis, all mutants were functional at permissive 
temperature. The mutants showed a prolonged G1-phase and shortened M-phase. In addition, 
nuclear export was impaired but this was not restricted to mutations within the NES-binding 
domain (Neuber 2008). The mutations characterized in this report were not located within the 
HEAT repeats eleven and twelve. However, also mutations not directly affecting the 
NES/binding domain may alter cargo binding due to a change in the overall steric arrangement 
of the NES binding groove. Since XPO1 is involved in the transport of so many proteins, the 
consequence of impaired XPO1 function is very difficult to predict. As all the mutations found 
in CLL are heterozygous it can be assumed that a homozygous state of the mutation in XPO1 
would probably be cell lethal.  
5.3.4 Therapeutic Targets in Leukemia  
For more than a decade, there have been intensive efforts to introduce targeted therapies to 
accompany and augment cytotoxic chemotherapy. Some of the altered proteins responsible 
for tumor growth and progression can be influenced by monoclonal antibodies (mABs) or small 
molecules. The proteins targeted by these compounds can also be present in normal tissue but 
in cancer cells they are frequently mutated or overexpressed (Gerber 2008). The blocking of 
tumor growth can be accomplished by several approaches: inhibition of signal transduction, 
inhibition of proteins regulating the expression of other genes, induction of apoptosis, blocking 
of angiogenesis, activation of immune response and the delivery of toxic molecules 
(www.cancer.gov/cancertopics/factsheet/Therapy/targeted). 
The ABL tyrosine kinase, which is constitutively activated through the fusion with BCR 
(BCR/ABL) is a well studied example for the effective use of specific tyrosine kinase inhibitors. 
By in-vitro screens for tyrosine kinase inhibitors, Imatinib (marketed by Novartis as Gleevec) 
was found to selectively inhibit the autophosphorylation of BCR/ABL, cKIT and the platelet-
derived growth factor receptor (PDGFR). Imatinib blocks tyrosine kinase activity through 
competition with adenosine triphosphate (ATP) for its binding site. In CML, the treatment of 
patients with Philadelphia chromosome (>95 %) has been proven to be hugely beneficial 
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(Druker et al. 2001; Kantarjian et al. 2002). Treatment with Imatinib can fail when patients 
have acquired mutations in the ABL part of BCR/ABL (Jabbour et al. 2006), therefore second 
generation tyrosine kinase inhibitors have been developed that overcome resistance 
mutations.  
Another approach is to target antigens found on the cell surface of cancer cells through 
monoclonal antibodies. Antibodies may act through the activation of an immune response, 
interrupting cancer processes or by the delivery of toxins to the target cells. The CD20 surface 
marker is a tetra-transmembrane protein that is expressed in early B-cells and during 
development and is lost on plasma cells. CD20 was one of the first therapeutic targets for 
monoclonal antibodies. The anti CD20 antibody Rituximab was approved 1997. It was 
manufactured by Genentech/Biogen in Europe and is now also marketed by Hoffmann-
LaRoche under the trade name of MabThera. Monotherapy with Rituximab shows therapeutic 
effects in CLL (Huhn et al. 2001) but best results are always obtained together with 
conventional therapy (Hallek et al. 2010). CD20 antibodies are broadly divided into two 
subgroups: Type I (Rituximab like) mABs cause complement dependent cytotoxicity (non-
specific immune system) and redistribute CD20 into lipid rafts; Type II ABs like GA101 
(obinutuzumab, manufactured by Hoffman-La Roche) mediate direct cell death. Both antibody 
types promote antibody-dependent cytotoxicity and phagocytosis (Cragg and Glennie 2004). 
Fine mapping of the epitopes of Rituximab and GA101 revealed that GA101 binds CD20 in a 
completely different orientation despite overlapping epitopes (Niederfellner et al. 2011). Of 
course, CD20 monoclonal ABs also bind to normal lymphoid cells and interfere with immune 
function. Therefore, these antibodies are also used to treat autoimmune diseases.  
Also XPO1 is such a potential druggable target, despite the difficulty in predicting the 
functional consequences of mutated XPO1, the overexpression of XPO1 is found in different 
tumor entities including AML (Kojima et al. 2013) and CLL (Lapalombella et al. 2012). The 
sensitivity of cancer cells to the XPO1 inhibitor Leptomycin B demonstrates the relevance of 
this pathway for abnormal cell growth. Leptomycin B, originally isolated from a Streptomyces 
species, has contributed to the discovery of hundreds of nuclear export targets. As a 
therapeutic agent, Leptomycin B proved to be inappropriate due to its strong side effects, 
which are not mediated by XPO1 inhibition but through unspecific off-target effects (Newlands 
et al. 1996). Leptomycin B covalently binds to cysteine 528 in human XPO1 and contacts 15 
additional residues and residue 571 is in contact with the prototypic PKI NES (Sun et al. 2013). 
Novel small-molecules that specifically inhibit XPO1 nuclear export, so called SINEs (selective 
inhibitors of nuclear export) have recently been developed. Lapalombella et al have 
investigated the efficacy of a SINE called KPT-185 in CLL cells. KPT-185 conjugates to cysteine 
528 of XPO1 and showed a cytotoxic effect in primary CLL cells which was stronger than in 
normal B cells. In addition, enhanced killing was shown in high risk CLL samples (Lapalombella 
et al. 2012).  
With next generation sequencing tools we will be able to detect even more druggable targets 
and will be able to screen large numbers of cancer related genes routinely in a short time. 
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5.4 NGS as Mutation Discovery and Diagnostic Tool in CLL  
CLL is a malignancy that can only be cured by bone marrow transplantation. In many cases, the 
transformed B cells are very slowly proliferating and treatment is not required in the initial 
phases of the disease, which can last for decades. As is the case for most malignancies, once a 
patient relapses after an initial treatment, there is a reduced response to second line 
treatment. Whole genome and exome sequencing has revealed a number of commonly 
mutated genes in CLL e.g. SF3B1 or NOTCH1. However, the frequency (≈10 %) of these 
mutations is relatively low in comparison to the common mutation found in cytogenetically 
normal AML like NPM1 mutations (45-64 %) or the FLT3 internal tandem duplications (28-
34 %) (Dohner et al. 2010). Thus, we face a so-called long tail distribution with a large number 
of infrequent driver mutations genes, which mirrors the great heterogeneity of CLL. This 
situation requires that we analyze even more CLL samples using whole exome or whole 
genome sequencing (Wood et al. 2007; Quesada et al. 2013). To avoid a bias in future studies 
it would be desirable to always secure a germline DNA control sample from each patient at 
diagnosis, for example a buccal swab. Challenging are also subclonal driver mutations, which 
have been shown to predict prognosis and clinical outcome (Landau et al. 2013). In future 
studies the presence of potential subclonal drivers should be evaluated at initial diagnosis for 
risk stratification and to guide treatment strategies.  
Certain mutations can also have an impact on the epigenomic landscape as we could 
demonstrate for secondary AML, where TET2 and IDH mutations correlate with reduced 
5-hydroxymethylcytosine levels (Konstandin et al. 2011). Whole genome bisulfite sequencing 
in CLL revealed a DNA methylation signature that distinguished new subtypes (Kulis et al. 
2012).  
As the cost of NGS decreases, it is very likely that whole exome or genome sequencing will 
become a routine diagnostic tool not only in CLL but in cancer in general. The wide spread use 
of NGS will reveal hundreds of subgroups in the various pathologically defined tumor entities. 
Currently we lack the knowledge what the prognosis and treatment response of these many 
“mutationally” defined subgroups will be. In a genetically heterogeneous disease like CLL, it 
might be required to associate the plethora of genomic and epigenomic lesions with a few 
common pathways to obtain larger patient cohorts that can be treated in traditional clinical 
studies. Eventually, the discovery of ever more small disease subgroups defined by a specific 
combination of somatic mutation will lead to the development of very personalized treatment 
strategies for the individual patient. 
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6 Summary 
The advent of next generation sequencing technologies has tremendously improved our 
understanding of cancer genomics within very short time. Genomic changes on DNA and RNA 
level can be systematically catalogued, thus the knowledge that we gain will improve our 
understanding of prognosis, bring us to more detailed diagnostics and increase the number of 
therapeutic targets. 
The aim of this project was to identify new, potentially predictive markers in CLL using whole 
exome sequencing on an Illumina platform (Illumina, San Diego, CA, USA). Therefore, a cohort 
of 25 CLL patients and their corresponding disease free remission samples were selected from 
the CLL REACH trial enclosing 552 previously treated patients. Disease free remission was 
defined as minimal residual disease levels of less than 1x10-3 as measured by the disease 
specific IGHV rearrangements using quantitative PCR and FISH negativity if a marker was 
available. According to flow cytometry data the CLL samples had median of 84 % CD19 positive 
cells which gives an estimate of the purity of the tumor samples. Flow cytometry 
measurements, FISH markers and IGHV mutational status were routinely determined. The 
patients selected for our exome cohort had significantly better prognostic markers (IGHV 
mutational status, del(13q), Binet status) than the entire trial, which is based on the fact that 
we used normal matched control samples from blood at the state of remission. Therefore we 
lack data from patients with worse prognostic markers who did not reach remission, like 
patients with a del(17p) or patients with more than one FISH abnormality. Out of the 25 
exome patients n=13 harbor a deletion at chromosome 13q, n=5 had no relevant CLL 
abnormality, n=4 harbored a trisomy 12, n=2 had a deletion at chromosome 11 q and one 
patient a deletion at locus 6q.  
Exome capturing of tumor and non-tumor samples were performed using the Agilent 
SureSelect target enrichment kit (Agilent Technologies, Santa Clara, CA, USA). Sequencing was 
performed with 76-80 bp paired-end reads on an Illumina IIx Genome Analyzer (Illumina, San 
Diego, CA, USA). The mean total number of reads per exome was 94 million (>7Gb per exome), 
of which in average 72 % could be mapped to the reference genome NCBI36/hg18 with a 
mapping quality of ≥10. Variant calling and coverage analysis was performed on a reference 
file containing the human RefSeq genes based on the assembly March 2006 NCBI Build 
36/hg18. In total 72.72 % of all bases used for downstream analysis map on or near (±250 bp) 
target. For all 50 exomes we obtained a mean target coverage of 57 (±11.7) and a median 
target of 47 (±9.8). More than 90 % of all RefSeq genes were at least covered once. For 85 % of 
all target positions a coverage of 10-fold and greater was obtained, sufficient enough for 
variant calling. Target positions covered less than 10-fold or were not covered, which made up 
around 15 % of the target, could not be used for SNVs or InDel calling in the tumor samples. 
We called SNVs and InDels specific for the CLL samples by comparing them to their normal, 
matched control samples from the same patient using VarScan with custom filter settings 
(Koboldt et al. 2009; Koboldt et al. 2012). We compared the output of tumor specific non-
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synonymous validated SNVs from three different workflows which were called with a p-value 
of <0.05 and with at least four variant reads from both strands. Using the somatic workflow we 
obtained best results with n=239 validated nonsynonymous SNVs and n=15 wrong calls for all 
25 exomes - that is a positive validation rate of 94 %. Including all validated InDels, 
nonsynonymous point mutations and splice site mutations, we detected 271 alterations in 260 
genes. That is a mean of 11 (±4.3) mutations per patient which is in good agreement with 
results from other CLL reports. When comparing the number of mutations of U-CLL and M-CLL 
we did not find a significant difference. In CLL, there is a great diversity of mutated genes 
among them proto-oncogenes, tumor suppressors, kinases, growth factors, cell differentiation 
markers and transcription factors possibly inducing leukemogenesis. 
In three CLL studies, 2399 different genes were found to be mutated in 200 patients. 194 of 
these genes were recurrently mutated (Puente et al. 2011; Wang et al. 2011; Quesada et al. 
2012). We found an overlap of 82 genes between our CLL cohort and the results from the 
published datasets. Of these 82 genes, 47 could only be identified as recurrently mutated 
when our data was taken into consideration. We were thus able to increase the number of 
known recurrently mutated genes in CLL by more than 20 %. 
Frequently mutated genes are always an indication for tumor drivers. Among the recurrently 
mutated genes, XPO1 which encodes a nuclear export factor was frequently mutated within 
our exome cohort with 4 out of 25 samples (16 %). Mutations in this gene almost exclusively 
affect residue E571. A screening in a larger cohort of patients enclosed in the REACH trial 
(n=445) revealed a frequency of 9.2 %. Furthermore the XPO1 mutation was associated with 
unmutated IGHV status and del(13q). Within the REACH XPO1 screening cohort the mutated 
gene was neither prognostic for patients treated with FC nor predictive when adding 
rituximab. Interestingly the frequency in previously treated CLL samples is much higher 
compared to reports from predominantly primary CLLs. So far the relevance of the XPO1 
mutation affecting amino acid E571 is unclear. As a known druggable target the described 
mutation may have impact on the effect of XPO1 inhibitors.  
In our lab, we have successfully integrated whole exome sequencing technology from sample 
preparation to bioinformatics analyses starting from matched leukemic and normal blood 
samples. Exome analysis revealed that CLL is a disease with a broad spectrum of biologically 
relevant mutational targets. Among all the candidates that could possibly be relevant for 
leukemogenesis, XPO1 was the most promising candidate to become a relevant biomarker in 
CLL. The high frequency of mutations in previously treated patients is indicating that this gene 
might be involved in disease progression. Further studies will clarify the relevance and function 
of mutated XPO1 in CLL. 
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7 Zusammenfassung 
Die Fortschritte in der Hochdurchsatzsequenzierung haben in nur wenigen Jahren unser 
Verständnis auf dem Gebiet der Krebsgenomforschung signifikant erweitert. Durch die 
systematische Analyse genomischer Veränderungen von DNA und RNA konnte in kurzer Zeit 
ein sehr breites Spektrum an Alterationen diverser Tumorgenome dargelegt werden. Diese 
Daten liefern uns prognostisch relevante Tumormarker sowie therapeutische Targets, was uns 
in Zukunft eine differenziertere Diagnostik ermöglichen wird.  
In dieser Arbeit wurde mittels Exome-Sequenzierung die kodierende Region von 25 CLL 
Patienten, die schon zu einem früheren Zeitpunkt einmal behandelt wurden, auf Alterationen 
hin untersucht. Diese Exom-Kohorte, welche aus 25 Patientenproben und den dazugehörigen 
Keimbahn Kontrollen (Blut zum Zeitpunkt der Remission) besteht, wurde aus einem größeren 
Kollektiv ausgewählt, welches im Rahmen einer Studie (REACH) behandelt wurde. Patienten 
der REACH-Studie wurden entweder nur mit Fludarabin und Cyclophosphamid oder zusammen 
mit dem CD20 Antikörper Rituximab behandelt. Von jedem der 25 Patienten wurde mittels 
eines kommerziell erwerblichen Kits (Agilent SureSelect target enrichment kit; Agilent 
Technologies, Santa Clara, CA, USA Agilent Technology) aus genomischer DNA das gesamte 
Exom zum Zeitpunkt der Erkrankung und der Remission angereichert und anschließend auf 
einem Illumina IIx Genome Analyzer (Illumina, San Diego, CA, USA) sequenziert. Um zu 
gewährleisten, dass im Material zum Zeitpunkt der Remission, welches aus Blut gewonnen 
wurde, möglichst wenige Tumorzellen enthalten sind, wurden nur Proben mit einer minimalen 
Resterkrankung von weniger als 1x10-3 CLL-Zellen ausgewählt, die mittels des erkrankungs-
spezifischen IGHV Rearrangements bestimmt wurde. Außerdem wurden nur Remissionsproben 
ausgewählt, in denen eine ehemals vorhandene chromosomale Aberration mittels FISH 
Sonden nicht mehr detektiert werden konnte. Der Anteil an B-Zellen in den Tumorproben 
wurde bestimmt, indem der Anteil an CD19 positiven Zellen mittels Durchflusszytometrie 
gemessen wurde, der Median für 23 von 25 gemessenen CLL Proben lag bei 84 %. Die 
Tatsache, dass wir für die Gesundkontrollen auf peripheres Blut zum Zeitpunkt der Remission 
zurückgreifen mussten führte in der Exom-Kohorte zu einer signifikanten Anreicherung von 
Patienten mit günstiger Prognose (mutierter IGHV Status, del(13q) und Binet Status B) im 
Vergleich zur Gesamtkohorte. Unsere Exom-Kohorte besteht aus n=13 Patienten mit del(13q), 
n=5 zeigten keine für CLL typische chromosomale Aberration, bei n=4 konnte ein Trisomie 12 
nachgewiesen werden, in n=2 Proben wurde eine del(11q) festgestellt und bei einem Patient 
eine Deletion auf Lokus 6q. Patienten mit prognostisch ungünstigeren Markern wie einer 
del(17p) oder das Vorhandensein mehrerer chromosomaler Aberrationen konnten auf Grund 
von fehlenden Remissionskontrollen nicht untersucht werden.  
Mittels Paired-End-Sequenzierung wurden durchschnittlich 94 Millionen Reads pro Exom und 
Lane erzeugt, das sind mehr als 7Gb pro Exom wenn man mit einer Read Länge von 80 Basen 
rechnet. Davon konnten wiederum 72 % auf das humane Referenzgenom (NCBI/hg18) aligniert 
werden, nachdem alle Reads mit einer Mapping-Qualität kleiner 10 ausgeschlossen wurden. 
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Die Detektion von Sequenz-Varianten sowie die Abdeckung der einzelnen Ziel-Positionen 
wurde an Hand einer Referenzsequenz ermittelt, welche alle RefSeq Gene (assembly March 
2006 NCBI Build 36/hg18) enthält. Insgesamt konnten 72.72 % der Basen die für die 
nachgeschalteten Analysen verwendet wurden, auf die RefSeq Gene gemapped werden. Im 
Mittel wurde eine 57-fache (±11.7) Abdeckung pro Exom erreicht, der Median lag bei 47 (±9.8). 
Mehr als 90 % der Zielregionen -was den hg18 RefSeq Genen entspricht- wurde mindestens 
einmal abgedeckt. Für die SNV und InDel Analyse ist eine minimale Abdeckung von 10 Reads 
pro Position erforderlich, was für 85 % der Positionen im Target der Fall war. Die Generierung 
CLL spezifischer SNVs und InDels erfolgte durch VarScan, einer Open-Source-Software (Koboldt 
et al. 2009; Koboldt et al. 2012). Mit individuellen Filtereinstellungen wurden drei 
verschiedene Workflows etabliert. Anschließend wurden die nicht-synonymen SNVs mittels 
Sanger-Sequenzierung validiert und die Ergebnisse der einzelnen Workflows miteinander 
verglichen. Mit dem sogenannten „somatic-workflow“ wurden die besten Ergebnisse erzielt. 
So konnten für alle 25 CLL Proben 239 nicht-synonyme SNVs bestätigt werden, n=15 wurden 
nicht bestätigt. Daraus ergibt sich eine Rate von 94 % für richtig bestimmte SNVs. Um die 
Workflows zu vergleichen wurden nur SNVs mit einem P-Wert von <0.05 verglichen, 
desweiteren mussten die Positionen des varianten Allels von beiden Seiten sequenziert und 
mindestens durch vier Reads abgedeckt sein. Nimmt man alle validierten InDels, nicht-
synonyme Punktmutationen und Mutationen an Spleißstellen zusammen konnten wir 
insgesamt 271 CLL assoziierte Sequenzveränderungen in 260 Genen detektieren. Im 
Durchschnitt wurden pro Patient 11 (±4.3) Mutationen gefunden, ähnlich wie bei anderen CLL-
Kohorten. Im Vergleich von U-CLL und M-CLL, gab keinen signifikanten Unterschied in der 
Anzahl der Mutationen. In der CLL wurde ein breites Spektrum an mutierten Genen gefunden, 
darunter einige Protoonkogene, Tumorsuppressoren, Kinasen, Wachstumsfaktoren, Marker für 
Zelldifferenzierung und Transkriptionsfaktoren. Viele finden sich in bekannten Tumor-
Signalwegen, die beispielsweise zu einer unkontrollierten Proliferation oder beeinträchtigter 
Apoptose führen. 
Der Vergleich mit publizierten CLL Genome- und Exomanalysen spiegelt die Heterogenität 
dieser Erkrankung wider. In drei weiteren CLL-Kohorten wurde das Material von 200 Patienten 
sequenziert und Mutationen in insgesamt 2399 Genen gefunden, davon wurden Mutationen in 
194 Genen bei zwei oder mehr Patienten gefunden (Puente et al. 2011; Wang et al. 2011; 
Quesada et al. 2012). Stellt man den drei publizierten CLL-Datensätzen die REACH-Kohorte 
gegenüber, so findet man eine Überschneidung von 82 Genen. Aus diesen 82 Genen konnten 
47 identifiziert werden die nur durch unseren Datensatz als rekurrent bezeichnet werden 
können. Durch den REACH-Exome-Datensatz konnte der Anteil an rekurrent mutierten Gene in 
der CLL um 20 % erhöht werden.  
Häufig mutierte Gene können darauf hinweisen, dass ein Gen für die Tumor/Leukemogenese 
von Bedeutung ist. Mit vier aus 25 Exom-Proben war XPO1, welches einen nukleären 
Transport-Rezeptor kodiert, das am häufigsten mutierte Gen (16 %). Mutationen in diesem 
Gen sind fast ausschließlich im Codon E571 zu finden, welches in der hydrophoben NES-
Bindestelle liegt. Ein Screening im Bereich des XPO1 Hotspots in einem größerem Kollektiv der 
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REACH Kohorte n=445, ergab eine Häufigkeit von 9.2 %. Desweiteren ist die XPO1 E571 
Mutation signifikant mit unmutiertem IGHV Status und del(13q) assoziiert. Im 
Gesamtüberleben der FC-behandelten Patienten zeigte sich jedoch zwischen Patienten mit und 
ohne Mutation im XPO1 Gen kein Unterschied, weshalb der Marker für diese Gruppe nicht 
prognostisch relevant ist. Auch in der Gruppe der zusätzlich mit Rituximab behandelten 
Patienten konnte für diesen Marker kein Unterschied im Gesamtüberleben festgestellt 
werden. Daraus ist zu schließen, dass der Marker für eine zusätzliche Behandlung mit 
Rituximab nicht prädiktiv ist. Es ist zu erwähnen, dass einige der detektierten Mutationen nur 
in Subklonen zu finden waren. Dies wiederum könnte auch der Grund dafür sein, dass die Rate 
der beschriebenen XPO1 Fälle in primären CLL Proben deutlich geringer ausfällt. Auf 
funktioneller Ebene wurde E571 Mutation noch nicht charakterisiert. Die hydrophobe NES-
Bindestelle des Proteins ist auch ein bekanntes Target für diverse Inhibitoren, die für die 
Krebstherapie relevant sein könnten, auch diesbezüglich ist der Effekt einer Mutation noch 
nicht untersucht worden.  
Mit dieser Arbeit konnten wir zeigen, dass wir die Methode der Exom-Sequenzierung zur 
Analyse leukämischen Materials und entsprechendem gesunden Kontrollmaterial von der 
Probenaufarbeitung bis hin zur bioinformatischen Auswertung erfolgreich etabliert haben. Auf 
Mutationsebene zeigte sich in der CLL ein breites Spektrum an biologisch relevanten Targets. 
In der CLL könnte zukünftig das häufig mutierte XPO1 Gen als Biomarker fungieren. 
Möglicherweise sind XPO1 Mutationen mit der Progression der Erkrankung assoziiert. Weitere 
Studien werden die Relevanz und Funktion des mutierten XPO1 Gens klären. 
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9 Appendix 
9.1 Per Base Coverage of Frequently Mutated Genes in CLL 
Per base coverage of each exome for frequently mutated genes in CLL and/or 
recurrently mutated genes as found in the REACH exome cohort. Per base coverage 
was computed with BEDtools and boxplots generated with R. On y-axis the coverage is 
depicted and the red line is drawn at ten-fold coverage. The coverage of a gene was 
calculated for each exome separately, on the left side the CLL samples are represented 
and on right sight the corresponding remission samples. Exomes 1-25 correspond with 
CLL patient sample P1-P25 and exomes 26-50 correspond with remission samples P1-
P25.  
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9.2 Mutations in Components of Cancer Pathways 
Mutations found within the 25 exomes in components of cancer pathways: Cancer pathways 
according to KEGG (http://www.genome.jp/kegg/kegg2.html), including somatically mutated 
genes in CLL as highlighted in red. 
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9.3 Demographics of XPO1 Screening Cohort 
Data were kindly provided by F. Hoffmann-La Roche. 
 
                    Randomized Treatment: FC                                 Randomized Treatment: FC-R 
 
9.4 Disease Characteristics of XPO1 Screening Cohort 
ECOG is a scoring system to quantify cancer patients by their general well-being and activities 
of daily life. Data were kindly provided by F. Hoffmann-La Roche. 
 
                      Randomized Treatment: FC                                  Randomized Treatment: FC-R 
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9.5 Abbreviations 
°C degree Celsius 
µ micro (1x10-6) 
AA Amino Acid 
ALL Acute Lymphocytic Leukemia 
AML Acute Myeloid Leukemia 
APS Adenosine 5’ phosphosulfate 
Array CGH Array-based comparative genomic hybridization 
ATP Adenosin triphosphate 
BAM binary version of SAM file 
BAQ per-Base Alignment Quality 
BED Browser Extensible Data (tabular file format) 
bp base pair(s) 
BWA Burrwos-Wheeler Alignment tool 
cDNA complementary DNA 
CIGAR compact idiosyncratic gapped alignment report 
CLL Chronic Lymphocytic Leukemia 
CLP common lymphoid progenitors 
CMP common myeloid progenitors 
CML Chronic Myeloid Leukemia 
dATP desoxyadenosine triphosphate 
dbSNP130 SNP database  build 130 
ddH2O double distilled water 
ddNTPs dideoxynucleotide triphosphates 
del Deletion 
DNA deoxyribonucleic acid 
dNTPs deoxynucleotide triphosphates 
dsDNA double stranded DNA 
ECOG Eastern Cooperative Oncology Group 
e.g. Example 
EDTA ethylenediaminetetraacetic acid 
FAB French-American- British classification system for acute leukemia 
FC Fludarabine Cyclophosphamide (treatment regime REACH study) 
FC-R Fludarabine Cyclophosphamide Rituximab (treatment regime REACH study) 
FISH fluoreszenz in situ hybridization 
g Gram 
Gb Gigabases 
GMP granulocyte-monocyte progenitor 
HEAT repeat domains in proteins, named after the proteins Huntingtin, Elongation 
factor 3, protein phosphatase 2A and TOR1 kinase where it was found first 
hg18 human genome 18 
HS High Stringency settings for variant calling 
HSC Hematopoietic Stem Cell 
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HGNC HUGO Gene Nomenclature Committee 
HUGO Human Genome Organization 
i.e. example 
IGHV immunoglobulin heavy chain variable region genes 
IGV Integrative Genomics Viewer 
InDel to summarize Insertions Deletions 
iqrpos in quantitative range positive 
kb Kilo base pairs 
kDa kilodalton(s) 
KEGG Kyoto Encyclopedia of Genes and Genomes 
kHz Kilo Hertz 
l Liter 
LOH loss of heterozygosity 
LS Low Stringency settings for variant calling 
LT-HSC long-term hematopoietic stem cell 
M Molar 
m- milli (1x10-3) 
mAB monoclonal antibody 
Mb mega base pairs 
M-CLL mutated CLL 
MEP megakaryocytic-erythrocyte progenitors 
min minute(s) 
miRNA microRNA 
MPP multipotent progenitors 
MQ mapping quality 
MRD minimal residual disease 
mRNA messenger RNA 
MSigDB Molecular Signatures Database (collection of annotated gene sets) 
n nano (1x10-9) 
NCBI National Center of Biotechnology Information 
NES nucleic export signal 
NGS next generation sequencing 
NIH National Institute of Health 
NLS nuclear localization signal 
oqrpos out of quantitative range positive 
OS Overall Survival 
p pico (1x10-12) 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEG polyethylenglycol 
PFS Progression Free Survival 
PPi pyrophosphate 
PhiX Control library generated from PhiX virus 
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RNA ribonucleic acid 
rpm revolutions per minute 
SAM Sequence Alignment/Map format 
sd standard deviation 
SINE Selective inhibitor of nuclear export 
SNP single nucleotide polymorphism 
SNV single nucleotide variant 
SOLiD Sequencing by Oligo Ligation Detection 
ST-HSC short-term hematopoietic stem cell 
Taq Thermus aquaticus 
TBE Tris-borate-EDTA 
TE Tris-EDTA buffer 
Tm melting temperature 
U-CLL unmutated CLL 
UCSC University of California Santa Cruz (provides Genome Browser)  
UV ultraviolet 
WHO 
ZAP-70 
World Health Organization 
zeta-chain associated protein kinase 70 
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Single letter codes for amino acids 
nonpolar 
A  (Ala) Alanine 
V  (Val) Valine 
L  (Leu) Leucine 
I  (Ile) Isoleucine 
M (Met) Methionine 
P  (Pro) Proline 
G  (Gly) Glycine 
polar hydrophilic 
S  (Ser) Serine 
T  (Thr) Threonine 
C  (Cys) Cysteine 
N  (Asn) Asparagine 
E  (Gln) Glutamic acid 
aromatic 
F  (Phe) Phenylalanine 
Y  (Tyr) Tyrosine 
W (Trp) Tryptophan 
positively charged 
K  (Lys) Lysine 
R (Arg) Arginine 
H  (His) Histidine 
negatively charged 
Q  (Gln) Glutamine 
D  (Asp) Aspartic acid 
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